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SUMMARY
The effects of natriuretic peptides on vascular control were investigated. In the major 
part of this thesis emphasis is placed on the effects of natriuretic peptides, in 
particular ANP, on regulation of regional vascular volume and venous tone in healthy 
volunteers (Chapter 3) and patients with chronic heart failure (Chapter 4). The second 
part of this thesis investigates the effects and mechanisms of action of ANP, BNP and 
CNP on large artery function in an ovine hind limb model (Chapter 5). Finally, the 
actions of the latest members of the natriuretic peptide family, namely DNP and NNP 
are investigated in vitro using rings of rabbit aorta in organ bath experiments (Chapter 
6).
The important new findings of this thesis are;
1. ANP regulates regional vascular volume and venous tone over a wide range of 
physiological and pathophysiological plasma levels without affecting 
compliance.
2. Most importantly, basal ANP plasma levels contribute significantly to 
regulation of resting vascular tone.
3. The rank order of potency of NP in the forearm capacitance vasculature of 
patients with chronic heart failure is A N P »  BNP>CNP/Urodilatin.
4. Venous ANP responsiveness is preserved in patients with chronic heart failure 
despite marked impairment in the resistance vasculature. This preservation 
may be due to preserved venous endothelial function.
5. ANP acting locally modifies pulse wave velocity via the NPRa receptor. 
Neither CNP (acting via the NPRb receptor) nor cANF (acting via NPRc) 
elicit any immediate vasoactive effects.
6. Novel natriuretic peptide (NNP), a newly isolated NP from the venom of the 
green mamba snake (dendroaspis angusepticus) has arterial vasorelaxant 
properties similar to those of ANP and DNP.
ACKNOWLEDGEMENTS
The work of this thesis was funded by the British Heart Foundation and by the 2001 
De Bono Research Fellowship from the British Cardiac Society. All radionuclide and 
plethysmographic studies were carried out at the Wales Heart Research Institute 
(WHRI). These work-intensive and time-consuming studies could not have been 
carried out without the helping hands of many peoples; The most frequent helpers 
were Prasad Gunaruwan, Leong Lee, Andrew Broadley, Justin Taylor, Angus 
Nightingale, Ross Campbell.
I am particularly indebted to Gordon Middleton, from the Department of Medical 
Physics, for his help in servicing the gamma cameras and for writing the program to 
analyse the splanchnic studies.
All sheep studies were carried out in the Graduate School of Biomedical Engineering 
at the University of New South Wales in Sydney, Australia. This work was made 
possible due to the support and skills of John Cockcroft, Albert Avolio, Ian 
Wilkinson, Carmel McEniery, John Klemes, Vicki Tatarinoff and Kate Knoble.
The organ bath studies organised, designed and supervised by myself were carried out 
in the WHRI by Sophie Reshamwalla with support and co-supervision of Derek Lang. 
Most importantly I would like to thank Professor Michael P. Frenneaux for 
introducing me to the interesting field of venous physiology and for infecting me with 
scientific curiosity. His unrestricted support has sustained the work that forms this 
thesis.
As well as valuable experience and hard work, the 3 and half years of my research 
produced many enjoyable times and most importantly good fnendships with my 
fellow researchers. I equally marvelled the calm and level-headedness of my 
colleagues Prasad Gunaruwan, Justin Taylor, Angus Nightingale, and Leong Lee, as I
admired the self discipline and organisational skills displayed by Andrew Broadley. 
Good humour, gossip at times, and a lively debate were guaranteed in equal measure. 
I am also particularly grateful to Professor John R. Cockcroft, not only for organising 
the NNP, and so willingly sharing his vast experience and knowledge in the field of 
cardiovascular pharmacology, but also for allowing me access to the ovine hind limb 
model and most importantly for the f\m and the good times spend “Down-under”. 
Finally I would like to thank my parents and my Fiancee Nicola, who by the time this 
thesis is bound and complete will be my wife, for their love and unconditional 
support.
SUMMARY..........................................................................................................3
ACKNOWLEDGEMENTS...................................................................................5
INDEX OF TABLES......................................................................................... 11
INDEX OF FIGURES........................................................................................12
INDEX OF PLATES (PHOTOS).......................................................................14
ABBREVIATIONS............................................................................................ 15
1.1 Heart Failure..........................................................................................17
1.1.1. Introduction................................................................................................................ 17
1.1.2. Epidemiology.............................................................................................................. 19
1.1.3. Prognosis .................................................................................................. 20
1.1.4. Aetiology and Pathophysiology................................................................................. 20
1.1.5. Classification.............................................................................................................. 21
1.2. Venous Physiology.............................................................................. 24
1.2.1. Introduction................................................................................................................24
1.2.2. Terminology................................................................................................................24
1.23. Importance of venous physiology.............................................................................. 26
1.2.4. Varying responses of individual venous beds...........................................................31
1.2.5. How changes in preload may affect cardiac output in health and heart failure .....36
1.2.6. Venous tone in chronic heart failure.........................................................................41
13. The natriuretic peptide system..........................................................49
13.1. Introduction .........................................................................................................49
133. Biochemistry and Molecular Biology of Natriuretic Peptides................................. 52
1.3.4. Natriuretic peptide receptors, intracellular signalling and metabolism ..................64
13.5. Physiological aspects in health (ANP)....................................................................... 67
1.3.6. Therapeutic principles and rationale........................................................................ 74
1.3.7. Problems and Pitfalls: natriuretic peptide resistance...............................................82
1.3.8. Conclusion and Perspective....................................................................................... 88
1.4. Original Hypotheses............................................................................. 89
CHAPTER 2 -  METHODOLOGY..................................................................... 91
2.1. History, Applicability and Basic Principle of Radionuclide 
plethysmography............................................................................................ 91
2.2. Practical Methodology........................................................................ 92
23.1. Red cell labeling............................................................................................................ 92
2.3. General Protocol...................................................................................93
2.3.1. Forearm studies:........................................................................................................... 93
2.3.2. Splanchnic/intestinal studies:.......................................................................................95
2.4. Data Analysis.......................................................................................97
2.5. Validation............................................................................................101
2.5.1. Variability................................................................................................................... 101
2.5.2. Validation against fluid displacement plethysmography.........................................101
2.5.3. Validation against strain gauge plethysmography................................................... 101
2.6. issues regarding red ceil binding................................................... 102
2.7. Effects of arterial inflow on venous volume................................. 107
2.8. Limitations of Radionuclide plethysmography............................ 108
2.9. Comparison to Available Methods to Assess Venous Function and
Capacitance....................................................................................................109
2.9.1. Established techniques................................................................................................ 109
2.9.2. Comparing Radionuclide plethysmography and Strain Gauge...............................112
methysmography ........................................................ 112
2.10. intravenous pressure versus cuff pressure................................. 113
2.11. RPY Conclusion and Perspective.................................................. 114
2.12. Animal work.......................................................................................115
2.12.1. General and historic consideration of the sheep as an experimental animal 115
2.12.2. Specific Methodology..................................................................................................117
2.13. Organ bath experiments.................................................................. 117
CHAPTER 3 -  THE EFFECTS OF ANP ON VENOUS CAPACITANCE IN 
MAN................................................................................................................ 118
3.1. Background /  introduction.................................................................118
3.2. Methods............................................................................................... 119
3.2.1. Subjects..................................................................................................................... 119
3.2.2. Assessment of venous function................................................................................. 120
3.3. Statistics.............................................................................................. 124
3.4. Results................................................................................................. 124
3.4.1. Subject characteristics...............................................................................................124
3.4.2. Experiment 1: effect of intrahrachial ANP on U W  and venous tone in forearm 124
3.4.3. Experiment 2: effect of intrahrachial A71915 on U W  and venous tone in forearm 
..................................................................................................................................... 129
3.4.4. Experiment 3: effect of intrahrachial A71915 on FBF........................................... 131
3.4.5. Experiment 4: effect of intravenous A71915 on I W ...............................................132
3.5. Discussion.......................................................................................... 133
3.5.1. Previous studies assessing the effects of ANP on venous function........................... 134
3.5.2. How can these discrepancies he explained?...............................................................135
3.5.3. Alternative explanations for increased vascular volume?...................................... 135
3.5.4. Effects of ANP-receptor antagonism.......................................................................... 136
3.5.5. Study limitations......................................................................................................... 136
3.6. Conclusion.......................................................................................... 138
CHAPTER 4 -  THE EFFECTS OF NATRIURETIC PEPTIDES ON VENOUS 
CAPACITANCE IN CHF.................................................................................139
4.1. Introduction........................................................................................ 139
4.2. Methods and Data Analysis..............................................................140
4.2.1. Assessment of Arterial Resistance-Vessel Effects................................................... 143
4.2.2. Assessment of Venous Function.............................................................................. 143
4.2.3. Protocol ......................................................................143
4.3. Results.................................................................................................145
4.3.1. Subject Character»tics:............................................................................................. 145
4.3.2. ANP Levels.......................  146
4.3.3. The Effects of NP on FBF in Health and cHF......................................................... 146
43.4. Changes in Forearm Venous Tone............................................................................. 147
43.5. The Effects of NP on F W  in Health and in cHF.....................................................148
4.3.6. The Effects of A71915 on FBF and F W  in Patients with cHF.............................. 149
4.3.7. The Effects of Endothdium-Derived NO on NP-Induced Changes in FBF and F W  
in Health and cHF.........................................................................................................................152
4.4. Discussion.......................................................................................... 152
4.4.1. Mechanism of the Attenuated Forearm Resistance-Vessel Response to ANP in cHF 
..................................................................................................................................... 153
4.4.2. Venous Effects of Natriuretic Peptides in cHF ................................................ 154
4.43. Effects of Basal ANP Levels____________________________  156
4.4.4. Rdative Potency of the Different NPs........................................................................157
4.4.5. Clinical and Pathophysiological Implications............................................................157
4.4.6. Study limitations..........................................................................................................158
4.5. Conclusion.......................................................................................... 159
CHAPTER 5 -  THE ROLE OF NATRIURETIC PEPTIDES IN THE 
FUNCTIONAL REGULATION OF CONDUIT ARTERY STIFFNESS......... 160
5.1. introduction........................................................................................ 160
5.2. Methods...............................................................................................161
5.2.1. Haemodynamic measurements.................................................................................. 162
5.2.2. Drugs...........................................................................................................................164
5.2.3. Protocol / Surgical preparation................................................................................. 164
5.3. Statistics............................................................................................. 168
5.4. Results................................................................................................168
5.4.1. The effects of ANP / BNP / CNP on Biac PWV.........................................................168
5.4.2. The effect of A71915 on Uiac PWV........................................................................... 169
5.4.3. The effect of ANP/A71915 co-infusion on Uiac PWV.............................................. 169
5.4.4. The effects of cANF on Uiac PWV............................................................................. 169
5.5. Discussion........................................................................................... 177
5.5.1. The effect of ANP and BNP on large conduit arteries..............................................177
5.5.2. CNP -  a vasoactive NP?..............................................................................................178
5.53. Effects of Basal ANP plasma levels on large artery distensibility............................ 179
5.5.4. Clinical considerations................................................................................................180
5.5.5. Limitations.................................................................................................................. 180
5.6. Conclusions......................................................................................... 182
CHAPTER 6 -  THE EFFECTS OF NOVEL NATRIURETIC PEPTIDES (NNP / 
DNP) ON ISOLATED RINGS OF RABBIT AORTA; COMPARISON TO ANP 
AND DNP........................................................................................................ 183
6.1. Background..........................................................................................183
6.2. Methods................................................................................................184
6.2.1. Isometric Tension Recordings................................................................................... 185
6.2.2. Drugs and Chemicals................................................................................................. 187
6 3 3 . Statistical analysis.......................................................................................................188
6.3. Results.................................................................................................. 188
63.1. Comparative ANP, DNP, NNP dose response study.................................................188
6 3 3 . The Effects of Nitric Oxide (NO) in NNP induced vasorelaxation..........................190
6 3 3 . The Effects of Prostaglandins in NNP-induced vasorelaxation.............................. 191
63.4. The Effects of sGC in NNP-induced vasorelaxation.................................................192
63.5. The Effects of NPRa-NNP interaction on vascular smooth muscle tone................193
6.3.6. The Effects of NPRc-NNP interaction on vascular smooth muscle tone ...............196
6.4. Discussion............................................................................................197
CHAPTER 7 -  DISCUSSION AND CONCLUSIONS................................... 200
7.1. Discussion.......................................................................................... 200
7.2. Future work......................................................................................... 211
REFERENCES............................................................................................... 213
10
INDEX OF TABLES
Table 1.2.2.1. Terminology. 25
Table 1.2.6.1 Causes of increased vascular tone in congestive heart failure. 43
Table. 1.3.3.1. The ANP family; Mature ANP’s and their amino-terminal cleavage 
products. 54
Table 1.3.5.1. Phenotype of genetically modified mice. 70
Table 2.6.1. Red cell labelhng efficacy in patients with chronic heart failure (ANP 
study). 104
Table 2.6.2. 3-hour ‘^^ Unbinding-stiidies ” Red cell labelling efficacy in patients with 
chronic heart failure (ANP study). 104
Table 2.12.1.1. The distribution of cardiac output in the resting sheep is shown. 118
Table 3.2. Baseline characteristics are shown. 120
Table 4.2.1. Baseline demographics of chronic heart failure patients and control 
group. 141
Table 4.2.2. Blood parameters, urinary sodium, heart rate and blood pressure at begin 
and end of study. 142
Table 4.3.3.1. Effects of NP’s on FBF ratio and F W  in %. 150
Table 4.3.7. Effects of LNMMA/ANP co-infusion on NP induced changes in FBF and 
F W . 151
Table 5.4. The Effects of ANP, BNP, CNP on hemodynamics. 176
Table 6.3.1. %-relaxation and -LogECso of ANP, DNP, and NNP. 188
11
INDEX OF FIGURES
Figure 1.1.5. Stages of heart failure and treatment options for systolic heart failure. 23
Figure 1.2.3.1. Vascular volume distribution within arteries and veins. 27
Figure 1.2.3.2. Changes in venous pressure/volume relation (PVR). 28
Figure 1.2.3.3. Venous compliance. 29
Figure 1.2.3.4. Arterial and venous pressure-volume relationships. 30
Figure 1.2.4.1. A mechanical analogue of the venous capacitance system. 35
Figure 1.2.5.1. The Frank-Starling relationship. 39
Figure 1.2.5.2. Schematic illustration of Diastolic Ventricular Interaction. 40
Figure 1.3.2.1. The amino acid sequence and ring structure of ANP is shown. 52
Figure 1.3.3.1. Ring structure and amino acid sequence of all 4 human natriuretic 
peptides. 53
Figure 1.3.3.1.1. ANP gene structure; From gene to peptide. 56
Figure 1.3.4.1. Membrane bound natriuretic peptide receptors. 66
Figure 1.3.5.1. Aspects of cardiovascular natriuretic peptide physiology. 69
Figure 1.3.7.4. Receptor dephosphorylation / desensitisation. 85
Figure 2.4.1. Grouped PVR of an ANP dose response study. 100
Figure 3.4.2.1. Typical PVR following ANP. 126
Figure 3.4.2.2. ANP dose response curve. 127
Figure 3.4.2.3. Vascular volume changes according to venous ANP levels. 128
Figure 3.4.3. T)q)ical PVR following A71915. 130
Figure 3.4.4.1. The effects of A71915 on ANP induced changes in FBF. 131
Figure 3.4.5.1. The effects of A71915 on intestinal capacity. 132
Figure 3.4.5.2. The contrasting effects of ANP and A71915 on forearm vascular 
volume. 133
Figure 4.3.3. A) Effects of ANP on FBF in health and chronic heart failure. 149
B) Effects of ANP on F W  in health and chronic heart failure. 149
12
Figure 5.2.1. Example of original wave form and changes in transit time following 
pharmaceutical intervention. 163
Figure 5.2.3. Schema showing the different infusions via the catheter (proximal) and 
sheath (distal). 170
Figure 5.4.1.a. ANP dose-response curve. 171
Figure 5.4.1.b. BNP dose-response curve. 172
Figure 5.4.I.e. CNP dose-response curve. 173
Figure 5.4.2. The effects of A71915 on iliac PWV. 174
Figure 5.4.3. The effects of cANF (NPRc-receptor stimulation) on iliac PWV. 175
Figure 6.2.1. Schematic representation of organ bath set-up. 185
Figure 6.3.1. Concentration response curves to ANP, DNP, NNP. 189
Figure 6.3.2. The role of nitric oxide in NNP induced vasorelaxation. 190
Figure 6.3.3. The role of prostaglandins in NNP induced vasorelaxation. 191
Figure 6.3.4. The role of soluble guanylate cyclase in NNP induced vasorelaxation.
192
Figure 6.3.5.a-c. The effects of NPRa-NNP interaction on vascular smooth muscle 
tone.
a) A71915 at a concentration of 1 pmol/1 193
b) A71915 at a concentration of 3pmol/l 194
c) A71915 at a concentration of 1 Opmol/1 195
Figure 6.3.6. The effects of NNP-NPRc interaction on vascular smooth muscle tone.
196
13
INDEX OF PLATES (PHOTOS)
Plate 1.3.2.1. Ultrastructure of human atrial myoendocrine cells: the perinuclear 
region containing the Golgi apparatus (G) is seen. The nucleus (N) is round and 
lobated, further myofibrils, lysosomes, and mitochondria are present. The secretory 
granules (SG) are slightly variable in density and size (Reproduced from Ref 198 with 
kind permission from Springer). 51
Plate 2.3.1.1. (a+b+c) A typical setting of a forearm study. Both forearms rest on the 
surface of a gamma camera collimator. The brachial artery is cannulated with a 27 
gauge steel needle sealed with dental wax to an epidural catheter for drug infusion. 
The cubital vein is cannulated with a venflon for plasma sampling. 94
Plate 2.3.2.1. An abdominal scintigram is shown. Lead markers (thick black lines) 
attached to the skin facilitate monitoring of a constant ROI (thin white line). The ROI 
is drawn clear of large conduit vessels. 96
Plate 2.4.1. A 1 minute dynamic recording split into six intervals of 10 seconds is 
shown. The lower panel (the last 30 seconds after pressure has equalized) is used for 
analysis. 98
Plate 2.4.2. Shows a ROI drawn over a forearm. It is suggested that the region should 
be drawn just clear of the edge of the arm (to allow for small expansion and 
movements) but inside the edge of the camera field. 99
Plate 2.6.1. a Shows blood samples taken over a 3-hour period (left to right; Baseline, 
30 minutes, 1-hour, 2-hours, 3-hours). 105
Plate 2.6.l.b. The upper panel shows whole blood-activity (at 1,2,3, and 4 hours) the 
middle panel concentrated erythrocyte-activity, and the lower panel the activity in 
plasma. The single ROI between upper and middle panel serves to correct for 
background radiation. 106
Plate 5.2.1. Boyle’s apparatus (respirator). 161
Plate 5.2.2 Study setting. 162
Plate 5.2.3. l.a-d Surgical preparations
a) Inguinal cut down. 165
b) Sheath and 5 French dual pressure sensing high fidelity catheter. 166
c) Operative setting. 166
d) Alternative set-up in animal with small sized iliac vessels. 166
Plate 5.2.3.2. Ovine pelvic vascular anatomy. 167
14
ABBREVIATIONS
CHF = congestive heart failure
cHF = chronic heart failure
SNS = sympathetic nervous system
RAAS = renin angiotensin aldosterone system
ESC = European Society of Cardiology
NP(s) = natriuretic peptide(s)
NPS = natriuretic peptide system
LV = left ventricular
PA^ = pressure/volume
NO = nitric oxide
PVR(s) = pressure/volume relation(s)
RPY = radionuclide plethysmography
DVI = diastohc ventricular interaction
U W = unstressed vascular volume
NA = noradrenaline
NB = norepinephrine
ACE = angiotensin converting enzyme
Angll = angiotensin II
CVP = central venous pressure
LVEDP = left ventricular end diastolic pressure
RVEDP = right ventricular end diastolic pressure
PCWP = pulmonary capillary wedge pressure
RV = right ventricular
RCT = randomised controlled trial
ANP = atrial natriuretic peptide
BNP = brain natriuretic peptide
CNP = c-type natriuretic peptide
DNP = dendroaspis natriuretic peptide
NNP = novel natriuretic peptide
SNP = sodium nitroprusside
ER = endoplasmatic reticulum
aa = amino acids
N = nucleus
G = Golgi apparatus
SG = secretory granules
LANP = long acting natriuretic peptide
ANF = atrial natriuretic factor
a-TNF = tumour necrosis factor a
GC = guanylate cyclase
NPR = natriuretic peptide receptor
AY = arterio-venous
eNOS = endothelial nitric oxide synthase
VSMC(s) = vascular smooth muscle cell(s)
NEP = neutral endopeptidase
BP = blood pressure
CO = cardiac output
TPR = total peripheral resistance
15
Aspl3 = aspartic acid in position 13
Phe26 = phenylalanine in position 26
Tic = tetrahydroquinoline-3-carboxylate
NPE = non-pigmented epithelial cells
d-MSH = delta-Melanocyte-stimulating hormone
SVR = systemic vascular resistance
PAP = pulmonary artery pressure
SVI = stroke volume index
Cl = cardiac index
HR = heart rate
PCWP = pulmonary artery wedge pressure
VP = vasopeptidase
VPI = vasopeptidase inhibition
OMA = Omapatrilat
ET = exercise tolerance
ETT = exercise tolerance test
ADM = adrenomedullin
EBPS = equilibrium blood pool scintigraphy
ROI = region of interest
SFOV = small field of view
FBF = forearm blood flow
VOP = venous occlusion plethysmography
SGP = strain gauge plethysmography
F W = forearm vascular volume
ECG = electrocardiography
I W = intestinal vascular volume
ANOVA = analysis of variance
SEM = Sandard error of the mean
LNMMA = N^-monomethyl-L-arginine
PWV = Pulse wave velocity
MAP = Mean arterial pressure
ISH = Isolated systolic hypertension
GSK = Glaxo Smith Kline
PE = Phenylepinephrine
ODQ = lH-[ 1,2,4] oxaddiazol94,3-alphaquinoxaline-l
L-NAME = N^-Nitro-D-Arginine-Methyl Ester
EDHF = Endothelium derived hyperpolarising factor
‘‘The very essence of cardiovascular practice is the early detection of heart failure^
Sir Thomas Lewis, 1933
16
CHAPTER 1 -  Literature Review
1,1 Heart Failure
1.1.1. Introduction
Chronic heart failure (cHF) is the potential end stage of any cardiac disease and is a 
complex syndrome rather than a single disease entity. Being a diverse syndrome 
arising from multiple underlying aetiologies it has defied a complete and accurate yet 
simple definition (1-4). Indeed there are no cut off values of cardiac or ventricular 
dysfimction or changes in flow, pressure, diameter or volume that can be used reliably 
to identify patients with heart failure (5). It is probably fair to say that the intense 
search for an ideal definition has, at times, been somewhat counterproductive as many 
proposals have not only confused the word “definition” of heart failure with 
“diagnosis” of heart failure but also disregarded the importance of an integrative 
approach towards the syndrome.
Nevertheless the hallmarks of heart failure described and defined by Sir William 
Osier (6) and modified and “modernised” by Eugene Braunwald (3) can still serve as 
usefiil description of the syndrome: “a pathophysiological state in which an 
abnormality of the cardiac function is responsible for the failure of the heart to pump 
blood at a rate commensurate with the requirements of the metabolising tissues”.
It should however be emphasised that today’s perception of heart failure is constantly 
evolving and quite different from that of only half a century ago.
Over recent decades it has become increasingly clear that the syndrome of heart 
failure is associated with a characteristic pattern of cardiac and extra-cardiac 
responses. The latter including renal, biochemical, neural, vascular and hormonal 
changes -  especially , stimulation of vasopressin, the sympathetic nervous system 
(SNS), the renin-angiotensin-aldosterone system (RAAS), increased release of
17
inflammatory markers and cytokines, increased oxidative stress and endothelial 
dysfunction.
In particular up-regulation of the natriuretic peptide (NP) system (NPS) has emerged 
as a hallmark of several cardiovascular disorders, most evident in CHF.
The diagnosis of heart failure continues to rely on clinical judgement based on a 
history, physical examination and appropriate investigations. Clinically heart failure is 
characterised by breathlessness, effort intolerance, fluid retention and poor survival. It 
is clear from the aforementioned complexities that any attempt to reduce heart failure 
to a sole problem of reduced myocardial contractility would be inadequate.
As cardiac output (CO) is a complex and dynamic relationship between preload, 
myocardial (myocyte) contractility, and afterload, it becomes clear that arterial 
compliance, venous capacitance, ventricular-interdependence, ventricular-arterial and 
veno-ventricular coupling all have their role to play in the complex adaptive and 
maladaptive processes taking place following an injury sufficient enough to lead to 
heart failure, not to speak about primary myocardial changes itself.
Whilst our understanding of resistance and conduit vascular function has expanded 
enormously over the past two decades, our luiderstanding and appreciation of venous 
physiology and pathophysiology in relation to congestive heart failure (CHF) 
remained rudimentary.
In this thesis the major emphasis is placed on the neurohormonal (in particular 
enocrine and paracrine), regulation of venous capacitance and tone (Chapter 3 + 4). 
Especially under consideration is the body’s endogenous response to the deleterious 
activation of the SNS and RAAS -  paticularly the role of the natriuretic peptide 
system (NPS). In the second part (Chapter 5 + 6) the role of natriuretic peptides (NPs) 
in the functional regulation of conduit arteries in vivo and in vitro is investigated.
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1.1.2. Epidemiology
The importance of heart failure as a public health problem predominantly relates to 
the prevalence of the syndrome, in particular that of more severe stages. The 
prevalence is determined by the incidence and the survival following the onset of 
heart failure. Whilst much is known about the epidemiology of heart failure in North 
America and Europe, regional differences (not only between the US and Europe but 
also between and within European Member States) exist in risk factors, prevalence, 
incidence, prognosis and hospitalisation rates. Estimates of the prevalence of 
sjmiptomatic heart failure in the general European population range from 0.4%-2% 
(7-9) and it is believed that asymptomatic left ventricular (LV) systolic dysfunction 
has a similar prevalence (10; 11). Each of these two groups probably comprise in 
Europe approximately 10 million people at any given time (5). Heart failure related 
health cost expenditures within the UK are estimated to be £ 751 million accounting 
for roughly 1.83% of the total NHS budget (12). The average yearly incidence in 
Western countries varies between 1-4/1000 (13) and is highly age dependent. In the 
45-55 years age group the prevalence of CHF is considerably less than 1% (14-16). 
This increases to 2-5% in the 65-75 age group (14; 16-18) and approaches 10% in the 
over 80 years old (14-16;19). Men are more frequently affected than women of the 
same age with a male/female ratio of roughly 1.5/1. The mean age of affected 
individuals is now in the mid seventies in Europe and North America. Heart failure 
prevalence has risen dramatically due to both population aging and the fact that 
thrombolysis has improved survival post myocardial infarction, but survivors often 
have significant LV dysfunction. A simulation model by Bonneux and colleagues (20) 
predicts a transition from acute to chronic cardiovascular disease, resulting in a 
dramatic increase in age adjusted prevalence rates of ischaemic heart disease in the
19
Netherlands by 2010, that is largely attributable to CHF. “In absolute terms 
prevalence rates are predicted to increase 70%; adjusting for the increasing age of the 
population the net increase will be around 20%” (21).
1.13. Prognosis
The prognosis of heart failure is poor (14). Half of patients carrying a diagnosis of 
heart failure will die within 4 years and in patients with severe heart failure more than 
50% will die within 1 year (14;16;22).
1.1.4. Aetiology and Pathophysiology
As noted above CHF can principally be the consequence of any cardiac disease. It is 
believed that in roughly 80-90% of patients the symptoms are caused by ventricular 
dysfunction, in possibly more than 60% due to systolic dysfunction with a reduced 
ejection fraction (EF<40%) (23-25). Systolic dysfunction results from a loss of 
intrinsic inotropy (contractility), either due to loss of viability or due to alterations in 
signal transduction mechanisms responsible for regulating inotropy. Diastolic 
dysfunction refers to the diastolic properties of the ventricle and occurs when the 
ventricle becomes less compliant (i.e. “stiffer”), which impairs ventricular filling. 
Both systolic and diastolic dysfunction result in a higher ventricular end-diastolic 
pressure which serves as a compensatory mechanism by utilising the Frank-Starling 
mechanism to augment stroke volume. In certain types of heart failure (e.g. dilated 
cardiomyopathy) this leads to ventricular enlargement as preload pressure increases in 
order to maintain normal stroke volumes. The leading cause of CHF in Western 
countries is coronary artery disease (CAD; ~ 54-70%), which in 35-52% of these 
patients is associated with arterial hypertension (13). Hypertension as the sole cause
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of CHF accounts possibly for 9-20% of cases, whilst idiopathic dilated 
cardiomyopathy is believed to account for 18-28% of cases. Rarer causes are 
congenital heart disease, degenerative valvular abnormalities, myocarditis, 
endocarditis, alcoholic cardiomyopathies and other causes including myocardial 
storage diseases (7;13-15;26-28).
Following an initial myocardial injury (tissue necrosis, volume overload, pressure 
overload) compensatory mechanisms become established to maintain stroke volume. 
These mechanisms lead to macroscopic (ventricular enlargement and change of 
ventricular geometry) and microscopic (myocyte hypertrophy and interstitial fibrosis) 
remodeling (29). Ventricular enlargement is a self-perpetuating process as stretch 
induced apoptosis leads to fixrther loss of viable myocardium (30). As a consequence 
of reduced organ perfusion and in an attempt to compensate for the reduced CO a 
complex neuroendocrine activation (activation of the SNS, RAAS, increased release 
of vasopressin, nitric oxide (NO), cytokines and endothelins) sets in (31-34). The 
consequences of long-term activation of these “short-term compensatory 
mechanisms” however include venous and arterial vasoconstriction (31;35), fluid 
retention (31;36), and facilitation of life-threatening arrhythmias, finally leading to 
increased symptoms and death (31).
1.1.5. Classification
Patients were traditionally classified on the basis of their symptoms according to the 
revised classification of the New York Heart Association (NYHA). This classification 
stages the exercise tolerance (ET) of patients into 4 groups (NYHA I-IV).
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NYHA I: cardiac diseases without physical limitation. Daily activities due not cause 
inadequate exhaustion, dyspnoea, arrhythmias or angina.
NYHAII: cardiac disease leading to mild limitation of ET. No rest symptoms but 
normal daily activity causes exhaustion, arrhythmias, dyspnoe or angina pectoris. 
NYHA III: cardiac disease with marked limitation in ET. No symptoms at rest but 
minimal daily activities can cause exhaustion, arrhythmias, dyspnoea, or angina 
pectoris.
NYHAJV: cardiac disease leading to symptoms at any level of exercise and at rest.
As heart failure is (at least in theory) a largely preventable disease, primarily through 
the control of blood pressure and other cardiovascular risk factors, the new guidelines 
of the American College of Cardiology and the American Heart Association (37) have 
expanded the classification of heart failure now encompassing patients at high risk for 
the development of heart failure, but without any evidence of structural disease. This 
new approach to the classification of heart failure emphasises its evolution and 
progression, and defined four stages: A-D.
Stage A: high risk without structural heart disease and no symptoms.
Stage B: structural heart disease, no symptoms.
Stage C: structural heart disease, previous or current symptoms.
Stage D: refractory sumptoms requiring special interventions.
This new staged classification and treatment options for systolic heart failure are 
summarised in Figure 1.1.5.
It remains to be seen if this newer classification will be universally accepted, 
clinically implemented and used in future heart failure trials. The usefulness of this
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approach is likely to lie in the extension, and combination with, rather than the 
replacement of the traditional NYHA classification.
Figure 1.1.5.
StageA 
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ACE inhibitors and beU blockers in all patients 
Act inhibitors or ARBs in aH patients,* beU blockers in selected patients
Treat hypertension, diabetes, dyslipidemia; ACE inhibitors or ARBs in som e patients 
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Patients with stage C heart failure have evidence of structural heart disease and a 
history of previous or ongoing symptoms, which can be classified as NYHA class I, 
II, III, or IV. (From Medical Progress - Heart Failure. In NEJM 2003;348:2007-18. 
With kind permission of the Massachusetts Medical Society).
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7.2. Venous Physiology
1.2.1. Introduction
Many cardiovascular drugs act predominantly on the peripheral circulation and their 
effects on resistance vessels can be relatively easily assessed by relating changes in 
pressure to changes in flow (27;38;39). The venous circulation however serves a 
capacitance function and is better described in terms of pressure/volume (?N ) 
relations (PVR) (40;41).
Vasodilators have long been established as of haemodynamic benefit in the treatment 
of CHF (42-50). They reduce aflerload and hence cardiac work, and can improve 
symptoms (42). However, acute haemodynamic improvements of arterial vasodilators 
fail to provide long-term benefit (51). Indeed, the only vasodilator agents which are 
associated with improved survival are angiotensin-converting enzyme (ACE) 
inhibitors (44;46), angiotensin U (Ang U) receptor antagonists (ATi) (52), and a 
nitrate-hydralazine combination (53), i.e. those which also (and potentially 
predominantly) act on the venous beds (54). This observation illustrates the 
importance of the venous circulation, and the need to gain a greater understanding of 
the role this relatively neglected part of the vasculature plays in the pathophysiology 
of CHF.
1.2.2. Terminology
Because confusion can arise over the terminology used to describe the physical 
characteristics of veins, I include (Table 1.2.2.1.) a short description of the terms used 
in this thesis.
24
Capacitance The tenn capacitance remains poorly defined and is not 
synonymous with venous volume as a smaller amount of 
volume resides within the heart and the arterial tree (Figure 1). 
In general terms it relates the total contained volume of the 
vasculature to a given transmural pressure over at least the 
physiological range of transmural pressures. In this thesis I will 
use, for simplicity, the term venous capacitance synonjmiously 
with venous volume.
Compliance Is a general term describing the change in dimension following 
a change in stress. Translated into venous physiology this means 
that compliance is the ratio of the change in volume (AV) 
resulting from a change in transmural distending pressure (AP), 
or AV/AP. It is the slope of the PVR at a given point of the 
“curve”, see Figure 2. Because venous compliance is very high 
at low pressures, the slope of the venous PVR over the 
physiological pressure range (10 to 40mmHg) is nearly linear.
Unstressed volume The volume of blood in a vessel at zero transmural pressure is 
defined as unstressed volume. It is a virtual volume established 
by extrapolating the linear portion of the PVR to zero 
transmural pressure.
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1.2.3. Importance of venous physiology
The veins and venules return the blood from the microcirculation to the heart. 
However they are far more than simple conduits. Indeed by regulating central blood 
volume and therefore preload, changes in venous tone regulate stroke volume via the 
Frank-Starling mechanism. Almost 80% of blood volume lies in these vessels, 
representing a large capacitance reservoir (41) (see Figure 1.2.3.1.).
Changes in regional venous volume can be mediated via 3 mechanisms. First, 
passively along the PA  ^axis (as illustrated by “A” in Figure 1.2.3.2.), for example if 
venous outflow is obstructed temporarily by pressures between 10-40 mmHg. 
Secondly, by a change in compliance (wiien the veins are not operating on the flat 
portion of the PA^ curve -  see Figure 1.2.3.3.), in which case the slope of the PA  ^
relation is changed, as illustrated by “B”. Thirdly, actively due to primary changes in 
venous tone, as illustrated by “C” (the latter results in a parallel shift of the P?V 
relation).
Veins are thinner-walled than arteries (see Figure 1.2.3.1.) and can therefore expand 
greatly. This explains why veins are much more compliant than arteries at low 
pressures (Figure 1.2.3.3. and Figure 1.2.3.4.). Despite this, there is sufficient smooth 
muscle in the walls of all but the smallest venules to actively modulate venous tone. It 
therefore follows that even small changes in venous tone are capable of translocating 
relatively large amounts of blood to and from the central compartment.
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Figure 1.2.3.1. illustrates the blood volume distribution, pressures within each 
vascular compartment, corresponding lumen diameters and wall thickness. Modified 
from Vascular anatomy. In: Aarson PI and Ward JPT, ed. The Cardiovascular System 
at a Glance. Oxford: Blackwell Science Ltd, 1999: Page 10. With kind permission.
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Figure 1.2.3.2. shows a venous PVR. Venous volume, depicted by the black dot can 
change in 3 ways. “A” illustrates an increase in venous volume along the slope of the 
PA^ relation (dotted line), e.g. when venous outflow is obstructed temporarily over a 
physiological pressure range. “B” illustrates an increase in venous volume following a 
change (here increase) in venous compliance, demonstrated by a changing slope of 
the PVR. “C” illustrates a decrease in venous volume, in absence of a compliance 
change. Parallel-shifls reflect changes in venous tone (up-ward shift = decrease in 
tone, down-ward shift=increase in tone).
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Figure 1.2.3.3. illustrates the venous transmural PVR over a wide range of pressures 
(note venous [transmural] pressure may be negative). The slope of the curve is 
referred to as compliance. Modified from The venous system. In: Aaronson PI and 
Ward JPT, ed. The Cardiovascular System at a Glance. Oxford: Blackwell Science 
Ltd, 1999: Page 46. With kind permission.
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Figure 1.2.3.4. demonstrates parallel shifting arterial an venous pressure-volume 
relationships. The figure illustrates the marked differences in compliance and 
capacitance between the arterial and venous circulation. Taken from Physiology and 
Mechanisms of Disease. Guyton AC, Hall JE. 6^ Edition, WB Saunders Company, 
Philadelphia, 1997, p. 120. With kind permission.
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1.2.4. Varying responses of individual venous beds
Much of the work on the venous system has been undertaken on conduit veins (e.g. 
dorsal hand veins or saphenous veins). Yet these large veins contribute modestly to 
the total blood volume compared with the small veins and venules. Furthermore, it is 
generally unwise to extrapolate findings from one vascular bed to another. Different 
stimuli (neural, humoral, or paracrine) may elicit varying responses in various beds. 
Quantitatively the two most important venous beds are the muscular beds and the 
abdominal compartment (including intestinal, splenic, renal and hepatic beds). Whilst 
the spleen and the splanchnic veins appear to react qualitatively and quantitatively 
similarly to reflex stimuli (55), the hepatic circulation, comprising of two systems, 
behaves differently (in particular in response to atrial natriuretic peptide (ANP) (56)) 
and meaningful assessment requires an invasive approach (57-59). Capacitance 
vessels in skeletal muscle may also behave differently and appears to vary between 
species. For example, some studies found little effects of arterial and cardiopulmonary 
receptors on limb venous capacitance (60) (61) despite marked changes in intestinal 
capacitance (62-66) whilst others found that the carotid sinus reflex had marked 
effects on skeletal muscle capacitance (67), indeed in one study there was a greater 
effect on skeletal muscle versus intestinal capacitance vessels (68). Part of these 
differences may depend on the species studied. Nevertheless part of the constricting 
effect on small muscular veins may be via a humoral effect, due to circulating 
catecholamines, following intense excitation of the vasomotor centre (68;69;69). In 
contrast, in larger veins such as the femoral veins and the vena cava, active changes 
can be elicited easily by the carotid sinus mechanism (70-72). From the response of 
the vessels to electric stimulation of the sympathetic nerves, as an index of changes in 
sympathetic outflow, it appears that a decrease in carotid sinus pressure causes the
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same increase in nerve traffic to the resistance and capacitance vessels of the 
splanchnic region but a greater increase in traffic to the limb resistance vessels 
(68;72;72-74;74). The density of adrenergic innervation of individual blood vessels 
varies widely, partly reflecting their degree of participation in centrally controlled 
responses. The cutaneous veins are densely innervated (75) and respond to a variety 
of stimuli (e.g. cold pressor, limb exercise or deep breathing which can be inhibited 
with alpha blockade, consistent with a neurally mediated mechanism). However, 
cutaneous veins show not only no consistent immediate response to changes in arterial 
baroreceptor activity but changes in sympathetic outflow to cutaneous veins are often 
opposite to those of other capacitance vessels, e.g. stimulation of carotid 
chemoreceptors and muscle metabo- receptors cause reflex constriction in the 
splanchnic circulation whilst dilating cutaneous veins (76). Furthermore, whilst 
thermoregulatory mechanisms are believed to predominate over other inputs in the 
control of venomotor tone at ambient temperatures, during prolonged exercise in the 
heat a cutaneous vasoconstrictor drive superimposes its effect upon a h i^  vasodilator 
drive and thus limits the absolute volume contained in the skin (77-81). The total 
amount of blood contained at a given time within the skin circulation at ambient 
temperatures is believed to be relatively small («3%). However, Fortney at al (82) 
could show that the degree of cutaneous vasoconstriction during exercise in the heat is 
greater after an acute reduction in blood volume than in normovolaemic conditions, 
implying that skin veins are indeed part of a ftmctioning efferent arm of the blood 
pressure regulating mechanism. Tripathi and colleagues (83) provided information 
that this venoconstriction could be due to low pressure baroreceptor unloading.
With a constant input from peripheral receptors of vascular beds with varying 
demands, metabolic states and function, the interaction between the pressor and
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depressor areas will be modulated both by the metabolic conditions in the brain and 
by the activity of higher centres such as the cortex, hypothalamus, and limbic system, 
thus flilfilhng the role of a central integration of all information in order to optimise 
the overall performance of the whole body.
It is clear from the foregoing that an understanding of the regulatory mechanisms 
involved in the control of venous tone is an important aspect of cardiovascular 
physiology. Yet our understanding of normal venous physiology in man is poor. 
Difficulties in developing valid and reliable techniques for assessing venous tone and 
compliance in the human capacitance bed have hampered attempts to gain a greater 
understanding of its precise role in human health and disease. Established techniques 
are available (84-89), but as discussed below, all have limitations when applied to the 
assessment of the capacitance bed. The introduction of “radionuclide 
plethysmography” (RPY) into the research arena more than 20 years ago (90-92) was 
able to overcome some of the limitations of conventional plethysmographic 
techniques and has contributed to a better understanding of human venous physiology 
(93-96) and exercise physiology in health (97) and disease (98-102).
I.2.4.I. A mechanical analogue of the venous capacitance system, or how changes 
in venous tone modulate cardiac preload
Gow suggested that a useful mechanical analogue when considering the reservoir 
function of the venous capacitance bed is that of a spring-loaded plimger in a syringe 
(Figure 1.2.4.1.) (103). The adjusting screw alters the position of the plunger and thus 
the capacity of the reservoir, analogous to alterations in venous tone. The compliance 
of the veins is represented by the stiffness of the spring, which may change when the 
position of the plunger (or tone) changes. In fact, changes in venous capacitance, and
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hence unstressed volume, tend to be dominated by changes in tone. In contrast to the 
arterial bed, such changes in tone are not usuaaly accompanied by significant changes 
in venous compliance (103-105).
It is evident from the plunger model that an increase in tone in the venous capacitance 
bed will reduce volume in the peripheral “reservoir”, displacing this volume into the 
central compartment, and consequently increasing central blood volume and right 
ventricular preload (volume). Initial support for such a theory, that changes in 
capacitance of the venous reservoir, mediated by changes in venous tone, determine 
central blood volume, came from Robinson’s work (106). He found that the cold 
pressor test, which it was assumed would decrease the volume of the capacitance 
veins, significantly increased the cross-sectional area of the conducting veins. More 
conclusive evidence arose from the studies of Smiseth and colleagues (107). They 
investigated the effects of the contrasting vasoactive agents angiotensin and 
nitroprusside on splanchnic blood volume, pericardial pressure, and the left 
ventricular pressure/diameter relationship in healthy dogs. Nitroprusside caused an 
increase in splanchnic blood volume, which was associated with a fall in pericardial 
pressure, left ventricular end diastolic pressure (LVEDP) and LV diameter. 
Angiotensin had exactly the opposite effect. Furthermore, changes in pericardial 
pressure with the two drugs were inversely correlated with changes in splanchnic 
blood volume. Thus tone in the venous capacitance bed regulates central blood 
volume and right ventricular preload, by causing shifts of blood volume between the 
venous capacitance bed and the heart. Further evidence of this is provided by studies 
in (chronic) heart failure.
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Figure 1.2.4.1. A mechanical analogue of the venous capacitance system. The 
adjusting screw alters the position of the plunger and thus the capacity of the 
reservoir, analogues to alterations in venous tone. The compliance of the veins is 
represented by the stiffness of the spring.
Modified from Gow BS. In: Bohr DF, Somlyo AP, Sparks HV Jr, eds. Handbook of 
Physiology. Volume II. American Physiological Society; 1980:353-408.
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1.2.5. How changes in preload may affect cardiac output in health and heart 
failure
As noted above the importance of preload in regulating CO is described by the Frank- 
Starling relationship (Figure 1.2.5.1.). Frank, in 1895 (108) and later Starling, in 1914 
(109), described the relationship between the volume of blood in the ventricles at the 
moment they begin to contract (end-diastolic volume) and the forced contraction 
developed by the ventricle. As left ventricular end-diastolic volume (LVEDV) 
increases, stroke work increases progressively, resulting in an increased CO. 
Starling’s original curve constructed from an isolated heart preparation, described 
both an ascending and descending limb. According to this model, when the 
descending limb is reached, further increments in EDV would cause a decrease in 
stroke work. Conversely, reduction in preload, i.e. LVEDV, would result in an 
increase in cardiac function. However, the degree of LV stretch required to elicit a 
“descending limb” is thought to be considerably greater than that seen in human 
physiology or pathophysiology. However in clinical practice LVEDP (or its indirect 
measure pulmonary capillary wedge pressure (PCWP)) is often used as an index of 
LV preload. Using this measure of “preload” a descending limb of the Starling curve 
is frequently observed in heart failure. This is because increases in LVEDP may be 
accompanied by proportionately greater increases in pericardial pressure and right 
ventricular (RV) end diastolic pressure (RVEDP) resulting in constraint to LV filling 
by the pericardium (pericardial constraint) and the RV (diastolic ventricular 
interaction (DVI)), a reduction in LV and diastolic volume, and a fall in stroke 
volume.
The Frank-Starling relationship has been thought analogous to the length-tension 
relationship of skeletal muscle. Clearly, if an increase in preload is causes an increase
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in stroke work, this must imply that an increase in sarcomere length causes an 
increase in tension. Indeed many authorities define preload as end-diastolic sarcomere 
length rather than end-diastolic volume (110). In skeletal muscle the explanation for 
this lies in the sliding filament theory, in which increased force generation occurs with 
increased sarcomere stretch due to stretching of the thin actin filaments to a 
configuration that allows maximal cross-bridge interaction with thick myosin 
filaments (111). However, there are clear differences in the behaviour between 
skeletal and cardiac muscle and the favoured explanation for the length-tension 
relationship in cardiac muscle is length-dependent activation. As sarcomere length 
increases, there is sensitisation of troponin-C to calcium, resulting in an increase in 
force development (112). Recently attention has focused on the role of titin, a giant 
protein spanning half the sarcomere, in the Frank-Starling phenomenon (113; 114). 
Titin is now believed to be responsible for passive and restoring forces in cardiac 
myofilaments during sarcomere elongation and compression, respectively(l 15-117).
In addition titin has been implicated in the length dependent activation that occurs in 
the stretched sarcomere, during the transition from diastole to systole (115). The 
Frank-Starling relationship thus illustrates clearly how ventricular preload is of vital 
importance in determining CO. It is the venous capacitance system which in turn 
regulates ventricular preload, and therefore critically influences cardiac function.
It is well established that CHF is associated with increased central blood volume 
(118). Similarly the efficacy of nitrate therapy to reduce central blood volume is 
clinically evident and scientifically proven (119-121). However, according to the 
Frank-Starling relationship, an increase in central blood volume and consequently 
ventricular preload should lead to an improvement in stroke work, whereas any 
treatment which reduces central blood volume, would be expected to result in a fall in
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CO. The explanation for this apparent paradox, which underpins the importance of 
venous regulation of ventricular preload in the pathophysiology of CHF, lies in the 
phenomenon of direct DVI, as described above
Cardiac performance is exquisitely sensitive to the state of cardiac filling such that 
stroke volume may change as much as 50% in response to a change in filling pressure 
of as little as 1 cm H2O if buffering reflexes are blocked or exhausted (40).
The importance of active control of the capacitance beds is especially relevant during 
exercise and in disease states when cardiac reserve is limited. For example, in healthy 
subjects upright exercise is associated with a 23% reduction in abdominal blood 
volume (liver 18%, kidney 24%, spleen 46%) and a 30% reduction of leg blood 
volume. This translocation of blood volume to the central compartment is closely 
correlated to oxygen consumption, contributing (via the Frank-Starling mechanism) to 
the increase in CO during exercise (97). Whilst impaired venoconstriction contributes 
to exercise hypotension in some patients with vasovagal syncope (98) and 
hypertrophic cardiomyopathy (99), an exaggerated response may potentially 
contribute to increased left ventricular and diastolic pressure on exercise in heart 
failure.
When acute heart failure is induced in a canine model, there is profound baroreflex 
mediated venoconstriction (due to hypotension) accounting for roughly 80% of the 
increase in LVEDP, the left ventricular dysfunction itself only accounting for 20 % of 
this increase in LVEDP (89;89;122;123). In CHF a rise in LVEDP (due to 
venoconstriction) may result in a fall rather than a rise in stroke volume (124). This is 
due to the aforementioned phenomenon of DVI (89;92; 124-126) in which filling of 
the LV is impeded by external constraint from the right ventricle (RV) and 
pericardium (Figure 1.2.5.2.). The implication is that whilst in most physiological
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situations, venoconstriction may be a compensatory mechanism to maintain stroke 
volume, in pathophysiological situations in which RVEDP and LVEDP are elevated, 
venoconstriction could be deleterious due to a reduction in stroke volume. In general, 
this phenomenon appears to be apparent when LVEDP is greater than approximately 
ISmmHg. This implies not only that ventricular interaction and venous capacitance 
modulate left ventricular preload (89) but also that there is an optimal LVEDP to 
maximize use of the Frank-Starling mechanism (Figure 1.2.5. L).
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Figure 1.2.5.1. Illustrates the Frank-Starling or ventricular function curve with a 
descending limb, implying that there may be an optimal left ventricular end-diastolic 
pressure (between 12-15mmHg) to maximize use of the Frank-Starling mechanism.
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Figure 1.2.5.2. Illustrates the phenomenon of DVI. In health lower negative body 
pressure (LNBP) reduces LV and RV volume. In CHF patients with DVI, LNBP 
reduces RV volume but increases LV volume.
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1.2.6. Venous tone in chronic heart failure
The concept of increased venous tone in CHF was first described over 40 years ago 
by J. Edwin Wood, who assessed venous volume and compliance in the forearm using 
fluid displacement plethysmography (127). He found that venous occlusion resulted 
in a much smaller increment in venous volume in patients with overt heart failure than 
in normal subjects or patients with compensated heart failure i.e. venous compliance 
was reduced in decompensated heart failure. He concluded that this was the first clear 
demonstration of peripheral venoconstriction in human CHF. In fact it is also 
consistent with a shift upwards to the steep portion of the PVR. A multitude of studies 
have since confirmed decreased limb vein distensibility in CHF, which can be 
reversed by either alpha-adrenergic blocking drugs or with appropriate anti-failure 
therapy (75; 128; 129). Elegant demonstrations of the increased tone in the venous 
capacitance bed, and its association with increased ventricular preload, have been 
provided by studies using canine heart failure models. Using a rapid ventricular 
pacing model and classic indicator-dilution methods, Ogilvie and Zborovska-Sluis 
demonstrated that the development of heart failure resulted in a profoimd parallel 
downward shift of the splanchnic venous PVR consistent with venoconstriction (130). 
They documented almost a 50% decrease in unstressed venous volume, with no 
associated change in compliance. Furthermore, central blood volume as a proportion 
of total blood volume increased markedly from 9% to 16%, indicating a shift of blood 
volume into the central compartment. These findings were replicated in a study of 
microembolisation-induced experimental acute ischaemic heart failure (122).
Induction of heart failure was associated with a decrease in the splanchnic unstressed 
vascular volume (U W ). Furthermore, the venodilator drug with the greatest effect on 
U W  had the greatest effect on LVEDP and vice-versa. These observations suggest
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that changes in LVEDP during development of heart failure, and during the 
administration of vasodilator agents, are mediated by the displacement of blood from 
the capacitance veins to the central compartment and from the central compartment to 
the capacitance veins respectively. They are compatible with the hypothesis that 
changes in venous capacitance modulate ventricular preload (89;92;104).
I.2.6.I. Causes of increased venous tone in chronic heart failure
The changes that occur in the regional circulations with CHF depend on a number of 
variables: (A) the stimulus for heart failure; (B) the severity of heart disease; (C) the 
stage of development of heart failure; and (D) the stress placed on the cardiovascular 
system. The development and progression of cHF are heralded by the activation of 
circulating neurohormonal systems that modulate vascular tone. In addition, more 
recent evidence has pointed to the importance of local changes in the peripheral 
vasculature, both structural and functional, which contribute to increased vascular 
tone. Table 1.2.6.1. summarises the causes of increased vascular tone in CHF. 
Although a considerable body of evidence exists to support the contribution of these 
factors to increased arterial tone, the importance of each in underlying the increase in 
venous tone which concerns this thesis is less certain.
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Table I.2.6.I. Causes of increased vascular tone in chronic heart failure
(A) Neurohormonal activation
1) Autonomic dysfimction
Activation o f the SNS
Increased a-adrenergic receptor responsiveness
2) RAAS activation
3) Vasopressin
4) Natriuretic peptide tolerance/resistance
(B) Local Factors
1) Structural alterations (loss of elastin)
Interstitial oedema
Increased sodium content o f vascular wall
2) Endothelins
3) Decreased NO bioavailability
4) Endothelium derived hyperpolarising factor(s) -  reduced activity?
5) Dysfunctional Prostacyclins?
A) Neurohormonal activation
Activation of the sympathetic nervous system
It is well established that SNS activity is increased in CHF (131). This is characterised 
by both increased adrenergic nerve outflow and an increase in circulating 
catecholamines (132; 133). The latter arises due to increased release of noradrenaline
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(NA) from nerve endings and its consequent “spillover” into plasma (134), reduced 
uptake of NA by nerve endings (135), and a reduction in renal excretion of NA (134). 
Furthermore, during comparable levels of exercise, much greater elevations in 
circulating NA occur in CHF patients than in normal subjects (136), presumably 
reflecting greater activation of the SNS during exercise in these patients. Wood first 
suggested that increased adrenergic activity was a cause of increased venous tone in 
CHF (137). He foimd that ganglionic blockade caused an increase in forearm venous 
volume in CHF patients, albeit slight. Zelis later demonstrated a more impressive 
increase in limb venous volume after administration of the a-antagonist 
phentolamine, indicating that circulating catecholamines have an additional effect to 
that mediated by direct adrenergic nerve activity (138). However, Zelis also noted that 
even after a-blockade venous volume remained considerably lower in CHF patients 
than in normal subjects. He therefore concluded that sympathetic activation is not the 
only cause of venoconstriction in heart failure.
Increased a-adrenoceptor responsiveness
There is conflicting evidence as to whether CHF is also characterised by an increase 
in a-adrenoceptor responsiveness. The only evidence that this may contribute to 
increased tone in veins comes from Forster’s demonstration of enhanced 
responsiveness to NA and phenylepinephrine in saphenous vein rings of dogs vsdth 
rapid pacing-induced CHF (139). No human study has yet attempted to corroborate 
this finding.
Activation of the renin-angiotensin system
Activation of the renal renin-angiotensin system occurs initially due to renal 
sympathetic nerve stimulation (140), and as a consequence of diuretic therapy (141). 
Later, renal hypoperfusion directly stimulates renin release. In patients with mild
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symptoms, plasma renin activity is normal at rest but rises on exertion (142). As 
symptoms become progressively more severe and renal perfusion pressure falls, 
plasma renin activity becomes elevated at rest, and the magnitude of the elevation 
parallels the degree of haemodynamic and functional impairment (143). In addition to 
the renal system, renin, angiotensin and ACE have been identified in blood vessels, 
resulting in local production of Ang II (144; 145). Ang II is a potent direct 
vasoconstrictor, but also facilitates the vasoconstrictor actions of the SNS, as well as 
the release of vasopressin (146). In addition, Ang II may contribute to endothelial 
dysfunction by stimulating free radical production via Ang Il-dependent NADPH- 
oxidase (147). In animal models of heart failure, Ang II has been shown to cause 
constriction of capacitance veins with a corresponding shift of blood volume into the 
central compartments (148). In patients with cHF, ACE inhibition results in a fall in 
Ang II levels (at least initially) and an associated reduction in venous tone (149; 150). 
Thus it seems highly likely that activation of the RAAS contributes to 
venoconstriction in CHF.
Vasopressin
Vasopressin has a direct vasoconstrictor effect, but may also mediate vasodilation by 
causing baroreceptor mediated withdrawal of sympathetic activity, and by increasing 
the synthesis and release of NO and vasodilator prostaglandins (151). High plasma 
vasopressin concentrations have been documented in some patients with heart failure, 
its release stimulated by a reduction in CO and ineffective peripheral perfusion 
(152; 153). In those patients in whom vasopressin levels are elevated, use of 
vasopressin antagonists has suggested that it contributes to arterial vasoconstriction 
(154). However, evidence that vasopressin may contribute to venoconstriction in CHF
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is sparse. Indeed it appears to be a far less potent constrictor of veins than arteries 
(148), and therefore is unlikely to play a significant role in increasing venous tone.
Natriuretic peptides
NPs are ontogenetically ancient hormones with vasorelaxant properties. Plasma levels 
are generally increased in patients with heart failure, and correlate with atrial filling 
pressures and disease severity (155-157). In addition to having a direct vasodilator 
effect, ANP inhibits biosynthesis, release and turnover of NA (158; 159), suppresses 
renin formation (157), opposes the systemic vasoconstrictor actions of Ang 11, and 
inhibits both the release and the vasoconstrictor effect of vasopressin (160).
Whilst the vasorelaxant effects of NPs are well documented in the resistance 
vasculature, controversy exists about their effects in the venous system. A number of 
human studies assessing the effects of NPs on human conduit veins such as the dorsal 
hand veins (161; 162) or the saphenous veins (163) have suggested that NPs have very 
little if any effects on these veins. However, ANP infusion consistently reduces 
central venous pressure (CVP), even in nephrectomised animals (164) and in patients 
with heart failure in the absence of significant diuresis or changes in haematocrit 
(165-167). This raises the possibility that ANP regulates regional venous volume by 
modifying venous tone in the small veins and venules. Further support for a 
venodilating role of ANP comes from a study by Roy et al who found that low dose 
infusion of ANP decreased left ventricular end-systolic and end-diastolic volumes in 
the absence of any change in, total peripheral resistance (TPR) or forearm vascular 
resistance. These authors concluded that short-term increases in plasma ANP within 
the physiologic range may primarily affect the venous vascular bed either by 
decreasing vascular volume or by venodilation (168). To date only a single study.
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using an in-vivo trout model, has provided direct evidence that NPs have venodilating 
effects in capacitance vessels (169). The effects of NPs on regulation of regional 
venous volume and tone in health and CHF will be the main focus of this thesis.
(B) Local Factors 
Structural
In CHF, abnormalities in vascular structure may contribute to increased vascular 
resistance at rest and impair the vasodilator response to exercise or hormonal stimuli 
(151). Whereas there is no direct histopathological evidence of altered vascular 
structure in humans with heart failure, physiological evidence suggests that 
(potentially reversible (170)) functional vascular remodeling does occur (171). Zelis 
found that calf venous volume was reduced in CHF patients compared to healthy 
controls, even after maximal venodilation induced by intraarterial injection of sodium 
nitrite (138). He concluded that there are mechanical factors limiting metabolic 
vasodilation. These latter mechanical factors have been called the heart failure 
“stiffness component” and are related to sodium retention and plasma volume 
expansion, which results in an increased vascular sodium content (172) and to 
interstitial oedema (35). In support of a role for salt and water retention in increasing 
vascular tone, it has been shown that administration of diuretics increases the arterial 
vasodilator response of reactive hyperemia (173).
Functional
Over the last 3 decades considerable interest has focused on the role of the 
endothelium in regulating vascular fimction. It has become apparent that the 
endothelium itself is the source and side of action of a multitude of vasoactive 
signalling molecules and peptides. The bioavailability of some of these agents is 
markedly altered in CHF. The role of NO and the endothelium in regulation of venous
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tone (96) and exercise limitation in cHF (174) were investigated by my colleagues 
and predecessors at the WHRJ; Dr Dan Blackman and Dr Angus Nightingale 
respectively. The role of endothelial dysfunction in regulation of vascular control has 
consequently not been the focus of the present work and is reviewed in detail in above 
referenced work and elsewhere (175-177).
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L3, The natriuretic peptide system
13.1, Introduction
Up-regulation of the NPS, most evidently in CHF and hypertension, is not only a 
hallmark of many cardiovascular disease states but also a useful diagnostic tool 
(178; 179), prognosticator (180), and potentially a guide to optimise therapy 
(181; 182). The early recognition of the NPS as a potential target for therapeutic 
intervention was an important driving force behind the concentrated research efforts 
in this field. This enthusiasm has recently been damped by the somewhat 
disappointing results of OVETURE (183), which was at the time the largest ever 
randomised controlled trial (RCT) undertaken in CHF.
13.2. Natriuretic peptide research -  a historic perspective
Historical descriptions of a phenomenon related to the endocrine heart were made 
more than 2000 years ago. Flavius, a Roman historian called the workers diving to 
build the maritime harbour of Caesarea “urinatores”. Due to intra-thoracic pressure 
changes during immersion, the increased diuresis forced these divers to urinate 
frequently.
Thus, the later discovery of the so-called Henry-Gauer-reflex (184) was anticipated 
much earlier. The Henry-Gauer hypothesis postulates that changes in left atrial 
pressure induce changes in the release of arginine vasopressin, which subsequently 
modulates the renal output of fluid (185; 186). However, results of subsequent studies 
indicate that this hypothesis is too simplistic in explaining the complexity of 
extracelular fluid volume control (187-189). The identification of atrial granules, 
using electron microscopy (190) (see plate 1.3.2.1), possibly marks the real start of 
natriuretic peptide research. This publication appeared simultaneously but
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independently from the physiological studies by Henry and Gauer (184) 
demonstrating that diuresis is induced by atrial distension, a phenomenon long known 
and described earlier by Karel Frederick Wenkebach in his work about cardiac 
arrhythmias and their clinical significance (191). Initially progress was slow, but 
following de Bold’s seminal observation (192) that infusion of atrial but not 
ventricular extracts into rats caused copious natriuresis, diuresis and hypotension, 
research gathered momentum and was advanced rapidly by the application of the 
emerging molecular biological methodologies. The bioactive substances causing this 
natriuresis were soon purified and their amino acid sequence identified by several 
researchers. In 1983 Flynn first purified ANP from rat atria to homogeneity and 
produced the first amino acid sequence of the molecule (193). One year later 
Kanagawa and Matsuo reported the complete amino acid sequence of a-human atrial 
natriuretic polypeptide (194), Figure 1.3.2.1. The structure of the prohormone 
revealed that the ANP peptide comprised of the c-terminal 28 amino acids of the 
precursor. It is sometimes written ANP (1-28) and often written ANP (99-126). In 
1984 the m-RNA’s of the cardiac peptides of several species were analysed 
(195;196;196;197;197-199) and the gene structure of human ANP was also identified 
and sequenced (200;201;201;202;202).
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Plate 1.3.2.1. Electromicroscopic ultrastructure of human atrial myoendocrine cells: 
the perinuclear region containing the Golgi apparatus (G) is seen. The Nucleus (N) is 
round and lobated, further myofibrils, lysosomes, and mitochondria are present. The 
secretory granules (SG) are slightly variable in density and size (Reproduced from 
Ref (203) with kind permission from Springer).
51
ANP
Leu
Arg
Arg
MetSer Phe
Ser Asp
Cys
Arg
HOOC GlyGly
AlaLeu
Figure 1.3.2.1. The aminoacid sequence and ringstructure of ANP (99-126) is shown.
1.3.3. Biochemistry and Molecular Biology of Natriuretic Peptides
The natriuretic peptide family consists of several “mature” NPs that share a common 
structural motif, consisting of a 17 amino acid loop formed by an intracellular 
disulphide linkage. Figure 1.3.3.1. Furthermore, some (few) authors also consider the 
amino- terminal cleavage products, arising during processing from the pre- 
prohormones via prohormones to the final mature hormones as essential parts of the 
NP-system (204) (Table 1.3.3.1.). In humans 4 “mature” NPs, ANP, Urodilatin, brain 
natriuretic peptide (BNP) and c-type natriuretic peptide (CNP) have been isolated. A 
further natriuretic peptide, dendroaspis natriuretic peptide (DNP), has been isolated 
from the venom of the green mamba (205) and “DNP-like immuno-reactivity” has 
recently been shown in patients with CHF (206). The significance of these findings is 
currently debated (207) and is the subject of ongoing research (208;209).
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Figure 1.3.3.1. Demonstrates the aminoacid and ringstructure of all four human 
NPs.
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Table 1.3.3.1. "ANP-Family
Mature ANP’s amino-terminal cleavaee oroducts svnthetic “ANP’s”
ANP99-126 LANP (i.e. pro-ANPi.3o)^^ °^^ cANF®"'
ANP95.126 Vessel dilator (i.e. pro-ANPsi^y)^^^^^ Anaritide®*^*’*
(i.e. ANP102-126)
Kaliuretic peptide (i.e. pro-ANP79.9g)^ ^^ °^ Mini-ANP<^"’
L33, L Processing of natriuretic peptides: from gene to peptide
The structure of the ANP gene, in humans located on the long arm of chromosome 1 
(p36.2), is schematically shown in Figure 1.3.3.1.1. The BNP gene is also located on 
chromosome 1 in close proximity to the ANP gene. The ANP and BNP genes both 
comprise 3 exons separated by 2 introns. The CNP gene is located on chromosome 2 
and is comprised of 2 exons and 1 intron.
Exon 1 encodes the signal sequence which is cleaved from the pre-prohormone 
(151aa) in the endoplasmatic reticulum (ER) to form a pro-hormone of 126 amino 
acid residues, which is the storage form of ANP, and the first 16 amino acid residues 
of the pro-hormone. Exon 2 encodes for the majority of the remainder of the pro­
hormone (i.e. aa 17-125 in humans), whereas Exon 3 encodes only for amino acid 126 
(Tyrosine) in humans, and the 3 C-terminal amino acids in rat, mouse, rabbit and cow. 
As noteded above, in humans, ANP is produced from a 151 amino acid pre-pro­
hormone, which after cleavage of a 25 amino acid hydrophobic signal sequence is 
stored in atrial granules, predominantly as pro-hormone 1-126. Figure 1.3.3.1.1. 
shows in schematic form the gene structure and post-translational processing from 
pre-pro ANP to pro-ANP, ANP and Urodilatin. The proteolytic cleavage of pro-ANP 
1-126 occurs normally at Arg98-Ser99 in the C-terminal region during secretion to
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yield mature ANP 99-126. This cleavage step is performed by corin, a cardiac serine 
protease and this protease may therefore be seen as the “pro-ANP-converting 
enzyme” (215;216;216).
Corin does not convert pro-CNP into CNP, the latter conversion step is highly 
dependent on the presence and activity of the endoprotease furin, and furin processed 
CNP has been shown to be biologically active (217).
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Figure 1.3.3.1.1. The ANP gene comprises three exons and two introns. Exon 2 codes 
for the majority of the pro-hormone (i.e. amino acids 17-125 in humans). Note the 
different posttranslational processing of the cardiac and renal peptides from the same 
gene.
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13.3.2. ANP, a cardiac hormone
In the very early stages of ANP research it was speculated that ANP may be stored in 
atrial cardiocytes, but produced elsewhere. This theory was based on the finding of 
axonal NP transport within the brain and the finding that especially in the brain but 
also in peripheral tissue there could be a mismatch between the presence of NPs and 
the presence of their corresponding receptors. However, it soon became clear that 
ANP was produced and stored, not only in the same region but also in identical cells. 
Histological and immunocytochemical studies, as well as in-situ hybridisation 
analysis confirmed expression of the ANP gene in human (218) and ovine fetal heart 
(219). Moreover, whilst ANP (220) and ANP mRNA (221) are present throughout the 
heart in the early embryological stages of development, the ventricular representation 
regresses markedly towards the later developmental phases (221) (for review see Ref. 
(222)). Mature ANP is a 28 amino acid peptide hormone with a molecular weight of 
3080.5 (C127H203N45O39S3). The structural motif is a 17 amino acid loop, formed by an 
intra-molecular disulphide linkage. The amino acid sequence of the ring of the NPs is 
highly conserved within a species (in humans only 6 aa within the ring differ between 
ANP, BNP and CNP) whereas the amino- and carboxy-terminal tail vary markedly. 
Whilst the sequential integrity of the last 4 C-terminal amino acids is important for 
high natriuretic peptide receptor (type A) (NPRa) binding affinity, the additional 
presence of Aspartic acid in position 13 and Phenylalanine in position 26 appears to 
be crucial for activation of guanylate cyclase (GC) and cGMP production following 
receptor binding (223;224). It is noteworthy that there are several reduced-size “mini- 
ANP” available that vary in their affinity to the NPRA-receptor as well as their ability 
to generate cGMP. Furthermore, due to variation in post-translational processing, 
several different “amino-terminal ANP’s” exist (204). The fate and biological activity
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of these cleavage products of the amino-terminal tail, occasionally called “long acting 
ANP” (LANP, i.e. proANP 1-30), “vessel dilator” (i.e. proANP 31-67), and 
“kaliuretic peptide” (i.e. proANP 79-98) is highly controversial. Whilst they were 
previously believed to have little or no biological effects, some evidence suggest that 
they have some natiuretic, kaluretic and vasoactive potency (210), but that the mode 
of action is different from mature ANP (225). For example, kaliuretic peptide and 
LANP are believed to exert their biological action via inhibition of a Na'* -^ATPase 
(226) by increasing prostaglandin E2 (227).
I.3.3.2.I. ANP secretion
Following processing from pre-prohormone to prohormone (the storage form), 
cleavage and secretion of mature ANP is predominantly in response to increased 
transmural atrial pressure or stretch (228), which in an intact physiological organism 
is mainly a consequence of volume expansion. However, several other stimuli are 
capable of inducing ANP release (for review see Ref. (229)). These include 
vasopressin-, adreno-, endothelin-, angiotensin II-, enkephaline- and morphine 
receptor stimulation. Very recent evidence also suggests that endothelin, tumour 
necrosis factor a  (a-TNF) and other cytokines may play a regulatory role in its 
production and release (230;231;23I;232;232;233;233).
1.3.3.3. Urodilatin
Urodilatin is the name given to a naturally occurring paracrine acting ANP 
homologue first reported by Schulz-Kappe in 1988 (234). The amino acid sequence 
reveals that it is an N-terminal extension of ANP (see Figure 1.3.3.1.). It comprises 
residues 95-126 of pro-ANP, and therefore it is very likely that both Urodilatin and
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ANP are derived from a common precursor ANP 1-126. Urodilatin is believed to be a 
kidney derived peptide and immunohistochemical studies identified high 
concentrations in the cortical tubules and around collecting ducts (235-237) 
contrasting with the predominant cortical location of renal ANP binding sites (238). 
Whilst the overall biological actions of Urodilatin closely resemble those of ANP 
(239) it is beheved that Urodilatin is more important than ANP in regulating renal 
sodium excretion (240-242). Like ANP, Urodilatin is cleared by the C-type receptor, 
but in contrast is not degraded by neutral endopeptidase 24.11. (243).
1.33.4. BNP
B-type or BNP was first isolated from pig brain as either a 26 or a 32 aminocid 
peptide (244;245). Human BNP was isolated in 1989 and found to comprise of 32 
residues, consisting of amino acids 77-108 of the BNP precursor peptide. Whilst these 
peptides, derived from the C-terminus of the pro-BNP molecule, show great similarity 
to the structure of ANP it is noteworthy, that in contrast to ANP, the amino-acid 
sequence of BNP exhibits marked inter-species variation. The same is true for the pro­
hormones. Furthermore, the post-translational processing of BNP appears to differ 
from ANP, in that conversion of BNP precursors occurs intra-cellularly rather than 
during secretion. BNP binds to the same receptors as ANP (see Figure 1.3.3.1.) and is 
believed to exert its biological actions, namely natriuresis, diuresis and vasorelaxation 
via the GC coupled NPRA-receptor. BNP is predominantly synthesised in the 
ventricles and when tissue weight is taken into accoimt, the total content of BNP 
mRNA is approximately 3-fold greater in the ventricles than in the atria. In marked 
contrast ANP mRNA content in the ventricle is only 7% of that in the atria (246). 
Interestingly, whilst 60% of circulating BNP is ventricular in origin the mature BNP
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tissue concentration in the ventricle is only 1% of that in the atria. This observation of 
a large amount of production and secretion but a small amount of storage of BNP in 
the ventricles (in health) is consistent with the previous finding that ventricular 
cardiocytes secrete ANP more rapidly after its synthesis via the constitutive pathway 
than atrial myocytes (247). Due to the greater augmentation of gene expression, the 
more sustained production and secretion process, and the longer plasma half-life,
BNP has certain practical advantages as a diagnostic tool over ANP. In disease states 
that cause hypertrophy, myocardial necrosis or heart failure there is greater induction 
and more rapid turnover of BNP mRNA and a much greater increase in circulating 
levels over basal levels compared to ANP (248). For these reasons it has been 
suggested that BNP may act as an evolutionarily younger ANP support peptide 
against ventricular FfV overload, compensating for an insufficient ANP-NPRa 
system. However, this theory is not completely supported by evidence from knockout 
mouse models where interruption of the ANP-NPRa system was not consistently 
accompanied by up-regulation of BNP production. BNP appears slightly less potent in 
generating cGMP in human arterial and venous tissue than ANP (249), has similar 
potency in endothelin pre-constricted conductance and resistance coronary arteries 
(250), but has been shown to have less powerful local vasorelaxant effects in the 
resistance vasculature of the human forearm in health (251;252;252), whilst it was 
found to be roughly equipotent to ANP in the forearm resistance vasculature in CHF 
patients (252). Hunt et al studied the biological effects of ANP and BNP infusions in 
normal subjects (253). Equimolar infusions caused a similar rise in ANP and BNP 
levels. Whilst the increase in cGMP was 4 fold higher with ANP than with BNP, 
natriuresis, contraction in plasma volume and inhibition of plasma aldosterone were 
comparable. Interestingly, whilst the pressor response to Ang II was unaffected by
60
ANP or BNP, ANP but not BNP significantly inhibited the plasma aldosterone 
response to Ang II (253). In a series of experiments the same group further 
investigated the interactions between several NPs in health (254;255) and disease 
(256),(257), (258). They found similar interactions between ANP-BNP and BNP- 
ANP infusions with regard to metabolic clearance rate and disappearance rate from 
plasma (in health) suggesting that additive effects in regard to cGMP stimulation and 
blood pressure lowering effects resulted from dissociation of pre-bound hormones, 
presumably from biological or clearance receptors. Intriguingly, no additive effect on 
the RAAS and SNS (heart rate (HR) and plasma catecholamines) was seen at the 
infused doses (leading to low pathophysiological concentrations) (254;255). In a 
study in mildly hypertensive subjects, both peptides (given intravenously) suppressed 
the RAAS to a similar degree (258), whilst in another study intra-renal BNP infusion 
did not induce changes in renal blood flow, secretion of active renin, or creatinine 
extraction (259).
Interestingly, a very recent study using a canine model of pacing induced heart failure 
showed that BNP infusion improved central hemodjmamics whilst there was 
resistance to the effects of ANP. The authors speculated that these findings would 
support the existence of a so far undetected BNP-selective NP receptor (260). Support 
for such a theory derives from an earlier study by Goy et al (261). Using a NPRa 
knockout mouse model these authors found that testis and adrenal gland retained 
statistically significant, high affinity responses to BNP, which could not be accounted 
for by NPRba:, suggesting the presence of a novel receptor in these tissues that prefers 
BNP over ANP. However, at pharmacological doses the overall hemodynamic profile 
of ANP and BNP, given to patients with CHF, appear to be comparable.
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I.3.3.5. CNP
CNP, originally isolated from porcine brain (262), exists in two mature forms, as 22 
amino acid form CNP-22 (see Figure 1.3.3.1.), highly homologous to ANP but 
lacking the C-terminal tail, and as CNP-53, which N-terminal sequence is extended by 
31 amino acids (263). Unlike ANP and BNP, both of which originate from the heart, 
humoral CNP is believed to be predominantly of endothelial origin. However, highest 
tissue levels in humans are found throughout the brain ( 1 0  times higher than 
concentrations of ANP or BNP), consequently CNP is believed to be a major non- 
conventional neuro-transmitter. Its actions include inhibition of vasopressin and 
ACTH secretion as well as modulating central regulation of blood pressure (264). 
Until recently there was no entirely convincing evidence for CNP-synthesis within the 
heart. Kalra et al (265) found that in patients with CHF the central arterio-venous 
(AV)-gradient for CNP is raised in a NYHA class dependent fashion, indicating a 
cardiac origin and up-regulation of CNP in this condition. Very recently, Horito et al 
could demonstrate that CNP is indeed synthesised in and released from cardiac 
fibroblasts suggesting that CNP has a suppressive effect on fibroblast proliferation 
and extracellular matrix production (266). This assumption would be in keeping with 
the earlier finding by Doyle et al which demonstrated that NPRb receptors in adult rat 
ventricle are predominantly confined to the nonmyocyte population, i.e. cardiac 
fibroblasts (267). Furthermore, findings that specific CNP receptors (NPRb) and CNP 
gene transcripts exists within the vascular wall, the kidney (268), and within the 
central and peripheral nervous system strongly indicate a possible regulatory role for 
CNP in cardiovascular homeostasis (for review see Ref. (269)). However, in contrast 
to ANP and BNP, CNP actions appear to be predominantly autocrine/paracrine rather 
than endocrine. CNP is vasorelaxant in dogs (270) and humans (271) and when tested
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in isolated canine vessels (272), was relatively more potent as a venodilator than 
ANP. Furthermore, in canine arterial vessel preparations there were differential 
responses to ANP and CNP. CNP was more active in saphenous rings and less active 
in renal artery rings (272). Similar findings were reported in the pulmonary 
circulation of newborn lambs were ANP caused greater relaxation of pulmonary 
arteries than veins, and CNP was more potent in relaxing pulmonary veins than 
arteries (273). CNP also possesses coronary vasodilator properties. The mechanisms 
of this vasodilatation appear complex and include at least the particulate GC system 
(in dog coronaries) (274) as well as smooth muscle membrane hyperpolarization 
through potassium channel activation (in pig coronaries) (275). In isolated canine 
femoral veins the soluble and particulate GC system as well as activation of large- 
conduction, calcium-activated, potassium channels contribute in mediating 
vasodilatation (276). In human preparations CNP has both veno- and arterial dilator 
actions (161;277;278). In-vitro experiments, using human vascular tissue, showed 
CNP to augmented cGMP production weakly (less than ANP) and equally in human 
saphenous veins, gastroepiploic and internal mammary arteries (279). Intra-arterial 
infiisions of CNP in humans also induced much less arterial dilatation than does ANP 
(278). Importantly, in contrast to ANP (280) the forearm arterial vasodilatation 
following local CNP infusion appears less dependent on endothelial NO synthase 
(eNOS) but at least in large part dependent on hyperpolarisation (271).
Other cardiovascular actions of CNP include inhibition of Ang II stimulated 
endothelin-1 (ET-1) release in porcine endothelial cells (281), where CNP was found 
to be more potent than either ANP or BNP. In addition CNP was found to inhibit 
vascular ACE activity (282). CNP-22 inhibits vascular smooth muscle cell (VSMC) 
growth in tissue culture (283) and inhibits intimal thickening after vascular injuiy
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(284) raising the possibility that CNP may have an important anti-mitogenic role in 
the prevention of atheroma. Taken together these findings support the existence of a 
vascular NPS (285) in which CNP participates as an endothelium derived 
autocrine/paracrine regulator of vascular tone and remodelling.
1.3.4. Natriuretic peptide receptors, intracellular signalling and metabolism
Circulating ANP is rapidly removed from the circulation by two mechanisms. First, 
by binding to the abundantly expressed NPRc receptor (also called the “clearance 
receptor^’), second, via enzymatic degradation through a zinc dependent 
metalloprotease termed neutral-endopeptidase (NEP 24.11). This enzyme was 
previously known as "enkephalinase”, because of its role in morphine and 
enkephaline metabolism. NEP 24.11 is an non-specific enzyme that is also involved in 
the breakdown of a variety of vasoactive peptides including the vasoconstrictors Ang 
II and endothelin-1, as well as several vasodilators including NPs, bradykinin, 
substance-P and adrenomedullin (ADM) (286). In sheep the contribution of each ANP 
eliminating factor is roughly equal (287). In humans the significance of both NP- 
eliminating systems is not well defined but the contribution of NEP is possibly less 
than that of clearance via NPRc binding.
The plasma half-life time of mature ANP is 150-200 seconds and the various amino- 
terminal pro-ANP-cleavage products are believed to have a half life of several 
minutes. In contrast to CNP, where plasma levels appear to be consistently higher in 
venous than arterial blood, ANP has consistently higher arterial than venous levels (at 
a ratio of around 2:1) in all vascular beds so far studied. ANP is believed to exert its 
biological effects predominantly via binding to the NPRA-type or NPRIa- Of all the 
known NPs, ANP exhibits the highest affinity for this receptor, found on the luminal
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surface of endothelial cells and the endothelial surface of VSMCs. The affinity for 
NPRa binding is AN P»BN P»>CN P (Figure 1.3.4.1). The same trend is 
demonstrated with respect to cyclic GMP production following ligand-receptor 
binding. Whilst ANP appears to be the natural ligand for the NPRa, CNP is the 
natural ligand for the NPRb. So far no natural/primary BNP receptor has been found. 
Whilst the acute haemodynamic effects of BNP are weaker, its secretion process is 
more sustainable than that of ANP. The structure of NPRa and NPRb bear close 
resemblance whilst NPRc differs (Figure 1.3.4.1 .). NPRa+b are membrane bound GC 
coupled receptors with a molecular mass of 130-180 kDa (288-291). The structure 
and roles of these GC-receptors in blood pressure regulation, cardiac and renal 
physiology have recently been reviewed in detail (292). NPRc, a homodimer of 64- 
6 6  kDa (293), is lacking a GC domain but contains a 39 amino acid intracellular tail 
that contains a G-protein activating sequence. It appears to mediate signal 
transduction (for review see Ref. (294)) either through inhibition of adenyl cyclase 
(possibly via Gi-2) (295-300) or activation of phospholipase C (possibly via the Py- 
subunit of Gil and Gi2) (294;301). Following receptor-ligand (ANP/BNP/CNP to 
NPRa+b) binding there is activation of the GC subunit. This in turn appears to be 
regulated by the attached protein kinase homology region, because if deleted, ligand 
binding and GC activity are uncoupled from each other (302). Increased intracellular 
cGMP levels alter the conductivity of several ion channels and ultimately result in 
VSMC relaxation. Furthermore, ANP is believed to affect metabolism of 
phosphatidyl-inositol biphosphate to IP3 and diacylglycerol, a recognised important 
signal transduction pathway for hormones mobilizing intracellular calcium, in distinct 
partially opposing ways. Resink et al initially observed this process (303) and Hirata 
(304) demonstrated that a truncated ANP analogue (amino acids 103-123), produced
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the same effect, thereby dissociating the action from the NPRa/b receptor. This ANP- 
NPRc mediated stimulation of phospholipase C was observed in quiescent cells. 
Conversely, hormone-stimulated phospholipase C activity was inhibited by either 
ANP or other stimulants of GC activity (305). Whilst stimulation of phospholipase C 
activity by ANP has been observed only in vascular tissue (303) an inhibitory effect 
has been observed in vascular tissue and the kidney (306;307). Although the ultimate 
significance of ANP actions on phospholipase C activity are still not completely 
known it is clear from the aforementioned that the proportional presentation of 
NPRa/b and NPRc within a vascular bed will affect the biological response to ANP 
exposure and may therefore differ in health and disease.
NPR - A NPR - B NPR - C
ANP>BNP>CNP CNP>ANP>BNP ANP>CNP>BNP
ANP BNP CNP
protein-kinase
domain
guanyiatecyclase
domain
GTP cGMPGTP cGMP
Figure 1.3.4.1. Note all 3 receptors have an extracellular ligand-binding domain, as 
well as a transmembrane segment. NPRa and NPRb also contain a protein kinase 
homology region, which appears to exert some regulatory function on the GC domain.
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1.3.5. Physiological aspects in health (ANP)
ANP is an almost ubiquitous hormone which has been detected in mammals, many 
reptiles, some single cell organisms (308) and in several chlorophyll containing 
plants, where it enhances solute flow (309). NP and ANP in particular appear to have 
a regulatory and integrating role in organo- and embryogenesis (2 2 2 ), i.e. they seem 
to play an active role in differentiation and regulation of multiple organ systems, 
including the skeletal- (stimulating osteoclasts and increasing bone-tum-over 
(310;311)), immune defence (312;313;313) (important role in host defence 
(314;315;315), histamine release (316), activation of natural killer cells (317)), 
somatostatin secretion from antrum mucosa (318), reproductive- (testosterone 
production), and the central nervous system where they act as a non-conventional 
neurotransmitter (319;320). Furthermore, ANP lowers intra-occular pressure in both 
normal and glaucomatous patients, unrelated to blood pressure (321;322). The renal 
actions, including a decrease in tubular Na^/H2 0  re-absorption, gave the hormone its 
name.
U .5.1. Cardiovascular effects
Its cardiac actions appear to be “NO-equivalent”, including increased lusitropy 
(323;324) and facilitation of vagal effects. As far as integration of the cardiovascular 
system is concerned, ANP is well established in its role as a hormonal regulator of 
blood pressure, sodium- and fluid homeostasis (325-327). Recent research has 
highlighted its anti-proliferative potency (328-333), a property shared by BNP and 
CNP (334-336), emphasising a potentially important role in cardiovascular 
remodelling. In CHF the NPS appears to be the body’s endogenous defence against 
the deleterious effects of a chronically activated RAAS (337-340). The vasorelaxant
67
effects of ANP, (BNP and CNP) on resistance vessels are well documented in vitro 
(341) and in vivo (161;251;342;343) and it was initially believed that this effect 
explained the rapid fall of blood pressure (BP) following intravenous ANP infusion 
(see Figure 1.3.5.1.). However, several animal studies (344;345) showed that the fall 
in BP and CO was almost invariably associated with a fall in CVP and in fact 
occurred despite an increase in TPR. Groban (346) demonstrated in humans that low 
dose systemic ANP infusion reduced CVP without affecting BP and Roy et al showed 
that low dose short term ANP infusion reduced left ventricular end-systolic and end- 
diastolic volume in the absence of evidence for arterial vasodilatation (no decrease in 
diastolic pressure, TPR, or forearm vascular resistance) (168). It is now generally 
accepted that the fall in CO/BP following systemic infusion of ANP is a consequence 
of reduced preload and the mechanisms involved may include a) volume contraction 
as a consequence of diuresis and increased capillary filtration (167;167;258;347) and 
b) direct venodilation (325). Whilst the former is well documented evidence for the 
latter is sparse and ambivalent. Indeed ANP has no effect on dorsal hand veins 
(161;348), and little (349), or no (163) venodilating potency on saphenous veins. 
However, Olson et al [166], using an in-vivo trout model, showed that ANP actively 
regulates venous capacitance (comprised predominantly of the volume of blood 
contained within the small veins and venules).
The development of genetically modified animals that either have augmented NPR 
populations or peptide production, or knockout of either the peptide production or the 
NPRa or NPRc have markedly improved our understanding of the role of NPs in 
cardiovascular control. Discussion of the rapidly expanding literature in this field has 
been done elsewhere (350;351) and is beyond the scope of this thesis. However, the 
most pertinent findings of this research has been summarised in Table 1.3.5.1.
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Finally, genetic targeting approaches to understanding hypertension have highlighted 
that molecular variants of the ANP gene may represent an independent risk factor for 
cerebrovascular accidents in animal models (352) and in humans (353) (for review see 
Refs (354;355)) . Interestingly, some of these genetic variations exert their biological 
effects clearly wdthout altering the amino-acid sequence of the mature ANP(99-126).
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Figure 1.3.5.1. Aspects of cardiovascular natriuretic peptide physiology
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Table 1.3.5.1. Phenotype of genetically modified mice.
Gene Human
chromosomal
location
Principal tissue 
distribution
Phenotype of 
knockout mice
NPRa(22 exons) lq2 1 Vasculature, 
kidneys, adrenal 
glands
Hypertension, 
cardiac- 
hypertrophy + 
dilatation, reduced 
testosterone levels 
and reduced live 
span
NPRb ( 2 2  exons) 9p21 Brain, ciliary body, 
vasculature
Not reported
NPRc 5pl4 Endothelium, 
VSMCs, kidneys, 
lungs, endocrine 
glands
Increased half-life 
of exogenous ANP, 
mild reduction in 
BP, increase in 
urine output and 
bone turnover, 
deafness
ANP (3 exons) lp36.2 Cardiac atria Salt-sensitive
h)q)ertension
BNP (3 exons) lp36 Cardiac ventricles, 
brain
Patchy ventricular 
myocardial fibrosis 
in absence of 
hypertrophy
CNP (2 exons) 2 Brain, endothelium, 
ovary, uterus, testes
Not reported
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1.3.5.2. The need for in vivo studies using ANP receptor antagonism
Whilst in-vitro studies and tissue culture experiments were indispensable in 
identifying cellular and sub-cellular mechanisms in response to ANP, the application 
of this information to and comparison with in vivo studies was often surprisingly 
limited, in fact often contradictory. This is for several reasons; Firstly, in vitro studies 
using vascular tissue were, for experimental and practical reasons, largely confined to 
the use of conduit veins and arteries, yet it is clear that arterial resistance (afterload) 
and venous capacitance (preload) are largely regulated by the small pre- and post­
capillary arterioles and venules respectively. Secondly, in vitro studies are unaffected 
by (do not take account of) the activation of complex counter-regulatory neuro- 
homonal mechanisms such as the baro-reflex and the renin-angiotensin-aldosteron 
system, which needs to be considered for an integrated approach, especially as there is 
ample evidence to suggest that the vasoactive and BP regulating actions of NPs are 
often through inhibiting the secretion or action of other vasoactive hormones (356- 
358). Thirdly, it has become evident that the process of culturing vascular smooth 
muscle cells itself may result in a significant phenotypic shift involving altered 
expression of the natriuretic peptide receptors. Suga et al (359) demonstrated that 
although cultured rat aortic smooth muscle cells express high levels of NPRc receptor 
binding sites and mRNA, receptor expression is reduced markedly in aortic media 
tissue derived from the same animals, in contrast, although cultured cells express low 
levels of NPRa and NPRb receptors, cells derived from aortic media tissue contains 
significantly higher levels of these receptors (359).
71
1.3.5.2.1, A71915 - ANP receptor antagonism
Receptor antagonists have traditionally provided powerful tools for understanding the 
physiological role of ligands. It is informative to recall arguments concerning the true 
functions of the RAAS. It was only when effective chemical inhibitors of the RAAS 
were discovered, e.g. ACE-inhibitors, ATi-receptor antagonists and Aldosterone 
receptor antagonists, that the true nature of the RAAS was appreciated.
Von Geldem et al (360) described a series of ANP analogues capable of interfering 
with ANP-induced cyclic GMP accumulation in bovine tansformed aortic cells. These 
agents were prepared using solid phase techniques on an automated synthesiser. 
Delporte et al (223) used cultured human neuroblastoma cells (NB-OK-1), which 
exclusively express NPRa but not NPRb or NPRc, to evaluate the potency of seven of 
this agents to suppress cGMP production in more details. ANP analogues with a 
shortened Cys7-Cysl8 bridge. Asp 13 and a hydrophobic tetrahydroquinoline-3- 
carboxylate (Tic) residue at position 16 expressed antagonistic activity, while Alal6  
provoked lower antagonistic potency and Phe 16 induced receptor activation. A71915 
([Cys2-Cys 13]H-Arg-Cys-Cha-Gly-Gly-Arg-Met-Asp-Arg-Ile-D-T ic-Arg-Cys-NH2; 
Mwt. 1634.0) emerged as the most potent antagonist with a binding inhibition of; pKi 
= 9.18, and a inhibition of ANP-induced cyclic GMP of; pAi = 9.48. The binding 
affinity of A71915 to NPRa was only 22 lower than that of ANP, and the antagonist 
itself (at a concentration of up to lOpM) had no intrinsic potency to increase cGMP. It 
also appears that selectivity towards the NPRa as opposed to the NPRc, is facilitated 
by the presence of the bulky, hydrophobic Tic residue at position 16 within the Cys^- 
Cys^  ^bridge (223).
Further evidence for NPRa selectivity for A71915 derives from a study by Crook and 
Chang (361). They examined the effects of NPs (ANP, BNP, CNP) on cGMP
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production and ^^^I-labelled-ANP binding to cultured NPE-cells (non-pigmented 
ciliary epithelial cells, believed to be devote of NPRa- but expressing NPRb- and 
NPRc), derived from human ciliary body epithelium, the site of aqueous humour 
production in the eye (ANP [and in rabbits more potent CNP] lowers intraoccular 
pressure in both normal and glaucomatous patients, unrelated to blood pressure 
(321),(362),(322)). In their experiments the fungal product HS-142-1, a non-protein 
antagonist of both NPRa and NPRb inhibited CNP induced cGMP production (via 
NPRb blockade; NPRb is the major GC containing NPR-subtype in choroids plexus, 
pituitary and brain as well as ciliary epithelium (363)). In contrast A71915 did not 
inhibit CNP- or ANP-stimulated cGMP production, which was 10 times greater 
following CNP exposure than ANP exposure (all three NPs bound to binding sites on 
NPE cells with high affinity, which is characteristic of NPRc but not NPRa).
Equally important evidence for functional antagonism derives from further studies. 
Brunner and Woelkert (364) using rat hearts showed that the reduction in coronary 
perfusion pressure (-46% decrease) achieved following ANP (lOnmol/1) infusion was 
diminished by half (-23%decrease; 50% inhibition) by co-infusion of ANP (lOnmol/1) 
and A71915 (0. lpmol/1). Furthermore, they investigated the physiological role of 
endogenous ANP in blood pressure regulation using a conscious mouse model. 
Intraperitoneal injection of A71915 (50 nmol) raised the blood pressure from 
120±3mmHg to a mean of 144±5mmHg within 10-20minutes (p<0.05), followed by a 
decline to baseline within 30 minutes (five measurements). Injection of saline (0.2ml) 
had no effect (121±lmmHg throughout the test). Finally Ni et al (365) using 
anaesthesised Sprague-Dawley rats showed that intrarenal infusion of A71915 
(5pmol/min) effectively inhibited the natriuresis induced by intravenous infusion of 
ANP (Ipmol/min). In contrast A71915 did not inhibit reflex mediated (delta-
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Melanocyte-stimulating-hormone [d-MSH] signalled) natriuresis following acute 
unilateral nephrectomy.
1.3.6. Therapeutic principles and rationale
The NP-system is the main endogenous defence system to counter-regulate the 
deleterious chronic activation of vasopressin, the RAAS and the SNS, found in 
several cardiovascular diseases (340). However, it appears that in advanced disease 
states the beneficial effects of the NPs are masked by the opposing actions of 
increased sympathetic drive, increased circulating and local cytokines, and 
vasoconstricting factors. Thus reversing this imbalance in favour of the NP-system, 
reducing vascular tone, inhibiting cardiovascular remodeling, and decreasing 
neurohumoral activation has been considered a promising therapeutic approach in the 
treatment of essential hypertension and CHF.
Enhancement of the NP-system can principally be achieved via 3 mechanisms:
1) Administration of NPs, peptide analogues or mimetics.
2) Increasing synthesis and release of endogenous NPs.
3) Prolonging life-time and preventing breakdown of endogenous NPs. 
Preventing the breakdown of endogenous NPs appeared to be the most promising 
approach and can generally be achieved either by agents targeted to block the 
clearance receptor or by blocking enzymatic degradation of endogenous NPs via 
blockade of NEP 24.11.
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1.3.6.1. NP-administration:
13.6.1.1. ANP administration
A large number of studies have assessed the efficacy (366-368) and mechanisms of 
action (251) (161;198;346;347;367;369-373) of ANP infusion in health and CHF. 
These studies varied widely in design (acute versus cHF, continuous versus repeated 
infusion etc.) and patient selection. Importantly, some studies used shorter ANP 
analogues (“mini-ANP”) with a reduced biological profile. Not surprisingly, theses 
studies have produced variable results, in particular regarding renal responsiveness 
following ANP administration. Whilst some investigators found little (166;374;375) 
or no (368) effect on sodium and water excretion in patients with CHF, others 
observed marked responsiveness (157). The causes of these discrepancies may be 
attributed to variations in study design. Since Ang II enhances cGMP degradation 
(376) it has been suggested (377) that concomitant ACE-inhibition or ATi-receptor 
blockade may actually enhance the biological effects of NPs, potentially explaining 
preserved renal responsiveness in some of the more recent studies (366). Interestingly, 
ACE-inhibition appears to blunt renal ANP actions in healthy controls (378) whilst it 
was shown to have little effect on ANP induced natriuresis, diuresis and creatinine 
clearance in CHF patients (375). In a more recent study, ATi-receptor blockade, using 
Irbersartan, has been shown to increase ANP levels (15.7% over a 30 day treatment 
period) despite a drop in BP and a decrease in atrial and ventricular diameter (379). 
However, a unifying feature of all the studies using ANP infusion is the almost 
invariable reduction in cardiac filling pressures. Elevating NPs either by infusion 
(167;366), or by augmenting endogenous NPs (367) has been shown to increase 
stroke volume (167) and cardiac index (Cl) (366) in patients with heart failure despite 
a fall in CVP (I67;366;367) a finding apparently in conflict with the Starling
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mechanism. This is almost certainly due to relief of constraint by the stretched 
pericardium (pericardial constraint) and the volume/pressure loaded right ventricle 
(DVI) resulting in an increase in true LV preload despite a fall in LVEDP as 
previously shown by Atherton et al (124) and discussed in chapter 1.2.7. The fact that 
ANP infusion is able to reduce cardiac filling pressures, too early to be solely 
accounted for by a fluid shift into the interstitial space (ANP has been shown to 
reduce cadiac preload in nephrectomised rats to a similar degree as in sham operated 
animals (164)), and in the absence of significant changes in diuresis and pulmonary 
and peripheral vascular resistance, has re-emphasised the potential role of ANP on 
venous tone.
13.6.1.2. Urodilatm
The rationale behind the use of the renal ANP homolog Urodilatin instead of ANP is 
multifold. It has been suggested that urodilatin, rather than ANP, regulates renal 
sodium excretion (240;242), and Urodilatin excretion has been found to be increased 
in CHF (380). Some studies also found Urodilatin to cause a less marked hypotensive 
effect when compared to ANP at equimolar doses (381). Furthermore, there is some 
evidence that exogenously infused Urodilatin interacts with the same receptors as 
ANP but is, presumably due to its amino-terminal extension, almost inert to 
enzymatic degradation by neutral endopeptidase (243). A recent study by Bonatti et al 
(249) assessing the potency of ANP, BNP, CNP and Urodilatin to stimulate cGMP 
production in rings of saphenous veins and internal mammary arteries showed that 
whilst Urodilatin had a slightly weaker overall effect, the ratio of its veno-arterial 
potency was higher than ANP and BNP. This may imply a better tolerability in 
patients with low output failure. Riegger et al (382) offered several arguments for the
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therapeutic role of Urodilatin in CHF. Further studies by Kentsch (383) and Eisner 
(384) also underscored a potential use of Urodilatin in CHF. In their studies 
Urodialtin improved Cl and stroke volume. Urodilatin was infused intravenously for 
10 hours at a dose of 15ng/kg per minute in 12 patients suffering from CHF 
(classified NYHAII/III). In this randomised double-blind, placebo-controlled trial 
(384), Urodilatin was shown to significantly decrease systolic blood pressure and 
CVP. However, diastolic blood pressure and HR were unaffected. No relevant side 
effects were observed, showing hat Urodilatin was well tolerated in this prolonged 
infusion. So far, clinical phase I and II studies using Urodilatin in the treatment of 
CHF, renal failure and bronchial asthma have been performed (for review of these 
studies see ref (385-387). The renal Urodilatin system, its implications and indications 
have been reviewed elsewhere (388).
I.3.6.I.3. BNP
Intravenous infusion of Nesiritide, a human recombinant B-type natriuretic peptide, 
has been investigated in more than 1700 patients with acute decompensated heart 
failure (389), and as such is the chnically most advanced NP in the drug development 
process. Indeed, it is the first new parental agent (Natrecor^’^ ) to be approved by the 
FDA for treating heart failure in more than a decade (390). Nesiritide causes rapid, 
dose-dependent vasodilatation that is sustained for the duration of treatment and it 
appears to have balanced arterial and venous effects as evidenced by decreases in 
systemic vascular resistance (SYR), systemic arterial pressure, and mean pulmonary 
arterial pressure (PAP) (391;392). Vasodilatation occurs without a change in HR and 
is associated with increased stroke volume index (SVI) and Cl (393). A recent 
landmark study investigated the clinical use of Nesiritide in patients with 
decompensated CHF (394). The study enrolled patients in either an efficacy trial
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(n=127, double blind parallel group design) or a comparative trial (n=305, open label 
parallel group, 7 day follow up). Nesiritide infusion significantly reduced pulmonary 
capillary ewdge pressure (PCWP), dyspnoea and fatigue and improved global clinical 
status in the efficacy trial at 6  hours. The improvements in global clinical status, 
dyspnoea and fatigue were sustained with Nesiritide treatment for up to 7 days in the 
comparative arm and were similar to those seen with standard intravenous therapy. A 
healthcare cost analysis in 261 patients with CHF from an open-label randomised 
study comparing Nesiritide versus standard care suggested that treatment of 
decompensated CHF using Nesiritide instead of dobutamine may reduce readntission 
rate, healthcare costs and mortality (391). The latter is most likely attributable to the 
better safety profile of Nesiritide which in contrast to the pro-arrhythmic and 
chronotropic effects of dobutamine actually reduces ventricular ectopy or has a 
neutral effect (395;396).
Similar to the use of ANP, reports about the renal effects of BNP in heart failure are 
also variable. Whilst Marcus et al (397) and Yoshimura and co-workers (398) found 
that Nesiritide or BNP respectively increased natriuresis and diuresis, Abraham 
reported that the magnitude of this response seemed to be blunted in 6  out of 10  
patients (399).
Despite impressive haemodynamic and neurohormonal responses, that are generally 
very similar for the use of varying NPs, some caveats remain; the short biological 
half-life, the need for parenteral administration and the high production costs are 
likely to limit the widespread use of NPs in the foreseeable future, at least in public 
healthcare systems such as the NHS.
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I.3.6.2. Vasopeptidase inhibition
Vasopeptidase (VP) - inhibitors are a class of drugs including Omapatrilat (OMA), 
Samapatrilat and Fasidotrilat, that simultaneously inhibit both ACE and neutral 
endopeptidase 24.11 (NEP 24.11) (for review see Ref. (400-402). NEP is a widely 
distributed ectodermal enzyme, present not only in endothelial cells, but also in 
cardiac myocytes, fibroblasts, smooth muscle cells, adrenal glands, brain-, lung-, and 
renal tissue. Because NEP is involved in the breakdown of both, vasodilators as well 
as vasoconstrictors, the balance of effects of NEP inhibition on TPR will depend on 
whether the predominant substrate degraded consists of vasoconstrictors or 
vasodilators (400). This may vary between vascular beds and may be more dependent 
on tissue levels than on circulating plasma levels of these vasoactive substances. For 
example, in the human forearm, NEP inhibition using Candoxatrilat caused resistance 
vessel constriction (400). Furthermore, the vascular responsiveness to NEP-inhibition 
may differ in the pulmonary and peripheral circulation independent or over and above 
the degradation ratio between vasoconstrictors and vasodilators. In CHF NEP- 
inhibition reduces PCWP without significantly affecting aflerload (400). Inhibition of 
breakdown of endogenous vasoconstrictor peptides (i.e. Ang II and ET-1) can, at least 
partly, offset the benefitial effect of NP augmentation. Therefore, combined inhibition 
of ACE activity to reduce Ang II and of NEP to enhance endogenous NP should 
theoretically provide additional benefits compared to mono therapy. Some promising 
small-animal experiments showed improved haemodynamics following VP-inhibition 
(VPI) over and above that of selective ACE-inhibition or NEP-inhibition (403-406). 
Similar findings have recently been reported in large-animal models of experimental 
CHF. Chen et al compared VPI with OMA and acute ACE-inhibition with 
Fosinoprilat in a canine model of pacing induced mild heart failure (407). Using
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intrarenal administration of a NP receptor blocker they demonstrated that the 
beneficial renal effects of OMA were mediated via augmentation of endogenous NP. 
The same group recently extended these findings, comparing the effects of OMA, 
with and without a diuretic, with those of ACE-inhibition plus a diuretic (ACI-I + D) 
in the same animal model of CHF. Again OMA, with or without a diuretic, resulted in 
a more favorable cardiorenal and humoral response than ACI-I + D. OMA given 
alone did not cause activation of the RAAS (408) (for review see Ref (409)). 
Administration of NEP inhibitors has also been shown to reduce bradykinin 
breakdown (4I0;411). Since bradykinin is also a substrate for ACE, inhibition of both 
ACE and NEP is likely to lead to an even greater enhancement of endogenous 
bradykinin activity (412). Whilst bradykinin clearly mediates some of the beneficial 
vascular effects of ACE- and NEP- inhibition, these benefical effects need to be 
weighed against the potential for an increased side-effect profile (including 
angioedema) arising from dual blockade of bradykinin breakdown during VPI (for 
review see Ref. (413)). However, angioedema seems to be a lesser problem in the 
treatment of CHF compared to hypertension.
Early human studies in advanced CHF were promising. In a study by McClean and 
co-workers in 48 patients 3 months treatment with OMA improved cardiac function 
and in turn clinical status (414). In a study comparing the effects of 40mg OMA 
against 20mg Lisinopril on ET in 573 patients with NYHA II-IV treatment with OMA 
lead to a better clinical status and lower incidence of combined mortality and 
morbidity (admission and discontinuation of study treatment for worsening heart 
failure), whilst there was no significant difference in ET, the pre-specified primary 
endpoint. Both agents increased ET to a similar degree (415). A further multicentre 
study, enrolling 369 patients with symptomatic heart failure evaluated the
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haemodynamic and neurohormonal effects, safety and tolerability of increasing doses 
of OMA after a single oral dose and after 12 weeks of once-daily oral therapy (416). 
Higher doses were associated with greater increases in vasodilatation and NPs, in 
addition to ACE inhibition. Furthermore, higher doses (20mg and 40mg) showed 
greater falls from baseline in PCWP and systolic BP than 2.5mg, whilst the incidence 
of adverse experiences and patient withdrawal were similar in all groups. First 
presentation of the only adequately powered mortality/morbidity trial (OVERTURE) 
at the American College of Cardiology in March 2002 received little enthusiasm 
(417). The results indicated a non-significant reduction of 6 % in the primary 
combined endpoint of all-cause death and cardiovascular hospitalisations with OMA 
versus ACE inhibition alone, making the drug equivalent, but not superior to ACE 
inhibitor treatment alone. Following a re-evaluation, using criteria for non-inferiority, 
based on the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial (46), 
the final publication of OVERTURE, however suggested a significant (HR of 0.89, 
p=0.012) incremental benefit on cardiovascular events with OMA of around 10% 
(183). It has been argued that in patients with advanced CHF (and a systolic BP < 110 
mmHg) the BP lowering effect of OMA may partly outweigh the beneficial 
neurohormonal effects. Consequently it has been suggested that VPI may be most 
beneficial in early heart failure when NPs are activated in the absence of significant 
RAAS activation (402). It remains to be investigated whether VPI can delay disease 
progression from (relatively) asymptomatic to symptomatic forms of heart failure.
I.3.6.3. Combined NP administration and NEP- / VP- inhibition 
Very recent work from the Christchurch Cardioendocrine Research Group and the 
Mayo Clinic has attempted to further augment the NP system in animal models of 
heart failure by combining inhibition of endogenous NP breakdown and exogenous
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NP administration, a concept first investigated by Seymour and colleagues (418;419). 
Rademaker et al (420) evaluated the combination of a 3 hour infusion of ADM and an 
endopeptidase inhibitor (SCH32615) in an ovine model of pacing induced CHF.
ADM induced directionally similar but greater changes in all hemodynamic variables 
compared to SCH32615. Coadministration of ADM and SCH32615 produced 
hemodynamic effects greater than those achieved during ADM infusion alone. The 
authors concluded that cotreatment with ADM and an endopeptidase inhibitor has 
beneficial renal and hemodynamic effects in heart failure beyond those of either agent 
separately. Chen and coworkers extended their previous studies, using subcutaneous 
administration of BNP (421), by comparing this treatment with VPI (using OMA) and 
with a combination of both treatments in a canine model of pacing induced heart 
failure (422). Similar to the study by Rademaker, combination therapy yielded greater 
renal, humoral and hemodynamic (increase in CO and reduction in filling pressures) 
effects compared to either treatment alone. Whilst these studies are encouraging it 
remains to be seen whether oral VP-inhibition, combined with subcutaneous BNP 
administration, is able to provide longer term benefits in patients with CHF.
1.3.7. Problems and Pitfalls: natriuretic peptide resistance
There is ample evidence of reduced vascular natriuretic peptide responsiveness (NP 
resistance) in CHF (199;423). The mechanisms underlying this NP-resistance are 
potentially complex and are not completely understood. Theoretically, all of the 
following may contribute;
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1.3.7.1. NPRa+b -receptor down-regulation
Decreased ANP binding in a rat model of CHF was reported by Tsunoda (424) in 
1988 and later suggested in humans following the observation that the good 
correlation between the arterio-venous decrease in ANP-levels and the AV-increase in 
cGMP levels seen across the lower hmb of patients with mild CHF, was lost in 
patients with advanced disease stages (425). This, albeit indirect evidence, was 
partially in keeping with an earher study by Hirooka that showed a decreased FBF 
response in CHF patients compared to normal controls following intra-arterial ANP 
infusion (199). However, the reduced hemodynamic response in this study was not 
paralleled by a reduced cGMP production, indeed absolute cGMP levels were higher 
in the CHF group.
1.3.7.2. Fetal gene activation / endogenous P-ANP
One should principally differentiate between the response to endogenous NPs and 
exogenous NPs. Wei et al previously showed that p-ANP, an anti-parallel dimer of a- 
ANP, with diminished cGMP generating potency, is the principal form of circulating 
ANP in patients with severe CHF (426). The fact that following ANP administration 
patients with advanced heart failure consistently exhibit a marked reduction in CVP 
and PCWP may be seen as supportive of the concept that NP-resistance in CHF is 
more likely the consequence of an impaired endogenous ligand rather than receptor 
down-regulation, at least in the capacitance vasculature and pulmonary circulation.
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I.3.7.3. Clearance receptor (NPRc) up-regulation
An additional, potentially alternative concept to explain NP-resistance is that of NPRc 
up-regulation. Matsukawa et al showed that the NPRc locally modulates the 
physiological effects of vascular NP responses (427). A preliminary report suggested 
increased NPRc gene expression in human failing hearts (428). This was supported by 
the finding of up-regulated NPRc expression in platelets of CHF patients (429). 
However, the latter line of evidence is particular controversial because platelets, in 
contrast to VSMC and endothelial cells, only express NPRc and because previous 
investigations have contrastingly reported ANP platelet receptor down-regulation 
(430).
U .7.4. Receptor desensitisation
NPRa-hb are densely phosphorylated transmembranous GC coupled receptors 
(431;432), Figure 1.3.7.4. Ligand binding leads to dephosphorylation which in turn 
appears to lead to desensitisation of the receptor towards the ligand (433;434). This 
mechanism per se could explain reduced vascular responsiveness despite sustained or 
even up-regulated ligand / receptor availability. However the ultimate significance of 
this process has not been determined since rephosphorylation of GC-A has not been 
accomplished.
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ACTIVATION DESENSITIZATION
GTP cGMP GTP cGMP
Figure 1.3.7.4. The receptor exists in a phosphorylated state in absence of ligand; 
when the ligand is bound, the receptor becomes dephosphorylated. Dephosphorylation 
correlates with desensitization of the receptor to its ligand. KHD, kinase homology 
domain; CAT, catalytic domain.
1.3.7.5. Endothelial dysfunction - soluble and particulate GC-crosstalk
There is accumulating evidence of intense cross-talk between both GC pathways 
(soluble and particulate) especially in disease states such as CHF. Hussain et al found 
a cooperative interaction between NO and ANP (435). In their experiments aortas 
from eNOS knockout mice were less sensitive to ANP than aortas from wild type 
animals. The potency of ANP in wild type animals was also decreased after pre­
treatment with inhibitors of either eNOS- or sGC. Wenneberg et al, using the non-
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peptide ANP receptor antagonist HS-142-1, revealed an interaction between NO and 
the NPS by demonstrating that coinhibition with L-NMMA and HS-142-1 
significantly inhibited acetylcholine induced vaso-relaxation in isolated coronaries of 
dogs to a magnitude greater than either inhibitor alone, whilst vasorelaxation to 
acetylcholine was unaffected by pre-incubation with HS-142-1 alone (436). These 
findings are of particular interest because endothelial dysfunction may well (explain 
and) contribute to reduced vascular ANP responsiveness in disease states such as 
hypertension and heart failure. Indeed, it could also explain the marked fall in 
intracardiac diastolic pressures during NP infusion in CHF patients because, as we 
have previously shown, venous endothelial function is preserved in cHF despite 
marked impairment of arterial endothelial function (437). Furthermore, in disease 
states signalling pathway abnormalities downstream from NP-NPR interaction and 
activation of either soluble or particulate GC may also play a role in diminished NP 
responsiveness (438).
1.3.7.6. Neutral endopeptidase up-regulation (NEP24.11)
Altemativelly, increased NEP-activity in CHF could also contribute to reduced NP- 
responsiveness. Indeed, a very recent study found increased NEP activity in kidneys 
of several different models of severe heart failure in the rat (439). For a review on the 
mechanisms of reduced renal ANP responsiveness in heart failure see reference (440).
1.3.7.7. Area of uncertainty; cGMP second messenger of vascular ANP 
actions ?
Whilst it is generally accepted that the renal actions of ANP, comprising of pressure 
diuresis and increased Na"^  excretion, are cGMP mediated, there is some doubt that
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the same is true for vascular ANP responsiveness. Von Geldem et al (360) showed in 
a murine in-vivo model that ANP receptor blockade using A74186 during ANP co­
infusion prevented the increase in cGMP increase which was paralleled by prevention 
of natriuresis and diuresis whilst vascular responsiveness remained unaffected; in 
other words A74186 did not antagonize the hypotensive or vasorelaxant effect of 
ANP. These authors concluded that, although it may mediate the renal responses to 
ANP, cGMP is not responsible for the vascular and hemodynamic effects that result 
from the action of the hormone. Using a multitude of ANP analogues the same 
authors also found that aminoacids Aspartic acid (in position 13) and Phenylalanine 
(in position 26) were important for cGMP production following ligand-receptor 
binding (360;441), whilst they were not essential for ANP-NPRa receptor binding 
(360). Furthermore, a study by Eisner and co-workers (442), using the lipohilic cGMP 
analogue 8-Br-cyclic GMP in a pacing- induced conscious dog heart failure model, 
provided evidence that the renal effects of ANP can be attenuated in CHF whilst 
vascular effects remained preserved. This was seen as in agreement with the 
hypothesis that an intracellular defect beyond cGMP might be involved in the 
phenomenon of NP tolerance/resistance in CHF. However, it could also be seen as 
indirect evidence that the renal and vascular ANP effects are mediated via differing 
pathways. Furthermore, as outlined above there is strong evidence of cross-talk 
between the soluble and particulate GC pathways and this might be of particular 
importance in disease states where one or both of these pathways becomes 
insufficient. It remains to be shown if this cross-talk is a clinically relevant 
compensatory or maladaptive mechanism.
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1.3.7.8. ACE-escape
Finally, the phenomena of aldosterone escape (443) and Ang II reactivation (444), 
sometimes summarised as “ACE-escape” can theoretically contribute to the decreased 
renal and vascular response to ANP in CHF. This is likely due to their ability to 
augment the SNS and interfere and oppose the actions of NPs on several levels. The 
presence of this phenomenon may be seen as evidence of a shifted neurohormonal 
balance following ACE-inhibitor treatment.
Furthermore, escape from the sodium-retaining effects of aldosterone is associated 
with significant increases in the circulatory levels of ANP (445), and failure of “renal 
escape” in patients with hydropic diseases such as cirrhosis (446), but potentially also 
CHF, may be due to the renal resistance to ANP with insufficient increase of urinary 
cGMP excretion, (for summary of mechanisms see reference (440)).
13.8. Conclusion and Perspective
NP-research has come a long way since de Bold’s seminal observations in the early 
80’s. Whilst NP administration in advanced heart failure is effective but expensive, 
and restricted to continuous intravenous use, the first outcome study using VP 
inhibitor in CHF was somewhat inconclusive. Because the NPs oppose RAAS and 
SNS actions, it remains important to further pursue their therapeutic potential in 
cardiovascular disease. The current emphasis in NP-research is in the field of 
molecular biology and genetics. However, in parallel it appears mandatory to gain a 
greater understanding of NP physiology and pathophysiology. In particular to 
improve understanding of venous ANP effects and to investigate the mechanisms 
underlying reduced NP responsiveness in CHF.
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L4, Original Hypotheses
The starting point of the present research work was that we generally thought it 
counterintuitive to believe that a hormone released in response to atrial stretch should 
lack veno-dilatory actions.
Consequently we first hypothesised that, despite the absence of significant effects on 
conduit veins, ANP may modulate regional venous volume by modifying venous tone 
in the small veins and venules (i.e. in the capacitance vasculature).
Furthermore, given the fact that the ANP gene knockout mouse (ANP -/-) (447) is 
hypertensive (20-30mmHg higher BP levels than wild-type animals (448)) I reasoned 
that basal ANP plasma levels are likely to contribute to resting venous (vascular tone).
Also, recent data suggests that ANP vascular effects may be in part endothelium 
dependent (364;435;436). Endothelial dysfunction may therefore, at least partly, be 
responsible for the phenomenon of ANP tolerance/resistance in arteries of CHF 
patients. However, we recently reported preserved endothehal function in the 
capacitance vasculature of CHF patients (437). The possibility therefore existed that 
venous ANP responsiveness was preserved in CHF and potentially due to preserved 
or even up-regulated activity of endothelial NOS activity.
Consequently we hypothesised.
• ANP regulates regional vascular volume by modifying venous tone in the 
small veins and venules.
• Physiological, including basal-, ANP plasma levels exert venodilating actions.
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Whilst there is “arterial tolerance” to the effects of ANP, venous 
responsiveness to ANP is preserved in CHF.
The endothelial NO/cGMP pathway contributes to ANP induced venodilation 
in health and/or CHF.
ANP locally modifies arterial distensibility, as assessed by PWV, via ANP- 
NPRa interaction.
Novel natriuretic peptide (NNP) relaxes rings of rabbit aorta via either NNP- 
NPRa/B/C interaction.
The background and rationale of each of these hypotheses is outlined in more details 
in the relevant chapters.
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CHAPTER 2 -  METHODOLOGY
2. i. History, Applicability and Basic Principle of Radionuclide plethysmography
Imaging of the peripheral blood pool, using labelled albumin (449) or red blood cells
(450), was first used to assess changes in venous volume and tissue fluid 
accumulation in animal experiments in the early 60’s by Ablad et al and Baker et al.
In 1981 Rutlen (90) and Clements (91) independently described the application of 
this technique, termed radionuclide plethysmography (RPY), to study the human 
peripheral circulation. The technique, which despite its name actually does not 
involve a plethysmographic element, combines equilibrium blood pool scintigraphy 
(EBPS) with a standard occlusive technique. In brief: red cells are labelled using a 
modified in-vivo labelling technique, based on the method described by Callahan
(451). Using this technique (details described below) at least 95% of injected isotope 
is bound to red cells, and therefore confined to the intravascular space. It follows that 
radioactive counts are proportional to intravascular volume. Since the vast majority of 
blood in the peripheral circulation is contained within the veins (41), and since veins 
are much more distensible than arteries, changes in counts largely reflect changes in 
venous volume. Following radiolabelling PA  ^relations (PVR) are constructed by 
obstructing venous outflow in a stepwise manner for 1 minute. During each 1-minute 
interval a dynamic image (split into 6 intervals of 10 seconds) of the region of interest 
(ROI) is continuously acquired. The technique allows the assessment of changes in 
venous tone with either local or systemic drug infusion, or physiological stimuli, such 
as lower body negative pressure, carotid stimulation or exercise. A parallel shift of the 
PVR implies a change in venous tone. A change in slope indicates altered compliance. 
The technique was fiirther validated and refined by Manyari, Wang, Tyberg and co­
workers who modified its use and expanded its application to assess splanchnic
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capacitance in animal experiments (92;122;123;161;452) and humans (94) in health 
and disease. This group also demonstrated the suitability and applicability of the 
technique to investigate venous reflex control in health and disease states associated 
with abnormal vasomotor response (453). Our group later expanded this application to 
investigate venous reflex responses in hypertrophic cardiomyopathy (99), post 
myocardial infarction (101), and during dynamic leg exercise (100-102;345;346). We 
have also adapted the technique to assess venous endothelial function in health 
(95;96) and CHF (437) and more recently improved the technique by expressing 
changes in one arm to changes in the contralateral arm, as is convention for 
plethysmographic techniques, to take account of potential systemic changes during 
pharmacological intervention and prolonged experiments.
Whilst some of the earlier studies assessed peripheral counts by means of simple 
scintillation probes, mobile small field of view (SFOV) gamma cameras now permit 
simultaneous imaging of the ROI (see below).
2,2, Practical Methodology
2.2.1. Red cell labeling
Red cells are labelled with ^^Technetium (^^Tc) using a modified in-vivo labelling 
technique (451). The content of one vial of Amerscan^^ Stannous agent (Amersham, 
UK) is dissolved in 6 ml of normal saline to form stannous medronate complex. 
Immediately after solution, 0.03ml/kg/body weight is withdrawn from the vial and 
injected directly into a vein of the non-dominant arm. In the presence of stannous ion 
^ T c  is reduced in the cells and becomes bound to the p-chains of the globin. Twenty 
minutes after injection of the stannous solution 3 ml of blood are withdrawn from an 
antecubital vein into a 10 ml syringe containing 750 MBq of ^ ^Tc pertechnetate
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diluted in 2.5 ml normal saline. The syringe is placed into a lead cylinder and gently 
agitated for 10 minutes to prevent clotting and facilitate binding. The now (ex-vivo) 
labelled blood is re-injected 10 minutes later via a separate butterfly. To further 
minimize the amount of free circulating ^^Tc and to allow complete in-vivo binding 
to occur, scintigrams are not recorded for a further 15 minutes. Using this technique at 
least 95% of the injected radionuclide is bound to red cells, and therefore confined to 
the intravascular space.
2,3, General Protocol
2.3.1. Forearm studies:
In studies using intra-arterial drug infusion antecubital veins of both arms are 
cannulated with 18 gauge indwelling cannulas for baseline blood sampling. After red 
cell labelling (see above), a 27-gauge unmounted steel needle sealed with dental wax 
to an epidural catheter is inserted into the brachial artery of the non-dominant arm 
under sterile conditions. The infused arm is then positioned on the face of a SFOV 
camera equipped with an integrated computer system. During intra-arterial infusion 
studies the non-infused arm may be studied using a second camera to take account of 
systemic vascular changes over time (see plate 2.3.1.1). Twenty to 30 minutes after 
infusion of saline is commenced, two baseline venous PVR are recorded (see below). 
This can be combined with assessment of forearm blood flow (FBF) and forearm 
vascular resistance (see below). Thereafter the infusion of the study drug commences 
at the chosen concentration and an infusion speed of <1 ml/min. Venous dose- 
response curves can than be created by repeating PVR at incremental drug doses. 
Venous-effluent blood samples from both arms can be taken for assessment of plasma 
concentration and for calculation of e.g. second messenger “spillover” at each dose.
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Plate 2.3.1.1. A, B, C illustrate a typical setting of a forearm study. Both forearms rest 
on the surface of a gamma camera collimator. The radial artery and a cubital vein in 
the intervention arm are cannulated.
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2.3.2. Splanchnic/intestinal studies:
A dorsal hand vein or antecubital vein is cannulated with an 18 gauge indwelling 
cannula and adequate baseline blood sampling is performed. The subject is then 
comfortably positioned on a bed in supine position. After red cell labelling both 
gamma cameras are positioned as follows: one gamma camera is positioned above the 
subjects abdomen to record (changes of) venous volume in the intestinal vascular bed 
(see plate 2.3.2.1.). The bladder and the iliac bifurcation are used as landmarks, and 
lead-strips applied to the skin facilitate monitoring of a constant region. The liver, 
spleen and kidneys are excluded from the ROI. A second camera may be positioned to 
monitor the count rate derived from the spleen. This setting can than be combined 
with either systemic drug infusion or physiological stimuli as outlined above.
Constant dynamic monitoring allows assessment of regional vascular volume at 
“baseline transmural pressure” (= Capacity). In order to assess capacitance, this 
setting can be combined with breathing continuous positive pressure in order to create 
PVRs. Subjects are first taught to releix while breathing with various levels of 
continuous airway pressure (CPAP). This procedure can then be combined with 
pharmacological interventions. Subjects are instructed not to move, and care is taken 
to maintain a constant subject -  camera position throughout the experiment. Changing 
the level of CPAP requires between 5-10 seconds. This technique has a coefficient of 
variation for changes in splanchnic vascular volume (S W )  of 2-3% (94)
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Plate 2.3.2.1. Shows an abdominal scintigram. A single splanchnic ROI is drawn clear 
of large conduit vessels (multiple ROIs can be drawn). The liver, spleen, bladder and 
bifurcation serve as landmarks. Lead strips attached to the skin facilitate monitoring 
of a constant region.
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2.4. Data Analysis
Following red cell labelling images are aquired as a dynamic study of 10-second 
frames, either continuously or as a series of 1-minute studies. Regional PVR are 
constructed by increasing venous transmural pressure in a stepwise fashion, either by 
inflation of upper arm cuffs (arm-studies) or by incremental CPAP (splanchnic- 
studies). Following any intervention (e.g. cuff inflation or alteration of CPAP) the 
first 30-second data-set is ignored (upper panel in plate 2.4.1.), to allow regional 
volume to stabilise and only the next 30 second data-set (lower panel in plate 2.4.1.) is 
used for analysis. The images are summed and a ROI is defined on the image (plate 
2.3.2.1 and plate 2.4.2.), obtained during normal saline infusion (baseline). All images 
in the study are viewed with this ROI to confirm that no patient movement has 
occurred during the acquisition. The counts from this ROI for each of the appropriate 
30-second intervals are corrected for physical decay and the count obtained with no 
intervention (baseline) is arbitrarily taken to reflect 100% volume. All subsequent 
readings are expressed as percentage change of this baseline value. These counts, or 
scintigraphic vascular volumes in %-units are plotted on the y-axis against cuffrCPAP 
pressure on the x-axis to form venous PA/^  plots (see Figure 2.4.1.). Linear regression 
is performed for each plot, and a linear model is accepted if the R  ^value is > 0.9. The 
slope of each plot is a measure of venous compliance. Therefore a parallel shift in PA  ^
relation not only reflects a change in venous capacitance, but in the absence of a 
change in compliance is simultaneously indicative of a change in venous tone. A 
parallel up-ward shift reflects a reduction in venous tone whilst a parallel downward 
shift reflects an increase in venous tone. This is exemplified in Figure 1.2.3.2.
Relative capacitance changes following intervention can be grouped and are 
compared to baseline and expressed as “% units” (Figure 2.4.1.).
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Plate 2.4.1. Shows a 1-minute dynamic recording split into 6 intervals of 10 seconds. 
The lower panel (the last 30 seconds after pressure has equalized) is used for analysis.
98
Plate 2.4.2. Demonstrates a ROI drawn over a forearm. It is suggested that the region 
should be drawn just clear of the edge of the arm (to allow for small expansion and 
movements) but inside the edge of the camera field.
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Figure 2.4.1. Illustrates grouped PVRs of a typical dose-response study. A dose 
dependent parallel up-ward shift, indicating increase in venous volume and decrease 
in venous tone, following intra-arterial ANP administration, is shown.
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2,5. Validation
2.5.1. Variability
In his original description of RPY in 1981, Rutlen (90) obtained absolute counts in the 
calf, under resting conditions, over a 30-minute period (n=14). Count rate varied very 
little under resting conditions. Manyari evaluated variability between two control 
measurements of forearm venous volume using the standard error of estimate (5v^), 
computed as the square root of the residual mean square as applied to consecutive 
quantitative radionuclide studies. Variability was 3.11%, which compared favourably 
with variability using strain gauge plethysmography (SGP) of 3.24% (454).
2.5.2. Validation against fluid displacement plethysmography
To determine if changes in intravascular volume obtained by imaging the 
radiolabelled blood pool correlated with changes recorded with a standard 
plethysmographic technique, Rutlen also simultaneously recorded changes following 
cuff occlusion (15 and 30mmHg), before and after GTN, in 9 healthy volunteers. 
Changes obtained in one arm as assessed by RPY were correlated in a linear fashion 
(r=0.71 to r=0.98) with simultaneously obtained changes in the contralateral arm, as 
assessed by water displacement plethysmography before and after these interventions 
(90).
2.5.3. Validation against strain gauge plethysmography
Manyari assessed changes in regional forearm volume in response to sublingual GTN 
and oral Nifedipine in 16 patients with a history of recurrent chest pains who had 
otherwise a low probability of coronary artery disease and no history or evidence of 
heart failure, hypertension, diabetes mellitus or peripheral vascular disease (454). He
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constructed PVR and assessed changes in one arm using RPY and SGP in the 
contralateral arm. Results using the different methods were closely correlated (r=0.91 
to r=0.99). Clements correlated %-changes in count rate and changes in forearm 
volume simultaneously in the same arm in 8 subjects. He also demonstrated a close 
correlation with r-values between 0.95-0.99 (91).
2.6. Issues regarding red cell binding
RPY uses radioactive counts within a ROI to represent venous volume. As binding to 
red cells is not 100% it is likely that a small amount of activity derives from tissue, 
i.e. is extravascular. Poor labelling efficiency will therefore impact on the accuracy of 
the technique and has the theoretical potential to lead to systematic overestimation of 
intravascular volume via extravasate of unbound ^^Tc. Furthermore, if binding varies 
between different subjects results would not be comparable. Therefore it is essential 
that red cell binding is as close to 100% as possible with minimal variation between 
individuals.
Principally there are 3 methods of labeling (455). In vivo technique; stannous (such as 
Amerscan Starmous Agent from Amersham International) is injected intravenously 
followed by ^^Tc pertechnetate injection after approximately 20 minutes. This is the 
simplest technique. However this technique has not only the lowest binding efficacy 
but also a high inter-individual variation. In previous validation studies from our unit 
(96) binding efficacy using this technique was 79.8 ± 16.7% (SEM, n=20). In vitro 
technique: a sample of blood is taken and red cells are separated and incubated first 
with stannous and than with ^ T c  pertechnetate. The cells are washed with saline 
before and after each step to eliminate unbound material. The cells are re-injected into 
the patient with little or no free pertechnetate, approaching a labelling efficacy of
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100%. This technique however is technically difficult and requires a higher level of 
logistic organisation. Modified in vivo technique: this technique (described above) is 
easier to perform and results in high labelling efficacy and little interindividual 
variability. In previous departmental validation studies, performed in healthy 
volunteers, we achieved a mean binding efficacy of 96.8 ± 0.6% (varying from 96- 
98%, n=20) (96). In my own validation studies, performed in patients with CHF, the 
binding efficacy was 94.6±1.7% (see Table 2.6.1.).
To estabhsh the reliability of binding throughout lengthy studies I also assessed 
unbinding from erythrocytes over a 3-hour period (see Table 2.6.2. and Plates 2.6.1. 
and 2.6.2.). I found no significant unbinding over this period (% labelling efficiency 
was determined by the ratio: Ac * 100/Ac+As, where Ac is the activity in the labelled 
cell suspension (middle panel in Plate 2.6.1.) and As is the activity remaining in the 
plasma supernatant -  lower panel in Plate 2.6.1.).
Whilst correction for physical decay is easily performed by a computer program on 
the basis of the tracer half-life (6 hours for technetium) and the study length, 
biological decay (biological decay refers to changes in the coimt rate due to loss of the 
isotope from the erythrocyte or change in haematocrit) may have to be taken into 
account depending on the study setting and nature of the intervention. For example 
when performing exercise studies it is good practice to correct for changes in 
radioactive counts/ml as this may change significantly due to release of erythrocytes 
from the spleen (97) that may escape effective labelling. We previously observed a 
10-12% fall in radioactive counts/ml blood in healthy individuals during maximal 
exercise.
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Table 2.6.1. Red cell labelling efficacy in patients with cHF (ANP study)
Subject number activity in erythrocyte activity in plasma 
cell susoension fc/s) suoematant fc/s)
labelling 
efficacv (%)
1 2754.5 116.75 95.76
2 912.2 28.4 96.89
3 1747 71 95.96
4 849.75 47.75 94.38
5 1227 56.5 95.4
6 1072 98.75 90.79
7 546.25 116.5 78.62
8 1120 18.4 98.31
9 1321 22.4 98.3
10 1450.5 33.8 97.67
11 1622 24.8 98.47
mean 94.59
SD 5.75
SEM 1.73
Table 2.6.2. 3-hour ^^Unbinding-studies ” Red cell labelling efficacy in patients wit)
cHF (ANP study)
Subject number baseline LE 1-hour LE 2-hour LE 3-hour LE
% % % %
1 95.76 95.62 95.6 95.59
2 96.89 96.92 96.61 96.7
3 95.96 96.1 95.8 95.85
4 94.38 95.4 95.5 95.3
5 95.4 95.9 95.7 95.5
6 90.79 92.0 92.7 92.5
7 78.62 82.3 83.8 83.2
8 98.31 97.1 97.3 95.9
9 98.3 97.9 97.6 97.2
10 97.67 97.43 97.4 96.7
mean 94.21 94.67 94.8 94.44
SD 5.91 4.64 4.12 4.15
SEM 1.87 1.47 1.30 1.31
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A)
Plate 2.6.1.a: shows blood samples taken over a 3-hour period (left to right; Baseline, 
30 minutes, 1-hour, 2-hours, 3-hours).
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Acq. # 2
Plate 2.6.l.b. The upper panel shows whole blood-activity (at 1, 2, 3, and 4 hours) the 
middle panel concentrated erythrocyte-activity, and the lower panel the activity in 
plasma. The single ROI between upper and middle panel serves to correct for 
background radiation.
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2.7. Effects o f arterial inflow on venous volume
A  crucial question is whether changes in regional blood volume are influenced by 
changes in arterial inflow. The vast majority of vasoactive drugs affect both arterial 
and venous tone and the possibility exists that changes in venous volume are at least 
in part consequence of the changes in arterial inflow. Whilst an increase in flow might 
be predicted to cause a passive increase in venous volume (along the same PVR) it 
would not be expected to alter venous tone. To investigate this issue, our group (i.e. 
my predecessor Dr D. Blackman) investigated the effect of brachial artery infusion of 
Hydralazine on both FBF and the venous PVR. Hydralazine is a selective arterial 
vasodilator, the peak effect of which is delayed for 30 (to 45) minutes after 
administration (49;161;456). Five healthy subjects had FBF measured by SGP for 30 
minutes following an intra-arterial infusion of SOOpg Hydralazine in 8ml at 1 ml/min. 
Hydralazine caused progressive arterial vasodilatation, with a peak increase in FBF of 
262±102% at 30 minutes, but there was no change in the forearm venous PVR (95). 
Our findings are in keeping with previous studies. Wathan et al (457) compared the 
effects of Hydralazine (10 mg i.v.) and GTN (0.6mg s.l.) using radiolabelled albumin 
and a collimated scintillation probe to assess calf venous volume. Both drugs reduced 
vascular resistance. Whereas GTN increased calf venous volume. Hydralazine did not 
change it. Wang et al (122) compared the effects of systemic Hydralazine, Enalaprilat 
and GTN on the intestinal venous PVR in a canine acute heart failure model. 
Enalaprilat and GTN both induced an upward shift of the PVR (=venodilation) and 
markedly reduced LVEDP, whereas Hydralazine had no effect on the PVR and 
minimal effect on LVEDP. Manyari et al (163;454;458) compared the effects of 
systemic Nifedipine and GTN administration. Both agents reduced BP. GTN caused 
an upward shift in the PVR (=venodilation), but Nifedipine had no effect. Further
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strong, albeit indirect evidence is derived from the observation that leg blood volume 
remains virtually imchanged during a work load increase between 50% to 100% of 
maximal VO2 (97) whilst there is a remarkable increase in blood flow (459). Given 
the fact that RPY is able to detect blood volume changes as little as 5ml (452), these 
data support the view that changes in the venous PVR are largely independent of 
changes in arterial inflow. Measurement of venous tone is therefore valid even when 
arterial inflow is also markedly altered.
2,8, Limitations of Radionuclide plethysmography
Beside the obvious disadvantages of the radiation exposure (roughly 6.4 mSV per 
study), the financial aspects (expensive equipment), the considerable logistic efforts, 
regulatory, ethical and health and safety aspects involved when performing studies 
using radioactive substances, the major disadvantage is the inability to express the 
changes in volume in absolute (volume) units. Thus changes are expressed as a 
percentage of control measurements. Simultaneous measurement of volume changes 
using radionuclide and SGP has the theoretical potential to overcome the latter 
limitation. Whilst invasive assessment of venous pressure is not necessary as there is a 
close relationship between cuff pressure and invasively assessed conduit vein pressure 
(460), the radionuclide technique shares the inheritent limitation of all venous 
occlusion plethysmographic techniques, that the pressure considered to plot venous 
PVR is an “upstream“ pressure and not that of the small veins and venules. However 
the pressure drop between the small veins and venules and the “upstream” veins is in 
most situations minimal. Finally, RPY does not provide a measure of capillary 
filtration. Therefore increased tissue attenuation as a consequence of increased
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capillary filtration can lead, at least theoretically, to underestimation of the 
vasodilating potency of the studied agent.
2.9, Comparison to Available Methods to Assess Venous Function and 
Capacitance
As outlined above measurement of changes in venous capacitance is essential to 
describe venous actions of cardiovascular drugs and key to assessing the importance 
of the venous system in cardiovascular haemostasis. Because the vast majority of 
blood is contained in microscopic vessels, hidden in tissue, blood volume and 
distending pressure are notoriously difficult to assess.
2.9.1. Established techniques
2.9.1.1. Dorsal hand vein technique
The principal method used for in vivo evaluation of human venous tone is the dorsal 
hand vein technique described by Aellig (86-88; 163; 163; 163;345). The diameter of a 
single superficial hand vein is recorded by measuring the linear displacement of a 
lightweight probe resting on the skin over the summit of the vein, when the pressure 
in a congesting cuff placed around the upper arm is lowered from 45 mmHg to 0 
mmHg. Changes in vein diameter following various interventions can be measured in 
order to determine the effects of these interventions on venous tone. However, this 
technique does not quantify intravascular volume, nor does it permit construction of a 
complete PVR. Thus it is not possible to distinguish whether an intervention is 
affecting tone alone, or whether it is causing alterations in compliance, passively 
altering volume, or having a combination of these effects. More importantly this 
technique measures diameter in a superficial conduit vein, and results from such
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studies should not be extrapolated to the small veins and venules (and vice versa) in 
which a much larger proportion of the blood volume lies.
2.9.I.2. Plethysmographic techniques for volume measurement
As outlined and illustrated in a detailed review (see reference (461)) conventional 
venous occlusion plethysmography (VOP) (water displacement or strain gauge) can 
be used to assess changes in “limb venous volume” (84;85;345;462;463) and when 
modifying the protocol accordingly to assess capillary filtration (369) or permeability 
(464) and microvascular monitoring (369;465). Measuring changes of the total 
volume of tissue, by placing the tissue (conventionally the forearm) in a chamber 
(plethysmograph) or measuring circumferential changes of a cross-sectional area of a 
limb (strain gauge) is the classical approach. Whilst this technique can provide a 
highly reproducible and accurate measure of tissue volume (462), several assumptions 
have to be made before concluding that the change in total tissue volume is 
representative of a change in vascular volmne.
2.9.I.2.I. Strain gauge plethysmography (SGP)
SGP measures changes in circumference of a cross-sectional area in a limb. It is based 
on the (usually reliable) assumption that circumferential changes reflect limb volume 
changes. It does not measure intravascular volume alone and assumes that the rate of 
venous pressure rise in the assessed cross-section equals the rate of capacity pressure 
rise, not taking account of varying viscoelastic properties of different veins leading to 
different filling pressures. Measurement of the entire PVR is not possible, nor is it 
possible to be sure that the preparation has returned to the same control volume after 
experimental stimuli (40). Whilst the technique is well validated and reproducible it is
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highly sensitive to limb movements which can lead to error over a prolonged period. 
When assessing vascular compliance using strain gauges, venous outflow is either 
obstructed abruptly or stepwise and the progressive change in volume (producing a 
lengthening of the tube and thus a thinning of the mercury column consequently 
leading to an increase in electrical resistance) is derived from the different sections 
(slopes) of the curve reflecting circumferential extension. After an early (seconds) 
rapid phase of circumferential increase, reflecting the rate of arterial inflow, the slope 
flattens out. This slope reflects a change in forearm volume, believed to be mainly 
caused by venous expansion. This is followed by a final slow steady state increase 
believed to represent interstitial fluid volume accumulation (leakage, lymph, 
secretion, viscoelastic creep). During this latter phase intravascular volume may 
actually start to decrease due to a change in transmural pressure. The difference 
between the asymptotic volume and steady state rate of change and the moment by 
moment changes in volume tend to follow a single exponential pattern between about 
30 seconds and less than 5 minutes after a sudden change in venous pressure (40). In 
other words the difference in volume of the studied limb before and after inflation of 
the occlusion cuff consequently reflects the blood pooled in the limb at the occlusion 
pressure applied. It does not however represent the total blood volume of this 
segment, but only the volume increase from basal volume after the occlusion (87). 
Furthermore the small continued increase in forearm volume following prolonged 
venous occlusion is sometimes used to assess capillary filtration (347;369). Finally, 
there are some caveats to be considered when applying these assumptions; although 
vascular capacitance refers to a static, time independent relation, veins and 
capacitance vessels in particular also elicit some stress relaxation (466;467) and 
delayed compliance (468), the time course of which extends to minutes (467-469).
I l l
The technique of VOP itself however is at its best when limited to relatively short 
time intervals because repeated and/or prolonged obstruction of venous outflow (via 
inflation of upper arm cuff) itself can cause a paradoxical decrease in forearm 
(vascular) volume for reasons outlined below.
2.9.2. Comparing Radionuclide plethysmography and Strain Gauge 
Plethysmography
Whilst PVR and acute changes in venous volume are highly correlated and 
reproducible (91;369;454) using both techniques, detailed analysis shows that they are 
not identical. Clements et al (91) performed a series of simple but elegant experiments 
comparing both techniques. They recorded simultaneous changes in forearm volume 
and forearm counts during sequential 1-minute acquisitions, in which they inflated an 
upper arm cuff (“collecting cufF’) in a stepwise manner, from 0 to 80 mmHg, 
followed by deflation back to 0 mmHg. One-minute equilibration was allowed after 
each pressure change at each 20-mmHg step before measurements were taken. A 
close correlation (r=0.94 to r=0.99) between % changes in count rate and forearm 
volume changes was present in each subject (n=6). However, whereas forearm count 
rates had returned to baseline following final deflation, forearm circumferential 
volume remained slightly elevated, probably due to tissue fluid accumulation. To 
investigate this finding further they obstructed venous outflow for 18 minutes in a 
single subject. After 2 minutes of continuous cuff pressure, forearm circumferential 
volume continued to increase but forearm count rate decreased. Following cuff 
deflation the count rate returned to baseline within 1 minute whilst arm volume 
remained elevated 5 minutes after cuff deflation. In a second experiment they 
occluded arterial inflow using a 2“  ^cuff inflated to 300 mmHg proximal to the
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collecting cuff. Whilst in this setting inflation of the collecting cuff had no effect on 
count rate it produced a sustained upward deflection in the strain gauge measurement, 
most likely due to forearm distortion. Other groups reported a similar inflation artifact 
(470). These findings are in keeping with earlier work by Zelis and coworkes (471) 
showing that “in normal human subjects short term venous congestion and subsequent 
edema fluid accumulation can result in qualitatively similar changes in limb vascular 
dynamics as are shown in heart failure patients”.
Whilst SGP is the gold standard for assessing FBF, in our view the technique is sub- 
optimal to assess venous capacitance when performing prolonged studies, dose 
response studies with cumulative drug infusion, or assessing capacitance effects of 
drugs with marked effects on vascular conductivity, such as natriuretic and other 
vasoactive peptides, which have well documented effects on capillary filtration 
(198;343;347;369). Indeed, VOP previously showed only spurious changes in venous 
vascular volume and tone in health (343) and CHF (423), whilst our own studies (see 
chapter 3 and 4) using RPY demonstrate that ANP has marked effects on venous 
volume and tone in health (472) and CHF (280;473). Also the issue of increased 
vascular permeability must be considered, especially in disease states with established 
increased capillary permeability such as type-1 diabetes (474), CHF or sepsis (464). 
More importantly conventional VOP does not provide a measure of unstressed 
volume or change in unstressed volume. In contrast RPY provides a direct measure of 
intravascular unstressed volume and relative changes in unstressed volume.
2.10, Intravenous pressure versus cu ff pressure
In this thesis cuff pressure is used as a surrogate for the average pressure in the veins 
of the forearm. The use of cuff occlusion pressure has previously been validated
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against directly measured conduit vein pressure and been found to be closely 
correlated (460). Furthermore, Brown et al. (475) argue that rapid cuff inflation can 
cause non-uniform filling of forearm conduit veins (which in their studies was 
exaggerated by increasing flow!), preventing reliable assessment of distensibility 
when relating forearm volume to pressure in a single vein.
2.1L RPY Conclusion and Perspective
Despite some theoretical limitations, SGP is regarded as the gold standard for 
assessment of changes in limb volume and has been used extensively to study human 
limb veins. Importantly, when modifying protocols accordingly, the technique is able 
to assess the effect of vasoactive drugs on capillary permeability. Whilst VOP serves 
a similar purpose as RPY (without the need of complex technology) when assessing 
limb hemodynamics and the effects of local drug infusions, the latter technique has 
the potential to assess (simultaneously) further vascular beds, such as the splanchnic 
and pulmonary circulation, inaccessible to VOP. Furthermore, RPY allows precise 
assessment of right and left ventricular function at baseline and during/following 
physiological (e.g. exercise or lower body negative pressure) and pharmacological 
stimuli. By combining the advantages of EBPS and conventional occlusive 
techniques, RPY has the potential to be used in the complex, acute hemodynamic 
assessment of cardiovascular drugs, a prerequisite for optimising and tailoring 
medical treatment in conditions such cHF, pulmonary and essential hypertension. 
Finally, as a research tool, RPY has the advantage of providing a direct measure of 
changes in unstressed intravascular volume and may be the more suitable technique 
for prolonged studies, and when assessing changes in vascular volume in disease 
states with known increased capillary filtration such as diabetes and heart failure.
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albeit at the cost of not providing a measure of the degree of capillary filtration. The 
latter weakness could be overcome by combining both techniques.
2,12, Animal work
2.12.1. General and historic consideration of the sheep as an experimental 
animal
The sheep’s (ovis aries) place in research, albeit comparatively small, has a long 
tradition. In 1667, Jean Dennis, physician to Luis XTV of France transfixsed a boy 
aged 15 years with blood taken fi-om the carotid artery of a lamb. The boy felt “a great 
heat along his arm”, probably the first description of a transfusion incompatibility 
(476). The first recorded transfusion experiments in England, demonstrated to the 
Members of the Royal Society also in 1667, again used sheep blood (477). In Paris in 
1790, a man whose name became a symbol of the French Revolution, Dr Guillotine, 
perfected his decapitating machine on sheep (478). For reasons that are largely 
historical the standard haemoglobin used for blood agar plates in bacteriology and the 
standard red cells for many immunological tests are from sheep. The large volume of 
sheep endocrine organs available in abattoirs has permitted the isolation of many of 
the sheep hormones in pure form. The sheep is also an animal ideally suited to 
surgical modification for experimentation and instrumentation. Its size is convenient 
and somewhat similar to that of man. This was the reason that many medical device 
manufacturers have in the past often used the sheep as their research animal of choice. 
For example early research into the development of an artificial heart was performed 
in sheep as the thorax of a sheep is large enough to accommodate an artificial heart 
suitable for implantation in a human (479). For each species of animal there are 
aspects of its physiology which are similar to general mammalian physiology and
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aspects that are different. It is these similarities and differences which mainly 
determine if a particular species can be used in experiments as a model for other 
species. Whilst ovis aries and homo sapiens for example differ markedly in their 
digestive system, for most cardiovascular parameters, the sheep is similar to man if 
allowance is made for the smaller weight of the average sheep. Published values for 
most cardiovascular parameters are summarized in Table 2.12.1.1.
Besides the availability and the surgical suitability the sheep was the animal of choice 
for the present work as there is no other mammal, apart from homo sapiens, in which 
the cardiovascular effects of NPs have been equally well characterised, in both health 
(287;480-485) and heart failure (420;486-497). This work has been performed by the 
Christchurch Cardioendocrine Research Group in New Zealand.
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Table 2.12.1.1. Selected ovine cardiovascular parameters
Parameter Range of published values
Heart rate (beats/min) 66 -129
Intrinsic heart rate 120
Maximum hear rate 260-280
Midwall aortic stress (dynes x 10 /^cm^) 6.9
Stroke volume (ml) 44-95
Cardiac output (1/min) B.2-5.5
Cardiac output (ml/min/kg) 115-143
BP systolic (mmHg) 115
BP diastolic (mmHg) 83-111
Peripheral resistance (dynes x m  ^/cm'^) 1840-2726
Arterial baroreceptor sensitivity (msec/mmHg) 29-45
Arteriovenous oxygen difference (ml/lOOml) 5.5
2.12.2. Specific Methodology
The specific methodology of the ovine hind-limb model is described in Chapter 5.2. 
2A3. Organ bath experiments
For isometric tension recordings 2 to 3mm rings of male New Zealand rabbit aorta 
were suspended in organ baths. The response to cummulative concentrations of NNP, 
DNP and ANP was obtained in presence and absence of inhibiting agents in order to 
determine the mechanism of this vasorelaxation. The detailed methodology is 
described in Chapter 6.2.
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Chapter 3 ~ The effects of ANP on venous capacitance in man
3.1. Background/Introduction
ANP plays an important role in cardiovascular control, being a major determinant of 
sodium homeostasis, plasma volume and BP. Although intraarterial infusion of ANP 
produces vasorelaxation of resistance vessels (161;251) this may not be the 
underlying mechanism of the fall in BP that accompanies systemic ANP infusion. 
Animal studies (344;345) have shown that the fall in BP and CO are almost invariably 
associated with a fall in CVP and, in fact, an increase in TPR. Indeed, Groban et al 
(346) demonstrated in humans that low dose systemic infusion of ANP reduced CVP 
without affecting BP. It is now generally accepted that the fall in CO/BP following 
systemic infusion of ANP is a consequence of reduced preload (498). Possible 
mechanisms include: volume contraction as a result of diuresis; increased capillary 
filtration (369); and direct venodilatation, even though no venorelaxant effects of 
ANP were observed in dorsal hand veins (161) and saphenous veins (163). Given that 
atrial stretch is the principal stimulus for ANP release (228), the apparent lack of a 
direct effect on venous tone in man seems counterintuitive. In addition, the 
contribution of basal levels of ANP to human resting vascular function is unknown 
but acceptance of ANP as a physiologically important vasoactive hormone in health 
clearly depends on its contribution being significant.
We hypothesised that, despite its lack of action on conduit veins, ANP may act as a 
venodilator on the small veins and venules that constitute the majority of the 
capacitance vasculature. To study the effect of ANP on vascular function in general 
and venous tone in particular, 4 experiments were performed. In experiment 1 we 
evaluated the effect of incremental doses of intraarterial ANP on forearm vascular 
volume (F W )  and venous tone. In experiment 2 we assessed the contribution of
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basal ANP plasma levels to F W  and venous tone, by intraarterial infusion of the 
NPRA-selective ANP-receptor antagonist A71915. In experiment 3 we further 
explored the specificity and potency of A71915 by measuring FBF during intraarterial 
co-infusion of incremental doses of this receptor antagonist and either ANP or sodium 
nitroprusside (SNP). In experiment 4 we determined whether or not the potential 
effects of basal ANP on vascular volume were specific to the forearm, by assessing 
the effects of intravenous (i.v.) infusion of A71915 on regional vascular volume in the 
physiologically important intestinal bed.
3.2. Methods
3.2.1. Subjects
Four groups of seven healthy volunteers with no history of or evidence for 
cardiovascular disease or other cardiovascular risk factors were studied. Baseline 
characteristics are shown in Table 3.2. None were taking any medication. All had 
normal clinical examination, electrocardiograms (ECGs) and ventricular function as 
assessed by radionuclide ventriculography. All gave written consent. The study was 
approved by the local research ethics committee. Heart rhythm/rate and BP were 
recorded continuously and samples for determination of hematocrit and total protein 
were taken at the beginning and the end of each study.
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TABLE 3.2. Baseline Characteristics of Subject Group
GrouD 1 GrouD 2 GrouD 3 GrouD 4
Age, y (range) 34 (26-48) 50 (27-66) 32 (27-36) 58 (35-79)
Sex, MyF, n 7/0 4/3 7/0 5/2
Body mass index, kg/m^ 24.110.6 25.911.3 24.010.4 26.811.5
Forearm volume, mis 1751172 15801105 1671182 1572198
LV ejection fraction, % 5713 5114 5913 5014
Serum Na^, mmol/1 140.310.6 140.210.8 140.410.6 140.110.7
Urinary N a \ mmol/1 105113 124125 112116 123117
Serum Creatinine, pmol/1 96110 8314 9418 10419
Serum Urea, mmol/1 5.410.9 5.110.2 5.310.7 5.810.4
Heart rate, min'^ 6216 6318 6115 6517
Blood pressure, mmHg
Systolic 12818 13119 12717 13018
Diastolic 7016 7117 6917 7217
Continuous data are presented as meantSEM.
3.2.2. Assessment of venous function
Changes in forearm and intestinal vascular volume (IW ) were assessed by EBPS. 
Combining EBPS with a standard occlusion technique ("RPY"), as described in 
details above (Chapter 2), we also determined forearm venous compliance from which 
venous tone was derived.
Briefly, a dynamic image of the forearm was continuously acquired and a ROI was 
defined (Plate 2.4.2). The count in the ROI, obtained with no occluding pressure, was 
taken as baseline or U W . Forearm pressure volume relationships were then 
constructed by inflating upper arm cuffs for 1 minute to pressures of 10,20 and 30 
mmHg. Scintigraphic vascular volumes were plotted against cuff pressure to form 
venous PVR. Linear regression was performed for each PVR, and a linear model was 
accepted if R  ^>0.9. The slope of each PVR is a measure of venous compliance. A
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parallel upward shift in PVR indicates a decrease in venous tone whilst a parallel 
downward shift indicates an increase. In order to allow presentation of grouped data, 
results are presented as percentages.
3.2.2.I. Experiment 1: effect of intrabrachial ANP on U W  and venous tone 
in the forearm
An antecubital vein in each arm was cannulated with an 18 gauge cannula. After red 
cell labelling with ^^Technetium, a 27 gauge steel needle, sealed with dental wax to a 
16 gauge epidural catheter, was inserted into the brachial artery of the left arm of 7 
volunteers (Group 1) under sterile conditions and kept patent by continuous infusion 
of saline at a rate of 1 .Oml/min. The left arm was positioned on the face of a gamma 
camera (Elscint Apex 215M). The right arm was also placed on a gamma camera 
(ADAC-Transcam) and thus served as a control for the left arm. Thirty minutes after 
needle insertion, two baseline venous PVR were recorded. Thereafter incremental 
ANP (Clinalfa) infusions at concentrations of 0.05pg/ml, O.lpg/ml, 0.5pg/ml, Ipg/ml, 
2.75pg/ml and 5pg/ml commenced, at Iml/minute (in pilot studies doses of lOpg/ml 
had shown to exert systemic effects). At each dose one PVR was performed after a 5- 
minute run-in period. Venous sampling from the infused arm was attempted at 
baseline and before the end of each infusion step for measurement of a) plasma ANP 
concentration (in all subjects) and b) plasmanorepinephrine (499) (in 4 subjects). For 
the former 10 ml of blood was collected in chilled polypropylene tubes containing 
400pl of propylalcohol-conserved aprotinin. Plasma was immediately separated and 
frozen at -70“C. 37 out of a possible 49 samples could be obtained without a visible 
degree of hemolysis. Natriuretic peptide analysis was performed in two assay runs 
and measured by radioimmunoassay as described elsewhere (500). Results from a
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further 4 samples had to be excluded because duplication of results was poor, even on 
repeat testing.
3.2.2.2. Experiment 2: effect of intrabrachial A71915 on U W  and venous 
tone in the forearm
The setup for this experiment was identical to that of experiment 1. Thirty minutes 
after needle insertion, two baseline venous PVR were recorded in a further 7 
volunteers (Group 2). Thereafter incremental A71915 (Clinalfa) infusions at 
concentrations of 0.5pg/ml and Ipg/ml commenced at 1 ml/minute. At each dose one 
PVR was recorded after a 20-minute run-in period. As the binding affinity of A71915 
to the GC-coupled ANP receptor (NPRa) is 22 times lower than that of ANP (223), 
the infused concentrations of A71915 were chosen to produce approximately 50:1 and 
100:1 ratios of A71915 and basal ANP in the venous effluent. The lengths of run-in 
periods in experiments 1 and 2 were chosen to allow a steady state to be reached, 
based on pilot data.
3.2.2.3. Experiment 3: effect of intrabrachial A71915 on ANP/SNP induced 
changes in FBF
In this experiment FBF was recorded simultaneously in both arms by strain-gauge 
VOP as described previously (501). The left brachial artery of 7 volunteers (Group 3) 
was cannulated as beifore and kept patent with a 15-minute infusion of saline. 
Thereafter ANP was infused at 0.1 pg/min followed by coinflision with A71915 at 
0.5pg/min, Ipg/min, 2pg/min and 5pg/min to achieve approximate ANP:A71915 
ratios of 1:5 ,1:10,1:20 and 1:50 in the brachial artery. In order to assess whether the 
inhibitory effect of A71915 on ANP induced vasodilatation was specific or non­
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specific, more than a week later 5 out of the 7 volunteers underwent a second study to 
assess the effects of A71915 (5pg/min) on SNP (Ipg/min) (David Bull Laboratories) 
induced changes in FBF. In all FBF studies measurements were made during the last 
90 seconds of each 6-minute infusion period and the ratio in FBF between arms was 
expressed as "%-change" (AFBF%) from baseline (FBF during saline infusion).
3.2.2.4. Experiment 4: effect of intravenous A71915 on regional IW
Measurement of regional I W  was performed in all 7 volunteers (Group 2) from 
experiment 2, over 90 minutes after completion of their forearm study, plus an 
additional 7 volunteers (Group 4) who acted as "time controls" but did not receive 
A71915. Volunteers were positioned supine on a bed. The gamma camera (ADAC- 
Transcam) was positioned approximately 2 cm above each volunteer's anterior 
abdominal wall. The bladder, the lower edge of the liver and the bifurcation were used 
as landmarks. Lead strips attached to the skin facilitated the monitoring of a constant 
ROI (Plate 2.3.2.1.). Volunteers were instructed to breathe regularly and not to move. 
A constant patient-camera position was maintained throughout. At baseline 5ml of 
saline were injected intravenously followed by an infusion at Iml/minute, during 
which a 200 second scintigram was recorded. The 7 subjects of Group 2 were then 
injected with 5pg A71915 in 5ml saline followed by an infusion of A71915 at Ipg in 
Iml/minute, during which another 200 second scintigram was recorded. The 7 time 
control volunteers underwent the same protocol but received only saline. Since the 
count from a region is directly proportional to the quantity of blood in that region, 
changes in count rate (corrected for physical decay) are proportional to changes in 
regional vascular volume.
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3.3, Statistics
Data are expressed as mean +/- SEM. In experiment 1 and 2 the effects of ANP and 
A71915 on F W  in the infused arm were assessed by 2-way analysis of variance 
(ANOVA) with post-hoc comparison to baseline. A value of p<0.05 was considered 
significant. Original data (counts/sec) were analysed when assessing drug effects. 
Conversion to percentage was then undertaken to allow presentation of grouped data. 
When additionally presenting “corrected data” in experiment 2, changes in the infused 
arm (venoconstriction) were first corrected for systemically occurring 
venoconstriction and converted into percentage before assessed by 2-way ANOVA as 
above. In experiments 3 changes in FBF were assessed either by 2-way ANOVA 
(ANP dose-ranging studies)) or the non-parametric Wilcoxon test (SNP) as 
appropriate. In experiment 4 regional I W  was analysed by unpaired t test.
A non-parametric Mann-Whitney test was used to compare changes in plasma 
norepinephrine.
3.4, Results
3.4.1. Subject characteristics
Grouped baseline characteristics are shown in Table 3.2. There were no significant 
changes in BP, HR, haematocrit or plasma proteins in any of the groups in any 
experiment.
3.4.2. Experiment 1: effect of intrabrachial ANP on U W  and venous tone 
in forearm
Intraarterial infusion of incremental ANP concentrations caused a dose dependent 
parallel upward shift in the PVR in all 7 subjects, indicating venodilation in the 
infused arm (Figure 3.4.2.1. and Figure 2.4.1.). ANP infusion of O.OSpg/min caused a
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modest but non-significant 6% (p=0.1) increase in U W . ANP infusions of 
0.1|j.g/min, 0.5|ig/min, l)Lig/min, 2.75^g/min and 5[xg/min caused significant increases 
in U W  of 8% (p<0.05), 13% (jXO.OOl), 14% (p<0.001), 18% (p<0.001), and 20% 
(pKO.OOl) respectively, compared to baseline in the same arm (Figure 3.4.2.2.).
U W  decreased gradually in the non-infused arm during the study, by 12 ± 6% (p=ns 
versus baseline) during the initial infusion rate and by 43 ± 8% (p=0.01 versus 
baseline) at the final/peak infusion step.
Baseline plasma ANP level was 14.6 ± 8.4 pg/ml. To further investigate the relation 
between venous ANP and venodilatation, we grouped the effect on U W  according to 
ANP levels in the venous effluent from the infused arm (Figure 3.4.2.3.). High 
physiological/low pathophysiological ANP levels (25-lOOpg/ml) were associated with 
a non-significant 11 ± 4% (p=0.1) increase in U W . Infusions achieving 
pathophysiological (101-400pg/ml) and high pathophysiological (401-600pg/ml) 
concentrations caused a significant 18 ± 6% (p<0.05) and 19 ± 5% (p<0.05) increase 
in U W  respectively. Pharmacological levels (>600pg/ml) caused a significant 16 ± 
3% increase in U W  (p<0.01).
Changes in plasma norepinephrine in the infused and non-infused arm
Plasma norepinephrine levels rose during the study by 269±99pg/ml in the non- 
infused arm (from 327±70pg/ml at baseline to 596±123pg/ml at maximum dose; 
p=0.07) compared to 58±87pg/ml (from 362±20pg/ml at baseline to 421±101pg/ml at 
peak dose; p=0.47) in the infused arm; Ap=0.34.
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Figure 3.4.2.1. Typical PVR of the infused arm following ANP. The parallel up-ward 
shifts in the PVR following 0. Ipg/min, Ipg/min, and 5pg/min ANP reflect a 
reduction in venous tone. The slope of each line reflects compliance. Linear 
regression equations; O y=8.0X + 424; R^=0.973, •  y=7.9X + 422; R^=0.973, O
y=7.2X + 492; R^=0.986, □  y=6.5X + 560; R^=0.976, A y=6.9X + 572;
R^=0.998.
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Figure 3.4.2.2. ANP dose response curve; Increase in vascular volume according to 
infused ANP concentration. *p<0.05, $p<0.001,2-way ANOVA, vs baseline.
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Figure 3.4.2.3, Increase in vascular volume according to plasma levels (n=33 
samples). Venous plasma levels similar to those seen in severe heart failure (i.e. 
between 100 and 400pg/ml) achieve near-maximal venodilatation. *P<0.05, fP<0.01 
vs baseline.
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3.4.3. Experiment 2: effect of intrabrachial A71915 on U W  and venous 
tone in forearm
Infusion of A71915 caused a dose dependent parallel downward shift of PVR (Figure
3.4.3.) in all but one volunteer, reflecting increased venous tone. Infusion of 
0.5pg/min and Ipg/min caused 7.7±2.3% (p=0.01) and 16.1±3% (p<0.01) reductions 
in U W  in the infused arm respectively.
U W  decreased gradually in the non-infused arm during the study, by 3.3±2.4% 
(p=ns) at 0.5pg/min and by 7.0±3.2% (p=0.08) at Ipg/min.
When correcting for the reduction in vascular volume observed in the contralateral 
arm, the net effect of A71915 infusion was 4.4±1.5% (p=0.01) and 9.6±1.1 %
(p<0.001) respectively.
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Figure 3.4.3. Typical PVR of the infused arm following A71915. Note the marked 
reduction in coimts/sec after 0.5pg/min (=12%) and after Ipg/min (= 26%) are not yet 
corrected for systemic venoconstriction. Furthermore, the dose dependent parallel 
down-ward shift reflects venoconstriction. Linear regression equations; O y=6.5X + 
651;R^=0.990,* y=6.7X + 635;R^=0.997, A y=6.6X + 569 R^=0.985, ■
y=6.9X + 478;R^=0.998.
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3.4.4. Experiment 3: effect of intrabrachial A71915 on FBF
The results of the dose-ranging studies are shown in Figure 3.4.4.1. At an infusion 
ratio of 50:1 A71915 almost completely abolished the effects of ANP on FBF. SNP 
increased FBF by 111±29 % (p<0.05). A71915 did not attenuate the SNP-induced 
increase in FBF.
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Figure 3.4.4.I. Effect of ANP and ANP/A71915 coinfusion on FBF. ANP 
(O.lpg/min) vs ANP/A71915 (1:50) coinfusion; $p<0.01, 2-way ANOVA.
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3.4.5. Experiment 4: effect of intravenous A71915 on IW
Intravenous bolus injection of 5|j,g A71915 followed by intravenous infusion of 
l|Lig/min for 200 seconds reduced regional I W  in all subjects of Group 2. The mean 
reduction was 2.6±0.5%; p=0.01. At the same time regional IVY in the 7 time control 
volunteers (Group 4) increased by 1.4±1.2%; p=0.3. The difference between both 
groups was significant; p<0.05. The results are also illustrated in Figure 3.4.5.1.
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Figure 3.4.5.1. The effects of A71915 and N-Saline on intestinal capacity (IW ) are 
illustrated. Recumbency tended to increase IW . This trend was reversed following 
A71915 administration.
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Figure 3.4.5.2. The contrasting effects of ANP and A71915 on FVV in vivo are 
illustrated
3,5, Discussion
In this study we provide direct evidence that ANP is a local regulator of F W  and 
I W  in health. This is in keeping with a previous study demonstrating that systemic 
ANP infusion increases intestinal blood content (56) but contrasts with other reports 
that ANP has minimal or no activity on conduit veins (161; 163). Venodilator activity 
was seen across a wide range of physiological and pathophysiological plasma levels 
with a near maximum venodilating effect at plasma levels similar to those seen in 
severe heart failure (between 100-400pg/ml). Importantly, we show for the first time 
that basal ANP levels influence vascular volume and resting venous tone in both
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forearm and intestinal beds. The forearm studies exclude ANP-mediated central 
S3mipathetic withdrawal as the mechanism.
3.5.1. Previous studies assessing the effects of ANP on venous function
Several studies showed that ANP consistently reduced CVP (344;345), even at very 
low doses, without measurable changes in BP (346). This was in keeping with a 
primary venodilating ANP effect. However, other studies failed to detect a direct 
venodilating action. Holtz et al observed that systemic infusion of ANP had little or 
no effect on venous tone in anaesthetised dogs (anaesthetics in general and 
pentobarbital inparticular have been shown to alter ANP responsiveness (502;503)), 
despite potent effects on arterioles (504). Studies in human dorsal hand veins (161) 
and saphenous veins (163) also failed to demonstrate any significant effect.
Doorenbos et al, using a strain gauge technique, investigated the effect of brachial 
artery infusion of ANP on venous compliance (343). ANP infusion alone had no 
effect, but antagonised the effects of Ang II on venous compliance during coinfusion. 
Ando et al used a water displacement plethysmography technique to compare the 
effects of brachial artery infusion of SNP and a single dose of ANP on the forearm 
vascular bed (369). Both agents shifted the forearm PVR upwards, but ANP had less 
marked effects than SNP and simultaneously increased capillary filtration. Because 
this technique measures total limb volume (i.e. tissue plus blood volume) it is difficult 
to be certain about the relative contributions of venodilation and increased tissue 
fluid.
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3.5.2. How can these discrepancies be explained?
It has become increasingly clear that conduit veins in general and dorsal hand veins in 
particular behave differently from the physiologically important small veins and 
venules. Furthermore, much of the in vitro work assessing the vascular effects of ANP 
has been carried out on mammary arteries and saphenous vein grafts harvested from 
patients undergoing bypass operations (163). The vascular response in these 
specimens may not reflect the in-vivo response in healthy people. In addition, the 
absolute number and proportional representation of NPR subtypes (NPRa+b versus 
NPRc) varies from tissue to tissue (505), and such differences may well account for 
the different response between the small veins and venules and large conduit veins. 
Moreover, some human studies employed doses of ANP that resulted in plasma 
concentrations far above those seen in health or disease (370). Because of the 
consequent fall in BP, baroreflex mediated changes may supervene, causing reflex- 
mediated constriction to over-ride any local venodilator effects.
3.53. Alternative explanations for increased vascular volume?
ANP has well documented effects on sympathetic nerve activity (198). Vatta et al 
demonstrated that ANP plays a role in the modulation of norepinephrine (NE) 
metabolism in the rat hypothalamus and adrenal medulla, affecting storage, release 
and uptake of NE (159). They concluded that ANP acts as an inhibitor of 
noradrenergic neurotransmission. Also, as Ang II is known to potentiate peripheral 
sympathetic activity (506) (the mechanism in veins is believed to be pre-synaptic), the 
well documented effects of NPs on reducing Ang II levels (370) could indirectly 
reduce NE release. However, withdrawal of S5nnpathetic activity was not the 
mechanism of venodilation in the present work, either at a central or a peripheral
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level, since we observed venoconstriction in the contralateral arm, and venodilation in 
the infused arm occurred despite an increase in plasma NE in the venous effluent from 
this arm.
3.5.4. Effects of ANP-receptor antagonism
Acceptance of vasoactive compounds as physiologically significant depends on the 
demonstration of changes in vascular tone in response to blockade of basal levels.
This has traditionally been achieved using receptor antagonism. A71915, an 
antagonistic ANP-analogue, has emerged as the most potent inhibitor of ANP- 
stimulated, NPRA-mediated, cyclic guanylate monophosphate production (223). 
Brunner and Woelkert used A71915 to show that basal ANP contributes to regulation 
of coronary and TPR in rodents (364). To our knowledge the present work is the first 
to assess the effects of ANP-receptor antagonism in a human (in vivo) study. We 
provide direct evidence that blocking the effects of basal ANP levels increases venous 
tone, thereby decreasing vascular volume. Furthermore, we provide evidence that 
A71915 inhibits ANP-induced increases in FBF in a dose dependent, NPRa mediated 
fashion.
3.5.5. Study limitations
Observations in the contralateral arm merit comment. During infusion of A71915 
vascular volume decreased in both arms, though significantly more in the infused arm. 
Because of this unidirectional behaviour, changes in vascular volume and venous tone 
in the infused arm were corrected for changes in the contralateral arm. In contrast, 
infusion of ANP increased vascular volume in the infused arm whilst there were 
opposing effects in the contralateral arm. Expressing volume changes in the infused
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arm in relation to the changes in the contralateral arm, as is convention in assessing 
FBF using VOP, would therefore have been potentially misleading and was ultimately 
not performed in the ANP dose/response study as data for the contralateral arm was 
not recorded in the first two study subjects. The contralateral arm venoconstriction, 
initially surprising, is a consistent phenomenon during our studies. Potential 
mechanisms include: increased sympathetic outflow caused by discomfort arising 
during the lengthy study; and reflex-mediated vasoconstriction via baroreceptors or 
cardiopulmonaiy receptors, in response to subtle changes in BP or central blood 
volume due to systemic drug effects and/or prolonged semi-recumbence. Our 
observation of an increase in plasma NE levels is consistent with any of these 
mechanisms. Furthermore, it has previously been shown that prolonged venous 
congestion per se significantly reduces venous vascular volume in the forearm of 
healthy volunteers (507). Consequently our measurements of the venodilating ANP 
action in the infused arm are likely to underestimate the true magnitude of its effect as 
ANP actions were opposed by the effects of increased sympathetic stimulation.
It is clear that the findings of this study cannot simply be extrapolated to the 
syndrome of cHF as there is evidence of hyporesponsiveness or “resistance” to ANP 
in situations associated with chronic elevation of ANP levels (199). Furthermore, it is 
important to note that the observations cannot be explained simply on the basis of 
increased arterial inflow. We and others have previously shown that limb PVR are 
unaffected by large increases in flow (for detailed discussion see Chapter 3). Finally, 
in experiment 1, the documented increase in count rate does not represent increased 
extravasate as a consequence of increased capillary permeability, since 95-98.5% of 
the technetium was bound to erythrocytes and vascular volume returned below 
baseline within 30 minutes following the cessation of ANP infusion. The
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measurement therefore reflects changes in vascular volume. Indeed, increased 
capillary permeability would tend to blunt the magnitude of the measured change in 
venous tone using this technique, by increasing tissue attenuation.
3.6. Conclusion
These studies provide direct evidence that ANP is a regulator of regional vascular 
volume and venous tone in healthy subjects. Importantly, we show that basal ANP 
levels contribute significantly to resting venous tone, and that plasma levels similar to 
those seen in severe heart failure exert a powerful venodilator effect.
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CHAPTER 4 -  THE EFFECTS OF NATRHJRETIC PEPTH)ES ON VENOUS 
CAPACITANCE IN cHF
4,1, Introduction
Animal and human studies have suggested a variable reduction in hormonal, renal and 
resistance-vessel responsiveness to NPs in heart failure (HF) 
(157;166;199;425;438;508-511). Despite minimal effects on plasma volume and 
resistance-vessel tone, infusion of NPs in patients with cHF has consistently been 
shown to reduce CVP (366;367). This raises the possibility that the venodilator effects 
of NPs may be preserved in HF.
Although earlier data suggested that NPs exert their effects solely via a non- 
endothelium-dependent, particulate GC pathway (512), recent evidence suggests that 
the vaso-relaxant effects may, at least in part, be mediated via an endothelium- 
dependent pathway involving NO and soluble GC (435;436). Endothelial dysfunction, 
a characteristic feature in the arterial vessels of patients with CHF (177), may 
therefore theoretically contribute to the phenomenon of NP hypo-responsiveness (“NP 
resistance”). We previously demonstrated preserved venous endothelial function in 
cHF patients despite the presence of marked arterial endothelial dysfunction (437). 
We hypothesised that cHF patients may have preserved venous NP responsiveness 
despite diminished resistance-vessel responsiveness and that this may be explained by 
preservation of venous endothelium-dependent NO release.
This studies had four aims: first, to compare the effects of the currently known human 
NPs (ANP^ '^^^ ,^ ANP^ '^^^  ^ [Urodilatin], BNP, CNP) on the forearm capacitance 
vasculature in 53 cHF patients on optimal therapy; second, to examine the 
contribution of basal NP plasma levels to regulation of regional vascular volume (W ) 
and venous tone by intra-arterial infusion of the NPRA-selective ANP-receptor
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blocker A71915; third, to test the hypothesis that venous responsiveness to exogenous 
ANP was preserved but resistance-vessel responsiveness attenuated in cHF patients 
versus controls; and fourth, to assess the contribution of NO to NP-induced changes in 
venous and resistance vessels by co-infusion with the NO- synthase inhibitor, A^- 
monomethyl-L-arginine (LNMMA).
4.2. Methods and Data Analysis
Subjects: fifty-three consecutive patients with clinical features of cHF, recruited from 
the Heart Failure Clinic at the University Hospital of Wales, were enrolled to receive 
intra-arterial ANP, BNP, CNP, Urodilatin, or A71915. All patients satisfied the 
European Society of Cardiology (ESC) criteria for the diagnosis of CHF (5) and had 
impaired left ventricular systolic function (EF<45%) as assessed by radionuclide 
ventriculography. Patients with hypertensive heart disease were excluded. All were on 
diuretics, a maximally tolerated dose of an ACE inhibitor or an AT i-antagonist, and 
unless contraindicated or previously not tolerated, on maximally tolerated doses of P- 
blockers. Their symptomatic status had remained unchanged on stable medical 
therapy for at least 2 months. Long-acting nitrates (n=5) were stopped 24 hours before 
the study and all medications were withheld on the morning of the study. Eleven 
healthy volunteers with no history of or evidence for cardiovascular disease or other 
cardiovascular risk factors were also studied as a control group. None was taking any 
medication. All had normal clinical examination, ECG’s and ventricular function 
(EF>45%) as assessed by radionuclide ventriculography. Volunteer and patient 
characteristics are shown in Table 4.2.1. and Table 4.2.2. All participants gave written 
informed consent. The study was approved by the local research ethics committee.
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Table 4.2.1. Baseline Characteristics
Controls cHF Patients
ANP ANP URODILATIN BNP CNP A71915
Age, y (range) 57 (34-69) 63 (42-79) 67 (53-77) 63 (38-79) 65 (54-76) 59(40-83)
Sex, M/F, n 10/1 18/0 8/0 8/0 7/1 9/2
NYHA class 2.3±0.1 2.410.2 2.410.2 2.410.2 2.210.1
Etiology, (IHD/DCM), n 12/6 7/1 4/4 5/3 6/5
Body mass index, kgW 25.1±1.2^ 29.2±0.7 29.411.0 28.111.6 31.711.7 27.9.012.4
Forearm volume, mis 1709±77 1694153 1690194 1646131 19291203 17021148
FBF, ml/lOOmlFV 2.14±0.37 2.1810.18 2.0110.17 2.1010.27 2.6310.36 2.3610.33
LV ejection fraction, % 50±1^ 2913 2414 2514 3815 3215
BP - Systolic, mmHg 119±4 11014 11718 10716 10415 12219
BP - Diastolic, mmHg 64±3 6513 5413 6113 6014 7317
Heart rate, min'^ 65±4 66±5 67±5 65±4 65±5 65±6
Diuretic / + Spironolactone 18/5 8/2 8/4 8/0 11/6
ACE/AT2 17/1 8/0 6/2 8/0 9/2
P-Blocker 10 4 6 5 6
Continuous data are presented as mean±SEM. Symbols p<0.01, *p<0.001 depict comparison between both ANP groups.
Table 4.2.2. Humoral, Urinary, and Hemodynamic Parameters at Baseline and End of Study
Controls cHF Patients
ANP ANP URODILATIN BNP CNP A71915
Baseline
Serum Na ,^ mmol/1 139.4±0.5 139.310.6 137.111.2 137.310.8 139.210.8 137.411.2
Urinary Na ,^ mmol/1 77±14 59113 81119 61117 89131 88115
Serum Creatinine, pmol/l 88±4 11817 112.9112 90.114 107.819 89.6110
Serum Urea, mmol/1 6.3±0.5 8.811.2 9.712 6.410.7 8.410.8 7.111.2
Serum Albumin, g/1 44.310.5 43.910.7 4410.7 4410.8 42.710.9 46.610.8
Hemoglobin, g/dl 14.210.3 14.410.3 14.110.3 14.610.6 13.910.5 14.310.7
Hct 0.4110.01 0.4210.01 0.4110.01 0.4310.02 0.4010.01 0.4210.02
Heart rate, min’^ 6517 6618 6818 6616 6616 6718
Mean BP, mmHg 8313 8013 7513 7614 7514 9015
End of Study
Serum Na ,^ mmol/1 138.210.5 138.610.6 137.011.2 137.411.0 139.710.8 136.210.8
Urinary Na ,^ mmol/1 96121 92116* 105i28 66112 154.5117 76.2119.2
Serum Creatinine, |jmol/l 8214* 9718* 102.5112* 83.313* 101.418 76.518.9*
Serum Urea, mmol/1 6.110.5* 7.811.2* 9.612* 6.310.7* 7.910.6 6.911.0*
Serum Albumin, g/1 42.110.8* 39.111.2* 4010.9* 39.511.0* 38.811.4 42.210.8*
Hemoglobin, g/dl 13.810.4* 13.610.3* 13.410.3* 13.810.6* 13.510.6 13.210.6^
Hct 0.4010.01 0.4010.01* 0.3910.01* 0.4110.01* 0.3810.02 0.3910.02*
Heart rate, min'^ 6617 6716 6718 6516 6516 6518
Mean BP, mmHg 8214 8114 7416 7616 7515 9015
Continuous data are presented as mean±SEM. Symbols *p<0.05, ^p<0.01, ^ <0.001, depict comparison to baseline
4.2.1. Assessment of Arterial Resistance-Vessel Effects
The foreami resistance vasculature was assessed using conventional VOP as 
described previously (501). We interpreted changes in FBF to have been due to 
changes in to changes in arterial (arteriolar) resistance. FBF was calculated according 
to the formula of Whitney (85). Changes in FBF (ml/lOOml/min) were assessed in the 
infused and non-infused arms and changes in the former were expressed as a ratio of 
those in the latter (513). Changes in flow ratios following NP infusions are expressed 
as percentage changes from the baseline (i.e., normal saline infusion) that preceded 
the administration of each drug. FBF results are expressed as mean values with 95% 
CIs, unless stated otherwise. With respect to the dose-response curves (Figures
4.2.1. la+b), the area under the curve (AUC) was calculated using the trapezoid rule 
(514).
4.2.2. Assessment of Venous Function
Changes in F W , compliance and venous tone were assessed by RP Y, as described 
previously (437;515;516) and outlined in the Methodology section of this thesis.
4.2.3. Protocol
All studies commenced between 8.30 and 9.30am and lasted between 2.5 to 3.5 hours. 
Patients were asked to abstain from caffeine-containing drinks for at least 12 hours 
beforehand. Forearm volume (FV) was assessed by water displacement. Antecubital 
veins of both arms were cannulated with 18-gauge cannulae and baseline blood 
sampling was performed. After red-cell labelling, a 27-gauge unmounted steel needle, 
connected to an epidural catheter and sealed with dental wax, was inserted into the 
brachial artery of the non-dominant arm under sterile conditions. Each arm was then
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positioned on the face of a gamma camera. Thirty minutes after infusion of saline was 
commenced, FBF was assessed. This was followed by recording of two baseline 
venous pressure-volume relations (PVR). Thereafter, incremental NP (ANP* [* = all 
Clinalfa, Laufelfingen/Switzerland], Urodilatin [Cardiopep, Hannover/Germany], 
BNP*, CNP*; 0.05|Lig/min, O.Spg/min, l.Opg/min) or A71915* (0.5pg/min and 
Ipg/min in 7 subjects and 20pg/min in 4 further subjects) infusions were commenced 
at a volume infusion rate of 1 ml/min. Following a 5-minute run-in period (10 minutes 
for A71915), FBF was assessed, followed by a 2-minute gap and measurement of one 
PVR. This was repeated during co-infusion of NP (1 pg/ml) + LNMMA* (12mg/ml), 
following a 15-minute run-in period.
4.2.3.I. Plasma ANP Levels and cGMP Spillover
Venous-effluent blood samples were taken from the infused arm at the end of each 
infusion period for assessment of plasma NP and cGMP. NP and cGMP 
measurements were performed by blinded operators using standard competitive 
radioimmunoassay (Peninsula Laboratories, Bachem Ltd UK) and enzyme 
immunoassay kits (Cayman Chemical, Michigan/USA), respectively.
In both ANP groups the difference between plasma cGMP concentration at the 
baseline and after the maximum dose of ANP was multiplied by the increase in FBF 
from the baseline level induced by the corresponding maximum dose, and the 
resulting values were taken as representative of the change in the amount of forearm 
cGMP spillover.
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4.2.3.2. Statistics
Continuous data are expressed as mean ± SEM. The baseline characteristics of the 
cHF groups (ANP, BNP, CNP, Urodilatin) were compared using chi-square tests and 
one-way analysis of variance (ANOVA) for categorical variables and continuous data 
respectively. Baseline characteristics between both ANP groups were compared using 
the unpaired t-test. Changes in FBF and F W  results are expressed as mean values 
with 95% CIs. The effects of NP on FBF and F W  (within-group comparisons) were 
assessed by 2-way analysis of variance (ANOVA) with post-hoc comparison to 
baseline. Between-cHF-group comparisons were performed using repeated measures 
ANOVA. The comparison of the ANP dose-response curves (Figure la+b) between 
cHF patients and controls was performed using the trapezoid rule (514), as is 
conventional when presenting FBF data. Correlation between baseline plasma ANP 
levels and venous responsiveness was assessed by Spearman rank correlation. A p- 
value less than 0.05 was considered statistically significant. In order to allow 
presentation of grouped data, results are presented as percentages.
4,3. Results
4.3.1. Subject Characteristics:
The patient groups were well matched, without any significant differences in their 
baseline characteristics, including humoral, urinary and hemodynamic parameters. 
The ANP control group had significantly higher EF and lower body mass index than 
the ANP cHF group. Importantly, there was no significant difference in mean FV (see 
Table 4.2.1.) or resting forearm counts between patients and controls (ANP-cHF; 
691 ±82 counts/s, controls; 793±60, p=0.3). Baseline characteristics are summarised
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in Tables 4.2.1. and Table 4.2.2. The renal and humoral changes are summarised in 
Table 4.2.2.
4.3.2. ANP Levels
Baseline venous plasma ANP levels in the control and cHF group were 21.7 ± 
4.8pg/ml and 100.5 ± 8.1 respectively, p<0.0001. Intra-arterial ANP infusions of 
0.05pg/min, 0.5pg/min, and l.Opg/min raised ANP concentrations in the venous 
effluent to 196 ± 62pg/ml, 785 ± 256pg/ml, 1113 ± 244pg/ml (p<0.01 for all) in the 
control group and to 208 ± 33pg/ml, 234 ± 38pg/ml, 280 ± 32pg/ml (p<0.05 for all) in 
the cHF group. The increase in venous ANP concentration at 0.5|Lig/min and Ipg/min 
was significantly higher in controls than patients (p<0.01, for both).
Baseline cGMP levels in the control and cHF group were 0.73 ± 0.15pg/ml and 8.98 ± 
l.Opg/ml respectively (p<0.0001). The cGMP spillover was 20.0 ± 9.2 pmol/min per 
100ml FV in the control group and 11. 6 ± 4.5 pmol/min per 100ml FV in patients 
(P=NS).
4.33. The Effects of NP on FBF in Health and cHF
The effects of ANP on the FBF ratio in patients with cHF and healthy controls are 
shown in Figure 4.3.3. A) and Table 4.3.
Intra-arterial infusion of incremental ANP concentrations caused a dose-dependent 
increase in FBF in both controls and patients. ANP infusions of 0.05pg/min, 
0.5pg/min, and Ipg/min increased FBF in the infused arm of controls from 
2.14±0.37mP100ml FV to 3.22±0.48ml/100ml FV (95% Cl, -O.I to 2.27), to 
3.65±0.44ml/100ml FV (95% Cl, 0.32 to 2.70; p<0.05), to 4.50±0.75ml/100ml FV
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(95% Cl, 1.17 to 3.55; p<0.001), respectively. In patients, FBF increased in the 
infused arm from 2.18±0.18ml/100ml FV to 2.86±0.78ml/100ml FV (95% Cl, -0.13 
to 1.09), to 3.02±0.54 (95% Cl, 0.12 to 1.3, p<0.05), to 3.27±0.47 (95% Cl, 0.48 to
1.7, p<0.001), respectively. Changes in FBF were significantly blunted in patients 
when compared with controls (AUC; p<0.01).
The effects of Urodilatin, BNP and CNP on the FBF ratio in patients are summarised 
in Table 4.3.
4.3.4. Changes in Forearm Venous Tone
For each subject, two baseline PVR were generated during infusion of normal saline 
and 1 during infusion of each dose of NP and NP/LNMMA co-infusion. Linear 
regression was performed for each PVR, and Revalues were 0.88 to 1 (mean 
0.96±0.03). Therefore a linear model was adopted. We then determined whether the 
slopes of the lines in each data set were different (i.e., to determine whether the lines 
were parallel or not) using a standard method for comparing 2 independent 
regressions (517). Although PVR varied in slope (compliance) between individuals, 
within individuals there was very little change in slope at different stages of the study. 
In other words, shifts in the plots induced by infusion of the active agents were 
parallel and were due to changes in venous tone rather than compliance.
The baseline slope of the PVR was 7.3±1.2 counts/s/mmHg in the ANP-cHF group 
and 7.5±0.8 counts/s/mmHg in the controls (p=NS). Furthermore these parameters 
were similar at baseline in the patient groups randomised to each of the NPs.
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4.3.5. The Effects of NP on F W  in Health and in cHF
ANP caused a significant and similar dose-dependent increase in F W  in controls and 
in patients. The results are summarised in Figure 4.3.3. and Table 4.3.
The effects of Urodilatin, BNP, and CNP on F W  in patients and controls are shown 
in Table 4.3.
The overall effects of ANP on F W  in cHF patients was significantly greater than 
those of Urodilatin, BNP and CNP, p<0.05 (for all, repeated measures ANOVA).
There was no significant correlation between baseline ANP plasma level and maximal 
venous responsiveness to i.a. ANP infusion (r s= -0 .1 9 ;  p=NS).
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Figure 4.3.3. Changes in F W  (Figure 4.3.3.a ) and FBF (Figure 4.3.3.b ) following 
incremental cumulative dose rates of ANP are shown. Symbols depict *p<0.05, 
^p<0.01, *p<0.001 and refer to within group comparison using 2-way ANOVA. P- 
values within the figures (p=ns in Fig la, and p<0.01 in Fig lb) refer to AUC 
comparison between both groups (patients = ■, controls = 0).
4.3.6. The Effects of A71915 on FBF and F W  in Patients with cHF
Intra-arterial infusion of A71915 at 0.5pg/min and Ipg/min [n=7] had no significant 
effect on FBF or FW . Infusion of 20pg/min [n=4]) reduced F W  by 4.4±1.2%; 
p<0.05 without significant changes in FBF.
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Table 4.3.3.1. Changes in forearm vascular volume and blood flow
Dose
Group 0.05|Lig/min 0.5|Lig/min ljug/min
ANP-Controls
Change in FBF ratio 
Change in FVV in %
+0.756* (0.03 to 1.49) 
+0.930 (-7.26 to 9.12)
+1.111  ^(0.38 to 1.84) 
+8.476* (0.28 to 16.67)
+1.438* (0.71 to 2.17) 
+13.424^ (5.23 to 21.62)
ANP-cHF
Change in FBF ratio 
Change in FVV in %
+0.122 (-0.08 to 0.32) 
+2.149 (-2.25 to 6.55)
+0.191 (-0.01 to 0.39) 
+11.057* (6.66 to 15.45)
+0.467*(0.27to0.67) 
+14.669* (10.3 to 19.1)
Urodilatin-cHF
Change in FBF ratio 
Change in FVV in %
+0.117 (-0.19 to 0.42) 
-1.938 (-4.76 to 0.9)
+0.397* (0.09 to 0.70) 
+1.438 (-1.39 to 4.26)
+0.695* (0.39 to 1.00) 
+6.49* (3.66 to 9.31)
BNP-cHF
Change in FBF ratio 
Change in FVV in %
+0.114 (-0.24 to 0.46) 
+1.120 (-4.43 to 6.67)
+0.03 (-0.32 to 0.38) 
+4.829 (-0.72 to 10.38)
+0.648  ^ (0.30 to 1.00) 
+7.281* (1.73 to 12.83)
CNP-cHF
Change in FBF ratio 
Change in FVV in %
0.020 (-0.44 to 0.48) 
-1.521 (-7.00 to 3.96)
-0.137 (-0.59 to 0.32) 
+1.106 (-4.43 to 6.54)
+0.238 (-0.22 to 0.70) 
+7.381* (1.90 to 12.87)
Symbols: * p<0.05, ^pKO.Ol, tp<0.001, depict within group comparison (2 way-ANOVA). FBF data are mean absolute changes in the 
ratio of infused versus non-infused arm, (95% confidence interval). Changes in FVV are corrected for systemic changes and expressed in %.
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Table 4.3.7. The effects of LNMMA on NP induced changes in FBF and FVV
Group
_____________________ANP-Controls ANP-cHF_________Urodilatin-cHF________ BNP-cHF_________ CNP-cHF
Mean Change in FBF
NP(1.0^g/min) versus -1.37 (-2.48 to -0.26)*-0.64 (-1.31 to 0.03) -0.81 (-1.20 to -0.43)* -0.73 (-1.19 to -0.26)* -0.56 (-1.07 to -0.05)*
NP/LNMMA Co-infusion
Mean change in F W
NP(1.0ng/min) versus -6.32 (-4.11 to -8.53)* -8.00 (-4.10 to -11.92)*-7.46 (-4.24 to 10.69)* -6.86 (2.70 to 11.03)* -8.97 (-4.84 to -13.09)* 
NP/LNMMA Co-infusion
Symbols *,  ^depict within group comparison (2 way-ANOVA). *p<0.05, ^p<0.01, $p<0.001. FBF is expressed as ml/100ml FV. Chan^
in FBF reflects mean absolute change, (95% Cl). FVV (forearm vascular volume) is expressed in %.
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4.3.7. The Effects of Endothelium-Derived NO on NP-Induced Changes in FBF 
and F W  in Health and cHF
eNOS-blockade reduced ANP-induced FBF changes in controls but not in patients 
(p<0.05), whilst similar reductions in F W  were seen in both ANP groups (both 
p<0.001) The effects of LNMMA/NP co-infiision on all NP-induced changes in FBF 
and F W  are summarised in Table 4.3.7.
4.4. Discussion
Many studies have detailed the central hemodynamic, arterial, renal and adrenal 
effects of exogenous (157;166;199;438;509-511) and endogenous (367;416;508) NPs 
in animal models of heart failure (438;508) and in human heart failure 
(157;166;199;509-511), but little is known about the effects of NPs on the capacitance 
vasculature in this condition. In the present study we assessed the effects of all 4 
currently known human NPs on the forearm vasculature in well matched groups of 
optimally treated cHF patients. Furthermore, we compared the effects of ANP on the 
forearm capacitance vasculature in patients with optimally treated cHF with those in 
normal controls and evaluated the contribution of endothelium-derived NO on NP- 
induced vasodilation in the forearm resistance and capacitance vasculature. Finally, 
we assessed for the first time the effects of basal NPs on forearm vascular fimction in 
patients with cHF.
The principal findings were as follows: first, we demonstrated that in cHF ANP is a 
significantly more potent venodilator of forearm capacitance vessels than other NPs, 
the rank order of potency in the forearm capacitance bed being A N P »  BNP > CNP/ 
Urodilatin. Second, basal NPs contribute to regulation of regional NW and venous 
tone in cHF, but the contribution appears to be less than that previously shown by us
152
in younger normal volunteers (516). Third, we demonstrated that venous 
responsiveness to exogenous ANP is preserved in patients with cHF, despite marked 
attenuation of its effects in the forearm resistance vasculature. Fourth, eNOS blockade 
reduced ANP-induced-induced FBF changes in controls but not in patients, whilst 
similar reductions in F W  were seen in both groups.
4.4.1. Mechanism of the Attenuated Forearm Resistance-Vessel Response to 
ANPincHF
Our observation of an attenuated forearm resistance-vessel response to intra-arterial 
ANP infusion is consistent with the majority of the literature, which documents 
attenuated arterial, renal and endocrine responses to ANP in patients with cHF 
(157;166;199;509-511). Hirooka et al (199), and Nakamura et al (278;510), reported 
reduced forearm resistance-vessel responses to intra-arterial infusion of ANP and 
BNP (but not CNP), in HF patients versus healthy controls. Interestingly, in these 
studies, responses (i.e changes in FBF) to BNP and CNP were less than those to ANP 
(on an equimolar basis) in healthy controls, but roughly equipotent in patients with 
CHF. Conversely, Kubo et al reported no significant difference between the forearm 
resistance-vessel responses to maximal doses of ANP in HF patients and controls 
(518). However, the maximal dose of ANP employed in this study was considerably 
higher than that used in other studies (199;510;519). There was a clear reduction in 
responsiveness at lower doses in HF patients versus controls, indicating a rightward 
shift in the dose-response relation.
The mechanisms responsible for reduced NP responsiveness in patients with HF are 
likely to be complex and may differ between the hormonal, renal, and vascular 
responses to these peptides. All of the following have been implied to contribute (for
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review see ref. (520)); NPRa+b receptor down-regulation, NPRc (clearance receptor) 
and NEP up-regulation, receptor desensitisation, fetal NP-gene activation, down­
stream signalling abnormalities beyond cGMP generation, and increased activity of 
functional antagonists of the NP system, such as increased sympathetic nerve activity 
(especially renal sympathetic activity) and activation of the RAAS. The present study 
provides evidence that endothelial dysfunction might contribute to arterial NP 
resistance. There was considerable impairment of the NO-mediated component of the 
vasodilator effect of ANP in cHF patients versus controls, but the non-NO-mediated 
component was preserved. Furthermore, our finding that identical ANP infusions 
caused a significantly greater increase in venous effluent plasma ANP levels in 
controls compared to cHF patients would be in keeping with the notion of up- 
regulation of NPRc-receptor density in this condition.
4.4.2. Venous Effects of Natriuretic Peptides in cHF
Studies in conduit veins (e.g., saphenous vein and dorsal hand vein) have suggested 
that NPs have minimal or absent vasorelaxant effect on veins (161;521). In contrast 
we have previously demonstrated that intra-brachial arterial ANP infusion causes a 
significant increase in forearm venous capacitance in healthy controls across a venous 
plasma concentration range spanning from physiological values to those seen in 
severe HF (516). These observations suggest that in contrast to the lack of effect seen 
in conduit veins, ANP dilates small veins and venules, which contain most of the 
venous (and total vascular) volume. In the present study brachial artery ANP infusion 
resulted in a similar increase in F W  in cHF patients versus healthy controls, in 
marked contrast with the attenuated effects in the forearm resistance beds. To the best 
of our knowledge, there is only one other published study of the venous effects of
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ANP in HF (423). That study differed from ours in three important respects. First, the 
ANP was given as a single systemic bolus dose that produced hj^tension. The 
authors commented that baroreflex-mediated adjustments to the hypotension may 
have overcome any local venodilator effects of ANP. Second, our patients were 
symptomatic (NYHAII/III) but on optimal contemporary medical therapy. In contrast 
that study (423) was undertaken in the pre-ACE inhibitor era. Third, they employed 
strain-gauge VOP which measures total limb volume, and this may be influenced by 
changes in tissue fluid content when capillaiy permeability is altered by a vasoactive 
agent; in contrast radionuclide-plethysmography provides a more direct measure of 
W  and is therefore a more rehable technique when assessing vasodilators which alter 
vascular permeability (515).
Our observations raise the fascinating question of why the venous effects of ANP are 
preserved in patients with cHF when the resistance vessel responses are markedly 
attenuated. There is growing evidence for an interdependence between both GC- 
systems (i.e. soluble and particulate), in particular in situations with altered NO-bio- 
availability (435;436). We recently demonstrated that carbachol-induced, NO- 
mediated venodilation was preserved in the forearm of patients with cHF, whilst 
endothelial fimction in arterial vessels was markedly impaired (437). Emmick and 
Cohen previously demonstrated that, in older animals, vascular ANP responsiveness 
declined in arteries whilst it remained preserved in veins (522). Taken together there 
seems to be an impairment in arterial, but a preservation in venous ANP 
responsiveness with aging and with cHF. The same appears to be true for vascular 
NO-responsiveness and it is therefore conceivable that a NO-dependent component of 
ANP induced vasodilation accounts for these observations.
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4.4.3. Effects of Basal ANP Levels
A71915 is an ANP analogue capable of interfering with ANP-induced cyclic GMP 
accumulation. The binding affinity of A71915 to NPRa is only 22 times lower than 
that of ANP (223). A71915 has previously been shown to antagonise the cGMP 
dependent renal (365) and vascular responses (364) of ANP (the renal and vascular 
tissue is rich on NPRa receptors) without inhibiting ANP (and CNP) induced cGMP 
production in non-pigmented ciliaiy epithelial cells (tissue believed to be rich in 
NPRb and NPRc receptors but devoid of NPRa receptors) (361).
Infusion of A71915 at a rate identical to that which had previously shown to induce 
venoconstriction in healthy controls (516) had no effect. Given that basal ANP plasma 
levels in our patients were 10-fold higher than in the normal controls of the previous 
(and the present) study, the lack of effect can be explained by a rightward shift of the 
dose-response curve, in keeping with a competitive antagonism between endogenous 
ANP and exogenous A71915. Indeed, infusion of a 20-fold higher concentration was 
able to elicit a significant, albeit in relative terms still reduced (4.4% in present study 
versus 9.6% in previous study (516)) reduction in FW . The latter might be explained 
by the observation that p-ANP, an antiparallel dimer of a-ANP with reduced 
biological action, is the principal form of circulating ANP in patients with cHF (426). 
These observations may also help to explain the finding that acute administration of 
exogenous NPs have marked beneficial hemodynamic effects (394) whilst 
potentiating endogenous NP by preventing their breakdown has been somewhat 
disappointing.
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4.4.4. Relative Potency of the Different NPs
With respect to the effects of ANP and BNP on forearm resistance vasculature, our 
study largely confirms previous findings discussed above (199;278;509;510).
We found no significant vasodilatoiy effect of CNP in the resistance vasculature, but 
some venodilation at pharmacological levels. This is at least partly in keeping with an 
earlier finding by Wei et al (272) demonstrating that CNP is a relaxing factor in 
isolated canine saphenous vein rings. It is noted that a previous study by Nakamura et 
al found no significant increase in FBF at similar doses to those used in our study but 
a significant, albeit small and similar increase in FBF in patients and controls at a 
dose equalling roughly twice our peak infusion rate (278). Our study suggests that 
CNP has little or no vasodilatory potency in the forearm resistance vasculature of 
patients with cHF, at least at physiological and pathophysiological concentrations. 
However, there remains an important caveat, as CNP is an abluminally secreted 
paracrine hormone measurements of plasma levels may be a poor indicator for more 
important tissue concentrations. Consequently studies utilising specific NPRb- 
receptor blockers have to be awaited to ultimately confirm or rule out a potentially 
vasodilating action of CNP.
4.4.5. Clinical and Pathophysiological Implications
Systemic infusion of NP (167;366) (or elevation of endogenous NP by inhibiting their 
breakdown) (367;416) has been shown to increase stroke volume (SV) (167) and Cl 
(366) in patients with HF, despite a fall in CVP (366;367), a finding apparently in 
conflict with the Frank-Starling mechanism. This is almost certainly due a decrease in 
the volume of the right ventricle and a decrease in pericardial pressure, which 
increases effective LV distending pressure despite a decrease in LVEDP (i.e., it
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reduces DVI) (124). ANP infusion reduces cardiac filling pressures too rapidly to be 
solely accounted for by a fluid shift into the interstitial space and in HF patients there 
is no significant diuresis or change in haematocrit (157; 166; 167). These observations 
re-emphasise the potentially important venous effects of ANP, despite studies in 
conduit veins suggesting little or no venodilator effects. Extending our previous 
findings in healthy controls (516), the present study suggests that ANP also has 
important venodilator activity in cHF, but only modest effects on the resistance 
vasculature. This is in keeping with an earlier study by Serizawa et al (523) who 
found that ANP reduced cardiac filling pressures in the absence of changes in SVR. 
The relatively selective venodilator action of NP in HF results in marked reductions in 
CVP and increases SV without a major fall in SVR, avoiding serious hypotension. 
This is a favourable haemodynamic profile in the treatment of patients with 
decompensated HF.
4.4.6. Study limitations
One caveat is that, using the radionuclide technique, changes in W  during brachial 
artery infusion are expressed as a percentage of baseline using the radionuclide 
technique. If F W  were reduced in cHF patients versus controls, a similar percentage 
increase in F W  might nevertheless represent a smaller absolute increase in volume. 
However, forearm radioactive counts at baseline and total forearm volume were 
similar in patients and controls, making it likely that baseline F W  was similar in the 
two groups. This is perhaps not surprising; although SVR is increased in untreated 
HF, it is normal or even reduced in patients with well-treated (but symptomatic) HF 
such as those we studied (524). Although small, statistically non-significant clinical 
differences (i.e. cardiovascular risk profile) may have had some bearing on the
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vascular responsiveness to the various NPs, the degree of atherosclerotic burden in the 
forearm circulation is generally believed to be relatively minor. Furthermore, this was 
not a randomised study. Patients were consecutively enrolled to receive ANP, BNP, 
CNP, Urodilatin, or A71915 in this order. However, patient characteristics between 
the NP groups were well matched and the study setting and protocol remained 
unchanged throughout. Finally, this study was intentionally performed in patients who 
were on contemporary medical therapy for cHF, although they were nevertheless 
symptomatic. Our findings may not therefore apply to untreated HF.
4,5, Conclusion
Venous ANP responsiveness is preserved in patients with cHF despite markedly 
diminished responsiveness of the arterial resistance vasculature. This difference may 
partially be due to arterial endothelial dysfunction.
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CHAPTER 5 -  THE ROLE OF NATRHJRETIC PEPTH)ES IN THE 
FUNCTIONAL REGULATION OF CONDUIT ARTERY STIFFNESS
5.7. Introduction
Aortic pulse wave velocity (PWV), a measure of distensibility is an important, 
independent determinant of cardiovascular risk (525;526). Structural components 
within the arterial wall (mainly collagen and elastin), together with transmural 
pressure and smooth muscle tone are all important determinants of arterial 
distensibility (527;528). Vascular smooth muscle tone is dependent on locally derived 
signalling molecules, such as NO (529) and endothelin-1,(530) but may also be 
influenced by paracrine and endocrine acting NPs. Although ANP is a potent 
vasorelaxant on smaller conduit and resistance vessels in vivo and in vitro, there is 
considerable heterogeneity in responsiveness dependent on size and site of the vessels 
(163;251 ;521 ;531 ;532). The in vivo-effects of ANP on large artery vasomotor 
control, however, have not been investigated. Therefore we aimed to establish 
whether NPs, acting locally, modify regional distensibility in large muscular arteries. 
In order to investigate the potency and mechanisms of action we performed 4 studies. 
First, we performed a comparative dose-response study assessing the effects of ANP, 
BNP, and CNP on PWV in a previously validated ovine hind limb model.(529) 
Second, to determine the contribution of endogenous ANP to basal arterial 
distensibility we studied the effects of the natriuretic peptide receptor A (NPRa-) 
selective ANP receptor-antagonist A71915 (223) on resting PWV. Third, we assessed 
the effects of A71915 on ANP induced changes in PWV. Fourth, to establish the role 
of the NPRc receptor in regulation of regional iliac arteiy distensibility we studied the
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effects of cANF, an ANP analogue that selectively binds to the NPRc 
receptor(211;533), on PWV.
5.2. Methods
Studies were conducted in 18 adult (n=number of sheep), crossbred Suffolk sheep 
aged between 12 and 18 months, weighing between 37 and 60 kg, at the University of 
New South Wales, Sydney, Australia. The studies were approved by the University’s 
Animal Care and Ethics Committee. Anaesthesia was induced by intramuscular 
injection of Zoletil 100® (lOmg/kg) (Virbac, Peakhurst NSW, Australia), and 
maintained by inhalation of 2-3% isofluorane, administered via a Boyle’s re-breathing 
apparatus with an oxygen flow rate of 2 L min'^ (see Plate 5.2.1.) Animals were 
studied in the supine position, breathing spontaneously (see Plate 5.2.2).
O B
Plate 5.2.1. Shows the animal-theatre; a Harvard respirator (red) to the left, the 
Boyle’s re-breathing apparatus and the OP- table to the right.
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Plate 5.2.2. Illustrates (supine) intra-operative positioning.
5.2.1. Haemodynamic measurements
Pressure measurements were made using a 6F end-hole catheter (Gaeltec, Skye, UK) 
with a 0.46 mm internal lumen, and dual high fidelity pressure sensors located 10 and 
60 mm from the distal end. Calibration of both sensors was performed simultaneously 
at the start of each experiment using a mercury sphygmomanometer. The analogue 
signal from the pressure control unit was fed directly into a portable microcomputer 
using a PC Lab analogue-to-digital converter (AD Instruments, Hastings, UK) with a 
sampling rate of IkHz. Data were recorded over 20 seconds to allow for variations 
within the respiratory cycle. Mean arterial pressure (MAP) was calculated from 
integration of the distal pressure waveform using CPIART software (Version 4). Data 
were then exported and re-sampled at lOkHz for further analysis with custom-written 
MATLAB analysis programme (Math Works, Cambridge, UK). This allows 
identification of the foot of each of the simultaneously recorded pressure waveforms 
and calculates the transit time from the foot-to-foot delay, as previously
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described.(529) An example is shown in Figure 5.2.1. The iliac PWV is calculated 
from the transit time and the fixed distance between the recording sites (50mm), 
which is inversely related to arterial distensibility by the equation of Bramwell and 
Hill,(534) PWV=>/ [V • AP/p • AY]
Where: V= artery volume, AY = change in volume, AP = change in pressure and p= 
blood density (assumed to be constant during he study). HR is derived over the 
measurement period from a simultaneously recorded electrocardiogram.
Catheter
(A71915)
Sheath
(A71915)Control
4 msec /t-13 msec
Figure 5.2.1. This figure shows the recording of an intra-arterial pressure wave form 
sampled at lOOOHz before and after infusion of the NPRa selective receptor blocker 
A71915. For illustration purposes the foot of each wave form is highlighted.
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5.2.2. Drugs
Human a-ANP, BNP and CNP (Clinalfa, Laufelfingen/Switzerland), A71915, c-ANF 
(Bachem, UK) were all prepared in 0.9% saline in an aseptic manner on the day of the 
study. The NP doses and infusion periods were based on our previous experience in 
the human forearm, (516) and were titrated to produce local and not systemic effects.
5.2.3. Protocol / Surgical preparation
The femoral artery was identified by palpation and a 30 mm segment of each artery 
was exposed by limited dissection into which a 7F sheath was inserted (see Plates 
5.2.3.1 a, b, c). The arterial catheter was then positioned in the common iliac artery 
with the tip below the level of the aortic trifurcation (see Plate 5.2.3.2), as previously 
described.(529) Sahne was infused through the sheath or catheter at 1 mL/min for a 
period of 30 min to allow for stabilization of the preparation. At the end of this period, 
measurements of iliac PWV, MAP, and HR were taken. This was followed by 
infusion of ANP, BNP, or CNP via the sheath. Measurements of iliac PWV, MAP,
HR and flow were then recorded in duplicate, or until measurements were stable 
(within 10% of each other). All drugs were infused at 1 mL/min, for 5 minutes in 
doses as outlined below. Repeated pressure waveforms were recorded for 20 seconds 
during the last minute of each infusion period. Potentially confounding changes in 
flow were controlled for by drug infusion via the catheter and the sheath. Infusion of 
drugs through the catheter expose the arterial segment under-study to the drug, while 
infusion via the sheath do not, since the drug is delivered distal to the pressure sensors 
(see Figure 5.2.3.).
With the exemption of study 3 no two drugs were infused in the same limb. Where 
animals were studied twice hemodynamics had returned to baseline and a minimal
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washout period of 40 minutes was interposed before the contralateral limb was 
studied.
Plate 5.2.3.1. a) illustrates a “minimal invasive” inguinal cut-down. The sheet is 
inserted via seldinger technique under direct inspection.
Plate 5.2.3.1. b) shows the two high fidelity pressure sensors, mounted at the distal 
end of the 5 French Gaeltec catheter. The pressure sensors are spaced 50 mmm apart.
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Plate 5.2.3.1. c) Illustrates the operative setting of a bilateral inguinal cut-down.
Plate 5.2.3.1. d) demonstrates the alternative study setting pursued in animals where 
anatomical variants, small vessel caliber, or technical difficulties prevented 
cannulation of the common iliac artery with a 6French sheeth. The catheter is directly 
inserted via an arteriotomy and advanced proximally whilst a 2^  ^vigon tube is 
inserted distally in downstream direction.
166
Plate 5.2.3.2. Illustrates the ovine pelvic arterial anatomy. The sheep has a very strong 
mediosarcal artery, essentially forming an aortic trifurcation.
5.2.3.1. ANP / BNP / CNP dose response studies
ANP (n=6), BNP (n=6), or CNP (n=6) (0.3nMol/min) was infused via the sheath and 
2 baseline recordings were taken. This was followed by infusion of equimolar doses 
of ANP (~0.03nMol/min [~0.1pg/min], ~0.15nMol/min [~0.5pg/min], ~0.3nMol/min 
[~lpg/min]), BNP (~0.03nMol/min [^.llpg/m in], ~0.15nMol/min [^.56pg/min], 
0.3nMol/min [-l.lpg/min]) or CNP (~0.15nMol/min and ~0.3nMol/min) via the 
catheter, in an incremental cumulative fashion.
5.2.3.2. Effects of A71915 on resting PWV
Following baseline measurement during normal saline via the catheter the NPRa- 
selective ANP receptor antagonist A71915 was infused at an infusion rate of 
6.1nMol/min (n=7) and measurements of HR, MAP and PWV were repeated.
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5.2.3.3. Effects of ANP/A71915 co-mfusion
In 4 sheep baseline measurements during normal saline infusion via the catheter were 
followed by co-infusion of ANP (0.15nMol/min)/A71915 (6.1nMol/min) a further 
measurement, infusion of ANP (0.15nMol/min) alone, and a final measurement.
5.2.3.4. Effect of cANF on regional PWV
The role of the NPRc receptor in mediating NP induced changes in regional PWV 
were studied by infusing the NPRc selective agent cANF (n=4). Following baseline 
measurements during normal saline infusion via the catheter, infusion of cANF was 
commenced at a dose rate of 0.3nMol/min.
5.3. Statistics
Data are expressed as mean±SEM. Data were analysed by 2-way ANOVA with post- 
hoc comparison to baseline. A value of /k O.05 was considered significant.
5.4. Results
Changes in HR and MAP are summarised in Table 5.4. Importantly, in the 
ANP/BNP/CNP dose response studies, NP infusion distal to the common iliac artery 
(via the sheath) did not have any (reflex) effects on (proximal) PWV.
5.4.1. The effects ofANP/BNP/CNP on iliac PWV
ANP and to a lesser degree BNP dose dependency decreased regional PWV. CNP, 
despite having a marked effect on BP, caused little change in PWV. The results, using 
0.3nMol sheath infusion as baseline, are summarised in Table 5.4. Additionally, the
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ANP and BNP dose response curves (using normal saline infusion as baseline) are 
shown in Figure 5.4.1.a.and Figure 5.4.l.b. respectively.
5.4.2. The effect of A71915 on iliac PWV
The effects of A71915 on iliac PWV are shown in Figure 5.4.2. A71915 increased 
iliac PWV from 2.97±0.13m/s to 3.06±0.13m/s; P<0.01.
5.4.3. The effect of ANP/A71915 co-infusion on iliac PWV
Iliac PWV did not change significantly during ANP/A71915 co-infiision (PWV 
increased from 3.32±0.2m/s during N-saline infusion to 3.36±0.2m/s during co­
infusion; p=NS). ANP infusion alone reduced PWV to 3.23±0.1ms; p<0.01.
5.4.4. The effects of cANF on iliac PWV
cANF infusion had no significant effect on resting PWV (see Figure 5.4.3.).
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TEST ARTERIAL > 
SEGMENT !
Sheath
Catheter
Catheter
 /
Peripheral
P1
I Sheath Drug 
' Infusion 
P2
Blood Flow
Figure 5.2.3. Schema showing infusions via the catheter (proximal) and sheath 
(distal).
PI = pressure sensor 1; P2 = pressure sensor 2.
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0 0.03 0.15 0.3
ANP Dose Riie (nMolftnln)
Figure 5.4.1 .a. The effect of intra-arterial ANP infusion on 
regional PWV is illustrated. Values represent means±SEM. Symbol f  
depicts within group comparison (2 way-ANOVA).
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Figure 5.4.l.b. BNP dose-response curve.
The effect of intra-arterial BNP infusion on regional PWV is illustrated. Values 
represent means±SEM. Symbol * depicts within group comparison (2 way-ANOVA).
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Figure 5.4.I.e. CNP dose-response curve.
The effect of intra-arterial COT infusion on regional PWV is illustrated. Values 
represent meanstSEM
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n=7 t  P<0.01
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N-Sallne A71915
Figure 5.4.2. The effects of A71915 (NPRA-receptor blockade) on iliac PWV.
The effect of inhibiting basal ANP plasma level on resting regional PWV is 
illustrated. Values represent means±SEM. Symbol f  depicts within group comparison 
(student’s t-test).
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Figure 5.4.3. Effect of cANF on PWV. The effect of cANF-NPRc- 
interaction on regional PWV is illustrated. Values represent 
means±SEM.
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Table 5.4. Effects of ANP, BNP, CNP on Hemodynamics
N=18 sheep ANP BNP CNP
Sheath 0.15 0.3 Sheath 0.15 0.3 Sheath 0.15 0.3
Iliac PWV, m/s 3.6±0.2 3.3±0.l'^ 3.3±0.1^ 3.210.1 3.110.1 3.010.1* 4.010.6 4.210.6 3.910.6
MAP, mmHg 84±5 82±7 82±6 8912 8813 8614 9017 8817 81±6^
HR, bpm 141±6 142110 14218 15117 15215 15216 10114 10115 97±3
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5.5. Discussion
Large artery stiffness, the inverse parameter distensibility, and aortic PWV are 
powerful, independent predictors of cardiovascular risk.(525;526) Whilst age-related 
arterial stiffening was thought to be mainly the consequence of structural changes 
within the arterial wall, we (529;530) and others (535) recently demonstrated a 
significant degree of functional regulation.
In the present study we investigated the role of NPs in the functional regulation of 
large artery distensibility.
The principal findings were as follows; first, we demonstrate that ANP and to a lesser 
degree BNP regulate regional large artery distensibility. Second, the effect of ANP 
was completely antagonised by the NPRA-selective receptor blocker A71915 
suggesting that this effect was solely mediated via the NPRA-receptor. Third, A71915 
infusion increased resting PWV suggesting that basal ANP plasma levels contribute to 
resting large artery distensibility. Fourth, neither CNP nor the NPRc-selective 
receptor agonist cANF altered regional PWV suggesting that the NPRb and NPRc 
receptors do not acutely modify large artery distensibility in vivo (keeping in mind the 
caveat referred to in Chapter 4.4.4 on page 157).
5.5.1. The effect of ANP and BNP on large conduit arteries
ANP and BNP exert well documented vasorelaxant effects in the resistance 
vasculature in vivo (251;521). Furthermore, in organ bath experiments various NPs 
have been shown to stimulate cyclic guanosine monophosphate production and to 
dilate rings of smaller conduit arteries, including human internal mammaiy 
(249;521;531;536). However, compelling evidence of a biological effect of ANP on 
in vivo large artery function, including resting distensibility is lacking. In the present
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study we provide direct evidence that ANP modulates regional large artery 
distensibility. The study design rules out central sympathetic or general systemic 
effects. The results therefore reflect local ANP actions.
5.5.2. CNP -  a vasoactive NP?
The NPS consists at least of ANP, BNP, both predominantly of myocardial origin, 
and CNP, largely of endothelial cell origin.(325) ANP and BNP are believed to exert 
their vasorelaxant effects mainly through binding to NPRa, a membrane bound GC- 
coupled receptor that signals via the messenger cGMP. CNP in contrast is the
natural ligand for the NPRb receptor. All 3 peptides have high binding affinity to the 
NPRc receptor,(537) the latter being devoid of a GC-domain. The NPRc-receptor 
(previously believed to mainly act as a clearance receptor) has now been recognised to 
play a crucial role in mediating the anti-proliferative action of the NP. Activation of 
NPRc inhibits adenylate cyclase, increases phospholipase C activity and has very 
recently been shown to mediate CNP induced endothelium derived hyperpolarising 
factor (EDHF) dependent vasorelaxation in mesenteric resistance arteries (533). In 
contrast to the latter study neither cANF-NPRc- nor CNP-NPRe/c-interaction elicited 
any immediate regional arterial effects in the present study. The latter is not surprising 
given that the amount of EDHF dependent vasorelaxation is believed to decrease with 
increasing vessel diameter (538;539). Furthermore, it has long been noticed that the 
effects of NP are size and site dependent (163;531). The potential vasodilatoiy role of 
CNP remains controversial. Whilst some in-vitro (533;540) and in-vivo studies 
(271;278), (the latter following local drug administration), have reported vasodilatoiy 
effects, at least at pharmacological concentrations, others have failed to demonstrate 
important hemodynamic effects at pathophysiological plasma concentrations
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(483;484;541;542). Our study suggests exogenously (intra-arterial) administered CNP 
has little local vasodilatory potency, at least in large muscular conduit arteries. 
However, as CNP is an abluminally secreted paracrine acting hormone plasmalevels 
are possibly a poor surrogate for more important tissue concentrationsin. Therefore, 
definitive assessment of a potential vasoactive role of CNP will have to await the 
results of studies using a selective NPRe-receptor antagonist (which has become 
commercially available in 2004).
5.5.3. Effects of Basal ANP plasma levels on large artery distensibility
The effects of NP on vascular function have traditionally been investigated by 
assessing changes in blood pressure, central hemodynamics, vascular tone, blood flow 
and resistance in response to either exposure to exogenous ANP (167;251;373) or in 
response to inhibition of breakdown of endogenous NPs (367). Most studies have 
employed doses of ANP that result in elevation of plasma peptide concentrations to 
values far above normal (370;371). Richards et al demonstrated that even very low 
dose infusions caused significant hemodynamic effects (543). However, acceptance 
of ANP as a physiologically significant vasoactive hormone depends on the 
demonstration of changes in vascular tone in response to inhibition of the effects of 
basal plasma levels. Studies by Brunner and Woelkert (364), using the ANP-analogue 
A71915, provided evidence that ANP-antagonism contributes to regulation of basal 
coronary and TPR, at least in rodents. Using the same receptor antagonist we 
previously demonstrated that basal ANP plasma levels contribute to regulation of 
regional vascular volume and venous tone in healthy volunteers. Furthermore, we 
demonstrated that A71915 dose dependently antagonised ANP but not sodium 
nitroprusside induced changes in FBF (516). Here we extend these findings to large
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conduit arteries. Indeed the present study, to the best of our knowledge, is the first to 
show that basal ANP plasma levels contribute to resting large artery distensibility in
VIVO.
5.5.4. Clinical considerations
Decreased arterial distensibility (increased stiffening) causes increased PWV so that 
wave reflection affects the systolic rather than the diastolic part of the wave, creating 
a secondary rise in pressure in late systole thereby increasing aflerload without 
adequately augmenting coronary perfusion pressure (544). The sequelae are isolated 
systolic hypertension (ISH), left ventricular hypertrophy and ultimately heart failure. 
Wave reflection itself arises from a myriad of sites at which there is a change in 
vascular impedance, including the aorto-iliac bifurcation. Besides the largely age 
dependent and at present untreatable structural abnormalities (fatigue and fracture of 
elastin), it is now well recognised that functional changes, most importantly smooth 
muscle tone, will also affect PWV. Interestingly patients with ISH exhibit lower 
baseline ANP plasma levels compared to age matched patients with essential 
hypertension, but exhibit a higher renal ANP sensitivity (545). If the same were true 
for their vasculature then NP based treatment regimes may prove particularly useful in 
this subgroup of hypertensive patients. Indeed, NPs have the potential to counteract 
both, pathological remodelling and increased vascular tone. Here we show that ANP- 
NPRA-interaction acutely modulates regional PWV thereby providing a potential 
mechanism by which NP based treatment regimes may exert beneficial effects in ISH.
5.5.5. Limitations
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The present study used an ovine hind limb as model of large arteries in humans. 
Therefore, general concerns of transferring data obtained from animal research to 
humans will apply to this study. However, whilst ovis aries and homo sapiens for 
example differ markedly in their digestive system, for most published cardiovascular 
parameters, the sheep is similar to man if allowance is made for the smaller weight of 
the average sheep. Besides these cardiovascular similarities and its surgical suitabihty, 
the sheep was the animal of choice for the present work as there is possibly no other 
mammal (apart from homo sapiens) in which the cardiovascular effects of NPs have 
been equally well characterised (480;484). In addition, inhibition of basal NO 
production with LNMMA, has a similar qualitative effects on arterial distensibility in 
ovine (529) and human iliac artery (own unpublished data) in vivo.
Furthermore, a non-homologues NP system was used in the present study. Given the 
different degree of species variation between the amino-acid sequence of human and 
ovine NP (minor for ANP and CNP but relatively large for BNP) the absolute 
vascular responses observed (in particular in the BNP study) have to be interpreted 
with caution. It is also self evident that the use of general anaesthesia may have 
influenced our results to some degree. However, due to the need to make very high 
fidelity recordings, it was not possible to use conscious animals.
Although PWV is a measure of distensibility, factors which influence distensibility 
include vessel diameter, wall thickness and wall stiffhess, possibly due to altered 
relative loading of elastin and collagen fibres within the arterial wall, accompanying 
changes in smooth muscle tone. Therefore, we are unable to identify which of these 
parameters are responsible for the observed changes in PWV in the present study. 
However, it would seem unlikely that alterations in vascular resistance in the hind
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limb is responsible for the changes in PWV since infusion of NPs via the sheath had 
no effect.
5.6. Conclusions
ANP, and to a lesser degree BNP, play a role in regulating regional large artery 
distensibility via the NPRa receptor. Neither CNP nor cANF altered PWV, suggesting 
that NPRb and NPRc do not acutely influence distensibility in vivo.
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CHAPTER 6 -  THE EFFECTS OF NOVEL NATRHJRETIC PEPTH)ES (NNP) 
ON ISOLATED RINGS OF RABBIT AORTA: COMPARISON TO ANP AND 
DNP
6,L Background
Unravelling of the NPS is a rapidly evolving process but far from complete.
Recently dendroaspis natriuretic peptide (DNP) a 38 amino acid peptide [Sequence: 
Glu-Val-Lys-Tyr-Asp-Pro-Cys-Phe-Gly-His-Lys-Ile-Asp-Arg-Ile-Asn-His-Val-Ser- 
Asn-Leu-Gly-Cys-Pro-Ser-Leu-Arg-Asp-Pro-Arg-Pro-Asn-Ala-Pro-Ser-Thr-Ser-Ala-; 
discuphide bridge Cys7-Cys23] with a Molecular Weight of 4190.7, has been isolated 
from the venom of the green mamba snake {Dendroaspis angusticeps) (205).
Apart from the 17 amino acid ring structure shared by all NPs, DNP shares eleven 
amino acid residues with CNP, twelve residues with ANP and fourteen with BNP but 
has a 15 amino acid carboxy terminal tail whereas ANP and BNP have only a 6  amino 
acid extension and CNP is completely devote of a c-terminal tail. Furthermore, DNP 
was found to contain 4 proline residues, three of which are clustered in the C-terminal 
region of the molecule. This characteristic is unique to DNP, as neither ANP, BNP 
nor CNP contain proline residues. Interestingly, DNP immimo-like reactivity has been 
found in the plasma of patients with CHF (206) but the significance of this finding is 
controversially debated (207). Meanwhile DNP has been shown to relax human 
arteries and veins in vitro (208), to be a potent natriuretic and diuretic peptide with 
tubular actions linked to cGMP (546), and when administered in dogs, with (547) and 
without heart failure (548), exhibited cardiac unloading and lusitropic properties.
Even more recently, a further novel natriuretic peptide, here preliminarily termed 
NNP, has been isolated in the research laboratory of Glaxo Smith Kline (GSK) from
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the same snake venom as DNP. There is so far no published literature about this 
peptide. NNP has a Molecular Weight of 3690 and its cDNA sequence revealed 
classic characteristics for NPs. A first cell based (PC 12) assay showed that its ability 
to produce cGMP is about the same as rat BNP(l-45) but less than that of ANP. In 
contrast its potency in primary cultured rat aortic smooth muscle cells is superior to 
that of ANP. Furthermore, NNP also exhibits some similarity to CNP but as ANP, 
BNP, and DNP has a c-terminal tail, which appears to be of the same length as that 
reported for DNP. In an in-vitro relaxation experiment using rat mesenteric artery 
NNP was roughly equipotent to BNP(l-45) (Liang Lee [GSK]; personal 
communication).
The aim of this work was to assess the vasorelaxant potency of NNP on conduit 
arteries, using DNP and ANP as comparative agents. Rabbit aortic rings were 
suspended in organ bath and the response to cumulative concentrations of NNP, DNP 
and ANP was obtained following phenylephrine induced pre-constriction and 
consecutive equilibration. Additionally, inhibiting agents were used to determine the 
mechanism of vasorelaxation.
6,2, Methods
Male, New Zealand white rabbits (2-2.5kg) were euthanased by intravenous injection 
of sodium pentabarbitone. The thoracic aorta was then removed into fresh Krebs 
buffer composed of (mmol/L) NaCl 138, KCl 5.3, KH2PO4 1.2, MgS0 4  1.2, Glucose 
15, NaHCOs 24, and CaCb 1.5, and gassed with 95% O2 and 5% CO2. The aorta was 
then carefully cleared of all blood, fat, muscle and cormective tissue.
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6.2.1. Isometric Tension Recordings
For isometric tension recording, 2- to 3-mm-wide aortic rings were mounted on a 
force transducer in tissue baths containing fresh Krebs buffer with a resting tension set 
at 2 g (see Figure 6.2.1.). After a 1 hour equilibration period, contractions were 
produced by addition of a submaximal concentration of (PE, Ipmol/L) and the 
responses allowed to reach a plateau. The aortic rings were then exposed to Ipmol/L 
acetylcholine to determine integrity of the endothelium. Tissues were then repeatedly 
exposed to PE (Ipmol/L) until a stable reproducible level of constriction was 
obtained. Experiments were then carried out as outlined below and all data are 
expressed as percentage relaxation of the appropriate PE-induced constriction (with 
the constriction produced by Ipmol/L PE considered as 0% baseline tension) (549). 
Contractions were recorded and analysed using MacLab 8 hardware.
FORCE
TRANSDUCER
F XED
Figure 6.2.1. Schematic representation of organ bath 
set-up. Aortic rings are mounted in 8ml tissue baths 
containing fresh Krebs buffer solution and attached 
to a force transducer. Aortic rings are allowed to 
equilibrate at a resting tension of 2 g.
ISOLATED RABBIT AORTIC RING
8 ml ORGAN BATH
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6.2.1.1. Effects of ANP, DNP and NNP on vascular smooth muscle tone
The effects of ANP, DNP and NNP on PE (1 jiimol/L -  final concentration in organ 
bath) pre-constricted rings of rabbit aortic tissue was measured by generating 
concentration-response curves. Relaxation to all three peptides was determined over a 
concentration range of 0. Inmol/L to 0.1 pmol/L (final concentration in organ bath). 
The relaxation response was measured during the 5-minute interval after each 
cumulative addition of the natriuretic peptide in question.
6.2.1.2. The Role of Nitric Oxide in NNP induced vasorelaxation
To determine a potential role of NO in NNP mediated vasorelaxation, O.3mmol/L of 
L-nitro arginine methyl ester (L-NAME), a NO synthase inhibitor, was added to the 
organ baths one hour before the pre-contraction with PE and subsequent NNP 
administration.
6.2.1.3. The Role of Prostaglandins in NNP-induced vasorelaxation
The role of prostaglandins in mediating NNP-induced vasorelaxation was investigated 
by pre-incubation aortic rings with the cyclo-oxygenase inhibitor indomethacin 
(0.01 mmol/L; final concentration in organ bath). Following 1 hour incubation rings 
were pre-contracted as above and cumulative NNP dose response curves were 
performed.
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6.2.1.4. The Role of Soluble Guanylate Cyclase (sGC) in NNP-induced 
vasorelaxation
To assess the potential role of soluble GC (s-GC) in NNP induced vaorelaxation, 
aortic rings were incubated for 1 hour with the s-GC-inhibitor ODQ (IH- 
[l,2,4]oxadiazol 9,4,3-alpha) quinoxaline-1, lOpmol/L; final concentration in organ 
bath).
6.2.1.5. The Role of NPRa in NNP induced vasorelaxation
To assess whether NNP induced vasorelaxation is mediated via NNP-NPRa 
interaction, we performed NNP dose-response studies in the presence and absence of 
the NPRA-selective receptor antagonist A71915 (Ipmol/L, 3pmol/L, lOpmol/L). A 
prior pilot dose-response study using A71915 had revealed no intrinsic vasodilating 
property of A71915 over the applied dose range.
6.2.1.6. The Role of NPRc in NNP induced vasorelaxation
To assess whether NNP induced vasorelaxation is mediated via NNP-NPRc 
interaction, we performed NNP dose-response studies in presence and absence of the 
NPRc-selective receptor antagonist cANF (Ipmol/L).
6.2.2. Drugs and Chemicals
NNP was donated by Glaxo Smith Kline (London, UK). DNP was purchased from 
Phoenix Pharmaceuticals (Belmont CA, USA). ANP, A71915, and cANF were 
purchased from Bachem LTD (St Helens, UK). ODQ, L-NAME, and Indomethacin 
and Phenylepinephrine were purchased from Sigma.
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6.2.3. Statistical analysis
Data are expressed as mean ± standard error of the mean (S.E.M.). In all experiments, 
n equals the number of vascular rings. All comparisons were performed by one-way 
ANOVA followed by Bonferroni's post hoc test as appropriate. Concentrations 
causing 50% of the maximal response (EC50) were calculated using GraphPad Prism 
Software. Significance is defined as p<0.05.
6.3, Results
6.3.1. Comparative ANP, DNP, NNP dose response study
ANP, DNP, and NNP produced similar concentration-dependent relaxation of PE-pre­
constricted rabbit aortic tissues (see Fig 6.3.1 and Table 6.3.1).
Table 6.3.1. Effects of ANP, DNP and NNP on vascular smooth muscle tone
Natriuretic peptide % Aortic Relaxation ± 
S.E.M.
-LogECso ±S.E.M. 
(mol/1)
ANP 91.46 ±1.50 7.957 ± 0.09
DNP 94.78 ± 0.45 8.10510.04
NNP 92.0410.61 8.15710.04
Maximal relaxations to O.lpmol/1 natriuretic peptide (final concentration in organ 
bath). -Log EC50 values are also shown Data are expressed as means ± Standard error 
of the mean (S.E.M.).
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Figure 6.3.1. Concentration response studies to NPs ANP (n=8 ), DNP (n=13) and NNP 
(n=16) (0.1 nmol/1-0. IpmoPl) on IpmoPl PE-induced preconstricted rabbit aortic tissue. 
Data are expressed as mean ± S.E.M.
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6.3.2. The Effects of Nitric Oxide in NNP induced vasorelaxation
Figure 6.3.2. Illustrates the role of endothelial NO synthase on NNP (O.lnmol/1- 
0.1|imol/l) induced vasorelaxation. Pre-incubation with L-NAME (O.3mmol/L) had 
no effect on NNP induced vasorelaxation.
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Figure 6.3.2. Concentration-response studies to NNP in the presence (n=3) and 
absence (n=3) of 0.3mmol/l L-NAME. Data are expressed as mean ± S.E.M.
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6.3.3. The Effects of Prostaglandins in NNP-induced vasorelaxation
Figure 6.3.3. Illustrates the effect of cyclo-oxgenase inhibition on NNP (O.lnmol/1- 
0.1|Limol/l) induced vasorelaxation. Pre-incubation with Indomethacin (l|Limol/L) had 
no effect on the subsequent relaxation response to NNP.
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Figure 6.3.3. Concentration-response studies to NNP (O.lnmol/l-O.lpmol/1) in the 
presence (n=3) and absence (n=3) of lpmol/1 Indomethacin. Data are expressed as 
mean ± S.E.M.
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6.3.4. The Effects of sGC in NNP-induced vasorelaxation
Figure 6.3.4. Illustrates the role of the sGC-cGMP pathway in mediating NNP 
induced vasorelaxation. Pre-incubation with lOpmol/l ODQ had no effect on NNP 
(0.1 nmol/1-0. ljLimol/1) induced vasorelaxation.
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Figure 6.3.4 Concentration-response studies to NNP (0.1 nmol/1-0.Ipmol/l) in the 
presence (n=3) and absence (n=3) of lOpmol/1 ODQ. Data are expressed as mean ± 
S.E.M.
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6.3.5. The Effects of NPRa-NNP interaction on vascular smooth muscle tone
Figures 6.3.5.a.-c. Illustrate the effects of selective NPRA-receptor blockade on NNP 
induced vasorelaxation. Pre-incubation with A71915 (Ipmol/L, 3pmol/L and 
lOpmol/L) had no effect on NNP induced vasorelaxation.
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Figure 6.3.5.a. Concentration-response studies to NNP (0.1 nmol/1-0. Ijumol/l) in the 
presence (n=4) and absence of (n=5) lpmol/1 A71915.
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Figure 6.3.5.b. Concentration-response studies to NNP (0.1 nmol/1-0, lpmol/1) in the 
presence (n=2) and absence of (n=5) 3pmol/l A71915.
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Figure 6.3.5.C. Concentration-response studies to NNP (0.1 nmol/1-0. Ipmol/l) in the 
presence (n=2) and absence of (n=5) lOpmol/1 A7191515.
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6.3.6. The Effects of NPRc-NNP interaction on vascular smooth muscle tone
Figure 6.3.6. Illustrates the effects NPRc-inhibition on NNP induced vasorelaxation. 
Pre-incubation with cANF caused a significant inhibition of NNP-induced 
vasorelaxation at the log molar concentrations of -8  (p<0.05) and -8.563 (pKO.OOl) 
with a greater significance found at the latter concentration.
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Figure 6.3.6. Concentration-response studies to NNP (0.1mnol/l-0.1|Limol/l) in the 
presence (n=4) and absence (n=4) of Ipmol/l cANF. Symbols depict *p<0.05),
**p<0 .0 0 1 ).
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6,4, Discussion
We tested the ability of NNP to decrease PE induced isometric tension in rabbit aortic 
rings. Our studies revealed that NNP has vasorelaxant potency very similar to those of 
DNP and ANP.
In line with previous studies (550) assessing the vascular reactivity of tissue from 
healthy animals to various NP’s our studies provide evidence that the vasorelaxant 
properties of NNP are independent of cyclo-oxygenase. Furthermore, as is the case for 
CNP (274;276) neither, eNOS nor soluble guanylate-cyclase appear to be involved in 
NNP induced vasorelaxation.
An important new finding of these experiments is that NNP induced vasorelaxation is 
diminished in the presence of cANF. This implies that NNP-NPRc interaction, like 
DNP-NPRc (550) interaction triggers a direct or indirect vasorelaxant effect. It is 
theoretically plausible that NNP-NPRc interaction, like CNP-NPRc interaction in the 
resistance vasulature (533), causes an EDHF dependent vasorelaxation. However, 
given the acknowledged small role of EDHF in conduit vessels (538;539) this is a 
rather unlikely mechanism. Nevertheless, indirect activation of potassium channels 
subsequent to changes to cGMP or more likely changes in cAMP with subsequent 
alterations in Calcium influx and release are distinct possibilities by which NNP could 
exert a NPRc mediated effect. Finally, NNP-NPRc binding could induce a 
conformational change in the 39 amino acid intracellular tail of the receptor thereby 
activating its G-protein containing sequence with subsequent signal transduction 
either via inhibition of adenylate cyclase (potentially via Gi2) or alternatively via 
activation of phospholipase C (potentially via the Py-subunit of Gii and Gii).
As with other NPs NNP induced vasorelaxation does not appear to depend on the 
soluble GC system, as evidence by a lack of effect of ODQ.
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The results of study 6.3.5. using the NPRA-selective receptor antagonist A71915 
deserve comment. Pre-incubation of aortic rings with A71915 at a concentration of 
lpmol/1 failed to affect NNP induced vasorelaxation. Pre-incubation of aortic rings 
with A71915 at a concentration of 3pmol/l and lOpmol/l tended to shift the relaxation 
curves up-ward (i.e. reduced vasorelaxation) without reaching statistical significance. 
Because of the need to perform dose finding studies, the limited amount of NNP and 
A71915 available at the time of experimentation, and the decision to test the 
interactions of NNP with several possible vasorelaxant systems (as outlined above) 
the studies are likely to be underpowered. It is therefore concluded that whilst the 
NPRa receptor is unlikely to be the natural receptor for NNP, NNP induced NPRa 
mediated effects can not be ruled out on the basis of these experiments and repetition 
of these experiments with higher numbers is needed.
DNP has structural features, receptor characteristics, second messenger activity, and 
some biological effects (i.e. vasorelaxation) in common with ANP and BNP.
However, despite some studies showing DNP-like immuno reactivity in human 
plasma (206;551) the significance of this finding and consequently the question if 
DNP is a member of the NPS in man remains controversial (207), even 11 years after 
its discovery (205).
It has been pointed out that albeit intriguing, the finding of DNP-like immunoreactive 
staining (206) and DNP-like immuno-reactivity in human plasma (206;551) "'do not 
establish DNP as a member o f  the mammalian cardiac natriuretic peptide family or 
even as an endogenous peptide in human beings ” (207). Because of the limitations 
associated with the techniques applied in aforementioned studies it will be mandatory 
to identify the peptide in human plasma and tissue using high-performance
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chromatography linked to immunoassay, followed by purification and analysis to 
establish the human aminoacid sequence. Furthermore, the gene must be identified in 
the Green Mamba so that appropriate probes for the cloning of the human homologue 
can be generated (207).
As far as NNP is concerned the same criteria will have to apply as for DNP. The 
publication of the aminoacid sequence is eagerly awaited in order to confirm that 
NNP and DNP are indeed different in their amino acid sequence and not simply 
different slicing products of an identical NNP/DNP pre-hormone. Time will tell if 
these peptides are true additions to the (human) natriuretic peptide family or just 
primitive evolutionary precursors to ANP and BNP, or even snake BNP itself given, 
the enormous species variation and the lack of an identified snake BNP.
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CHAPTER 7 -  DISCUSSION AND CONCLUSIONS
7.1. Discussion
Over the last two decades several well conducted large randomised controlled clinical 
trials, in patients with heart failure on the basis of systolic left ventricular impairment, 
have unequivocally demonstrated reductions in overall mortality for the use of ACE -  
inhibitors (46;552-554) or alternatively ATi-antagonists (52;555), p-blockers (556- 
561), and spironolactone (562). However, epidemiological surveys, including the 
Framingham Study, have not documented any meaningful reduction in overall death 
rates (563). Instead it appears that the aforementioned therapies delay the 
development of heart failure following myocardial injury (45) and possibly slow 
down disease progression after heart failure has set in, thereby prolonging a life with 
heart failure (563).
Heart failure is also the reason for at least 20% of all hospital admissions among 
persons older than 65, and over the past decade the rate of hospitalisations has 
increased by 159% (564). Besides the pharmacological interventions listed above, 
coronary artery bypass grafting in ischemic heart disease (565;566), mitral valve 
repair (567), left ventricular geometry restoration (568), implantation of left 
ventricular assist devices, implantable cardioverter-defibrillators (569;570) and/or Bi­
ventricular pacemakers (571), have all been proven to be beneficial in (more or less) 
selected patients. Finally, the use of multidisciplinary teams (572) has been 
demonstrated to be cost effective and to reduce the rate of hospitalisation (573).
In line with these findings and because of the large burden that heart failure presents 
not only to the affected individual but also to the society, modem RCTs are now also 
assessing the effects of the studied intervention on rate of hospital admissions and 
other markers of morbidity and economic factors (574).
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From a pathophysiological point of view heart failure remains imperfectly imderstood. 
A variety of different model approaches have placed different weight on different 
aspects of the clinical syndrome. The present thesis is performed at a time when the 
neurohormonal model of heart failure is popular. Indeed, current therapies of heart 
failure are largely based on inhibition of neuroendocrine responses, and the diagnostic 
(178; 180) and prognostic (575-577) value of an abundant number of circulating 
peptides and proteins (578) (be it of myocardial (578) or vascular in origin (579)) 
have been proven beyond doubt.
However, it is acknowledged that the recent failure of several therapeutic concepts, 
grounded in the neurohormonal concept have sobered the “scientific heart failure 
community”. The findings and/or failures of OVERTURE (183;580), ENABLE (581), 
and RENEWAL (= RENAISSANCE+ RECOVER) (582) have raised the questions if 
we have either reached the “asymptote of efficacy” (580) and/or, if some of the 
concepts that appeared so promising in animal models of heart failure are simply 
“imsuccessful, to be specific” (583) in the clinical scenario.
Several “opinion leaders” recently commented on these issues and discussed a 
possible scenario of “the foreseeable future” (584) for some of the agents that failed to 
deliver on earlier promises (582;585-587).
From a clinician’s and more importantly a patient’s point of view the existing 
armamentarium of heart failure medication, complemented by non-pharmacological 
and dietary interventions, already seems to be a sizable challenge to completely 
comply with. With this in mind and recognising that Nesiritide (a recombinant BNP), 
a drug that only confers marginal symptomatic benefit over existing much cheaper 
therapeutic alternatives, is the only true new drug that has been licensed for the
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treatment for heart failure by the FDA over the last two decades, it is possibly fair to 
assume that (immediate) further improvements in morbidity and/or mortality in the 
management of heart failure, is most likely to be achieved only by a truly 
individualised treatment approach. Such an individualised approach will have to take 
account of the degree and pattern of neurohormonal activation. Encouragingly a 
recent, albeit small randomised study, showed that pharmacotherapy guided by 
plasma N-BNP reduced the number of cardiovascular events as compared to trial- 
based therapy dictated by clinical acumen (181).
Heart failure has all too long remained a “low profile diagnosis” despite a prognosis 
worse than most cancers (588;589). The introductory Chapter 1.1. briefly describes 
the pandemic dimensions, pathophysiology and classification of this disease.
Chapter 1.2. outlines the physiological importance of the venous capacitance bed in 
man, and describes the adverse pathohysiological consequences of increased venous 
tone in heart failure.
The dearth of knowledge concerning these small veins and venules and the 
mechanism of venoconstriction in heart failure is in no small part the consequence of 
absence of simple techniques that allow their study. The methodology chapter 
(chapter 2) describes the basic principle, applicability and validity of RPY, a 
technique that combines EBPS and conventional VOP, thereby allowing detailed 
assessment of the small veins and venules (i.e. the capacitance circulation).
For reasons outlined in chapter 2.8. RPY will remain limited in its application. 
However, in view of the unique information that this technique can provide it is hoped 
that RPY will find its niche and indeed a wider application than at present (to the best 
of our knowledge Cardiff is currently worldwide the only institute applying RPY in 
human research). Combining the advantages of EBPS and conventional occlusive
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techniques has the potential to be used in the complex assessment of cardiovascular 
drugs, physiologic, and mechanistic interventions (e.g. cardiac resynchronisation 
therapy) in order to optimise individual treatments in patients with e.g. heart failure 
(or essential and pulmonary hypertension). The use of multiple gamma cameras and 
mobile “nuclear vests” will permit investigation of the effects of variable 
interventions on right and left ventricular volumes (and function) and dynamic blood 
volume shifts (or regional re-distributions) in health, disease states, and importantly 
following mechanistic interventions, and during exercise.
Several such studies are already underway and it is hoped that the work of this thesis 
provides a platform and a rationale for a wealth of further studies of the venous 
capacitance bed, in particular in heart failure but also in pulmonary and essential 
hypertension.
Venodilatation, has been shown to confer some of the symptomatic benefits derived 
from diuretic (590;591) and morphine (592;593) therapy and may partly account for 
the superior outcome data of ACE-inhibitors when compared to pure arterial dilators 
(54). In view of the fact that only vasoactive agents with a balanced veno-/arterio- 
dilating profile have so far been shown to improve outcome in heart failure the 
marked imbalance of scientific focus on the arterial circulation and the relative 
neglect of the venous circulation, in particular the small veins and venules, seems 
somewhat unjustified.
The interpretation of studies assessing venous physiology and pathophysiology will 
depend on the conceptual framework that is deployed. The methodology and concepts 
used in the present thesis are based on Tyberg’s (and co-workers, for review see 
(89; 104)) extended PA  ^model of the circulation, and ultimately based on Levy’s
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(594) concepts. The applied methodology is, from a theoretical and practical point of 
view, presented in chapter 1 .2  and 2  respectively.
The principal objective of the work presented in this thesis was to investigate the role 
of ANP in the regulation of regional vascular function, in particular regional volume 
and tone, in both health and heart failure.
We generally thought it counterintuitive to believe that a hormone released in 
response to atrial stretch should not have an effect on venous tone. A starting point 
was that, despite the uniform observation of a reduced CVP following ANP 
administration, and the specific finding that low dose ANP reduced CVP without a 
fall of SVR, the majority of studies in the mid eighties and early nineties concluded 
that ANP had very little, if any effect on venous tone. These negatives studies can 
generally be divided into two groups; The first group are studies assessing the effects 
of ANP on conduit veins, either using the “Aellig-dorsal hand vein technique” (8 6 ) in 
vivo, or assessing other conduit veins, such as the saphenous vein, in vitro using 
organ chamber experiments. Besides the general limitations that need to be considered 
when applying these techniques (for discussion see chapters 2.9.1. and 3.5.1.-4.) 
A(NP) indeed appears to have little effect on conduit veins. However, in analogy to 
the arterial circulation where it has long been recognised that there are marked 
differences in the control of conduit and resistance arteries, it has become clear that 
conduit veins in general and the dorsal hand vein in particular behave differently from 
the physiologically more important small veins and venules. Some of the reasons for 
such differences have been discussed in chapter 3.5.2. The second group of studies 
finding a lack of A(NP) actions on venous tone are grounded in Guytonian Physiology 
and specifically in the concept of increased resistance to venous return (595;596).
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In contrast to the approach presented in the current thesis, which as stated above is 
based on Tyberg’s modified PA  ^model of the circulation, the Guytonian approach to 
the veins is based on pressure-flow relationships and the concept postulates that the 
driving force behind venous return is the difference between mean circulatory filling 
pressure (MCFP) and RA pressure. Based on this understanding, the venous- retum- 
right-atrial-pressure representation was used to argue that venous return increases 
because right atrial pressure (“back-pressure”) decreases, given a constant MCFP 
(596). Levy (594) questioned the assertion that venous return increases because of a 
decrease in right atrial pressure, repeated Guyton’s experiment, and interpreted the 
results exactly oppositely -  that right atrial pressure decreased because CO increased. 
It is possibly worthwhile mentioning that Guyton was one of the referees of Levy’s 
work and his comments were judged to merit publication (and make interesting 
reading) (597). In his comment he found himself “/« complete agreement with Levy 
on all but two minor points, neither o f which is important conceptually and both o f 
which justify discussion only from a semantic view '^ (597).
However, deductions about venous tone from standard hemodynamic studies may be 
misleading since filling pressures may be reduced by improved left ventricular 
function (54;75) (improvement in left ventricular function following (A)NP 
administration is undisputed). Recognising this, M. Packer (598) pointed out that the 
concept of venous return may be semantically (if not also fundamentally) problematic 
when analyzing the hemodynamics of CHF.
Further, we suggest that there are significant problems with Gauer’s approach (599), 
as used by Holtz (504) and Trippodo (600) and their associates. Before and after the 
intervention, they defined pressure-volume relationships by quickly and substantially 
changing total blood volume while measuring mean circulatory filling pressure
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(MCFP). Recently, Tyberg’s group (601) has studied the effects of acute volume 
infusion (40 ml/kg) and hemorrhage (sufficient to reduce MAP by 50-60%) and foimd 
that volume infusion increased capacitance (i.e., the volume contained at a given 
pressure) by -60% and hemorrhage decreased it by -15%. As venous capacitance is 
so sensitive to changes in blood volume, we contend that the results of previous 
experiments are difficult to interpret and need to be re-evaluated.
Further, we contend that our method has fundamental and substantial advantages in 
that it disturbs the total circulation so minimally. In un-sedated, comfortable patients, 
we define the vascular pressure-volume relationship of the forearm simply by 
inflating a cuff to -30 nun Hg, in marked contrast to the experimental studies of 
anesthetized (anaesthesias itself alters the response to ANP (502;503)), surgically 
operated animals in which MCFP was measured by stopping the heart repeatedly for 
many seconds.
Finally, although in his recent review (92) Tyberg has acknowledged that both the 
Guyton and Levy models are both intemally consistent and that it is difficult to prove 
one at the expense of the other, we feel we have very good reasons to prefer the Levy 
model. First and foremost, capacitance is a pressure-volume property and to 
investigate it by studying pressure-^Zow relationships (i.e., right atrial pressure vs. 
venous return) is profoundly indirect, at the very best. Second, venous resistance, 
which forms such an important part of the Guyton-Permutt approach, is only an 
extremely small fraction of the total SVR and assumes significance only in Guyton’s 
model — and that, primarily, in the unsteady state when the peripheral capacitance is 
being discharged (most clinical situations of interest are steady-state, in which 
capacitors completely disappear from the circuit). Third, our approach is entirely 
consistent with classical pre-Guyton venous physiology (602-604), in fact, Guyton
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provided a figure (Figure 1.2.3.4.) showing parallel shifting arterial and venous 
pressure-volume relationships in several of his textbooks (e.g., Guyton AC, Hall JE: 
Human Physiology and Mechanisms of Disease. 6 ^ Edition, WB Saunders Company, 
Philadelphia, 1997, p. 120). Because venous capacitance is a measure of the volume 
that the veins contain at a given pressure (40) it is in our view the most intuitive way 
to describe venous capacitance in terms of PVRs.
The studies by Ando et al (369), Olson et al (169) and Peters et al (56) hinted that 
ANP affected venous compliance and/or capacitance in the small veins and venules. 
The study by Peters (56) (a randomized, vehicle controlled, double blind study 
evaluating how ANP altered the regional distribution of blood in the capacitance 
vessels of eight healthy volunteers) found that a significant decrease in cardiac 
radioactivity (and fall in CVP) was paralleled by a significant increase in intestinal 
activity (56). This study in our view is strong evidence that ANP regionally “pools”, 
indeed translocates central blood reserves into intestinal (and skeletal) capacitance 
vessels.
Applying our P/V model we demonstrate in chapter 3 that ANP increases regional 
vascular volume over a wide range of physiological, pathophysiological, and 
pharmacological plasma levels without significantly affecting compliance.
The finding of regionally increased blood volume in absence of compliance changes 
therefore allows us to conclude that changes in regional volume were the consequence 
of venodilatation. Interestingly the studies confirmed that plasma levels similar to 
those in severe heart failure, achieve a near maximal venodilating effect and that 
further increases fail to elicit an additional increase in venodilatation, possibly (partly) 
due to systemic effects and overriding baro-reflex-mediated venoconstriction. Most 
importantly, we demonstrate for the first time that basal natriuretic peptide levels
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modulate vascular tone. It is worthwhile pointing out (and in my own view this is 
indeed the greatest merit of the present work) that the studies summarised in chapter 3 
are the first investigating NPR blockade (NPRA-receptor blockade to be specific) in 
humans.
In chapter 4 we present the effects of all four currently known human NPs on regional 
vascular function in symptomatic patients with cHF on maximal medical therapy. In 
particular we tested the hypothesis that venous but not arterial ANP responsiveness is 
preserved. We demonstrate that ANP despite lesser effects in the resistance 
vasculature has significantly more potent effects on the capacitance vasculature 
compared to BNP, CNP and Urodilatin. This finding is not only supportive of the 
original hypothesis but also renders indirect support to our previous validation studies 
demonstrating that changes in venous volume due not merely reflect changes in 
arterial inflow (95). Indeed, in the present studies ANP causes the least increase in 
FBF but the highest increase in FW . The finding of preserved venous ANP 
responsiveness in presence of impaired arterial responsiveness together with the 
indirect observation that the older patients in chapter 4 had an almost identical venous 
responsiveness to the younger patients in chapter 3 despite clearly decreased arterial 
responsiveness, is in keeping with an often overlooked study by Emmick and Cohen 
which examined the possibility that vascular relaxation to atrial NPs may be affected 
by (animal) age (522). These investigators found that in vitro relaxation to atrial 
peptide 25 (AP-25) and atriopeptin (AP-21) in serotonin contracted aorta, carotid 
artery and mesenteric artery was greatest in young animals (rats 1-2  months of age) 
with a roughly 2 0 % reduction in vascular responsiveness in older animals (rats 18-19 
months of age). Unlike the arterial preparations examined, portal veins from rats of all 
ages relaxed similarly to AP-25. Interestingly, AP-25 given intravenously lowered
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blood pressure to a similar extent in animals of all ages. Thus the greater arterial in 
vitro sensitivity of yoimger animals did not result in a greater reduction in BP in these 
younger rats (522). This observation is in keeping with the aforementioned studies by 
Groban (346) and Serizawa (523) showing that ANP could lower CVP without 
affecting SVR. In other words the effect of atrial peptides on blood pressure may not 
be associated with an arterial event but instead may be the consequence of its venous 
effects with subsequent reduction in cardiac preload.
Decreased ANP binding, first observed in a rat model of heart failure (see also chapter 
1.3.7.l.NPRA+B-receptor downregulation) was reported by Tsunoda (424) and later 
suggested in humans (425). It is conceivable that modest down-regulation of NPRa- 
receptors occurs as ANP levels increase with age and with certain diseases, including 
heart failure and hypertension. Indeed ANP induced NPRA-receptor down regulation 
has been observed in aortic VSMCs (605). To a certain degree the venous circulation 
may be protected fi’om such a down-regulatory process due to the abundance of 
NPRc-, or clearance receptors.
Our studies, albeit not specifically designed to investigate receptor density, 
nevertheless provided nevertheless some interesting findings. Baseline cGMP levels 
in heart failure patients were 10-fold higher than in controls, potentially arguing 
against NPRa/b receptor down-regulation. Most intriguingly, and somewhat in support 
of the assumption of a protected venous circulation (protected against ANP induced 
NPRa receptor down-regulation), we found that identical infusion rates raised venous 
ANP plasma levels significantly more in controls than in cHF patients. Given that 
these ANP concentrations were infused directly into the brachial artery this can only 
mean that there was a higher clearance activity across the forearm bed of patients than 
controls, which raises the distinct possibility of NPRc-receptor up-regulation.
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Chapter 5 focusses on conduit arteries. The ovine hind limb model was chosen mainly 
for 3 reasons. First, the sheep is similar to man for most cardiovascular parameters 
and the cardiovascular effects of NPs have been extensively studied in ovis aries in 
both, health (287;480-484) and heart failure (486-488;490;491;493;495). Second, the 
aforementioned surgical suitability (and of course the possibility of access to sheep) 
and pre-existing sound validation (529;530) of this model.
Third, and most importantly the ovine hind limb model was chosen because of its 
unique potential to investigate the mechanisms of NP tolerance/resistance (for 
discussion see chapter 1.3.7) in the future (see future work).
Besides the fact that the in-vivo effects of NPs on regional large artery function had 
not been studied adequately a further important aspect of this work (which because 
cANF is not licensed for human use could only be studied in an animal model) was to 
gain some knowledge about the role of the NPRc-receptor in regulating vasomotor 
tone. Whilst this receptor was long believed to play a somewhat dormant role as a 
clearance receptor, some recent work had demonstrated that cANF-NPRc interaction 
could elicit vasomotor changes in resistance arteries.
The data presented in chapter 5.4 in my view provide compelling evidence that ANP 
modulates large artery distensibility predominantly, if not exclusively, via the NPRa. 
Neither CNP, acting via the NPRb, nor cANF, a NPRc-selective agonist, altered PWV 
suggesting that NPRb and NPRc do not acutely influence distensibility in vivo.
In chapter 6 we present first results assessing the vasorelaxant properties of a 
potentially new member of the natriuretic peptide family. Glaxo-Smith-Kline 
provided us with a small amount of a peptide preliminarily termed NNP. This peptide 
was isolated from the venom of the green mamba snake (Dendroaspis angusticeps).
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According to personal communication (Liang Lee -  GSK) the peptide’s cDNA 
sequence revealed classic characteristics for NPs. Interestingly, its carboxy-terminal 
tail is of the same length as that of DNP but its molecular weight differs (3690 for 
NNP versus 4190.7 for DNP). Consequently there are two possibilities; Either NNP is 
indeed a new member of the (serpent) natriuretic peptide family, or NNP and DNP are 
both derived from an identical precursor (“pre-NNP/DNP”) and are only spliced at a 
different amino-terminal side (analogy to ANP and Urodilatin). Only the publication 
of the fiill amino-acid sequence and/or identification of the serpent NNP / DNP gene 
will clarify this issue and reveal the full significance of the NNP discovery. Whatever 
the outcome, the data in chapter 6.3. demonstrate that this peptide is roughly 
equipotent to ANP and DNP in its vasorelaxant properties. The mechanisms of this 
vasorelaxation will need further study.
7.2. Future work
The most important question arising from a countless number of studies investigating 
the effects of NPs in heart failure is;
What are the mechanisms of natriuretic peptide resistance and/or tolerance?
The answer to this question will help to explain why, NP-based, treatment strategies 
have so far failed to provide a tangible success, and may indeed open up new 
therapeutic avenues.
A further question directly arising from our previous work (437) and chapter 4 is; 
What are the reasons for the apparent preservation of natriuretic peptide responsivness 
in the venous circulation?
Starting from the current understanding of NP-resistance^ reviewed in chapter 1.3.7., I 
recently extended our established ovine hind limb model into a pacing induced heart
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failure model based on the earlier work of Fitzpatrick and Rademaker (486- 
488;490;491;493;495). Ethical approval has meanwhile been granted for a large 
animal study to investigate the mechanisms of natriuretic peptide resistance.
Following successful completion of the feasibility pilot studies (all 8 animals survived 
a left lateral thoracotomy and 6-8 days epicardial pacing [4 animals] I now hope to 
embark in the main study. All studies will be conducted using the above mentioned 
model. PWV will be conducted by the foot to foot methodology as described in 
chapter 5. Additionally iliac arteiy blood flow will be measured with electromagnetic 
flow probes in response to local administration of NPs, selective and unselective NPR 
antagonists, as well as endothelium dependent and independent vasodilating agents. 
Commercially available radio-immuno assays will be used for NP analysis, including 
determination of p-ANP sub-fraction. Segments of iliac artery will be harvested (post 
mortem) from sham operated and paced sheep for characterisation of gene expression 
of biologically active natriuretic peptide receptors. Gene expression of NPRa+b will 
be characterised by reverse transcriptase polymerase chain reaction method (279). 
NPRc density will be assessed using an immuno- fluorescence method.
In the long term this model could be used to study pharmacological interventions, e.g. 
with an clearance receptor antagonist.
The study of “signalling abnormalities” down-stream from cGMP-generation will be 
facilitated by the current arrival and development of agents selectively inhibiting 
varies sub-fractions of G-proteins.
**Only those who risk going too far can possibly find out how far one can go”
T.S. Eliot
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